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Summary
Over the last two decades, monoclonal antibodies improved the treatment options
for various cancers significantly. However, the production process for these protein-
based therapeutics is considerably more demanding than that for small molecule
drugs. This is particularly true for complex proteins such as bispecific antibodies.
The purpose of this thesis was to develop a production process and a preliminary for-
mulation buffer for the bispecific FLT3ˆCD3 antibody NF-CUN297Q, which was de-
veloped for the treatment of acute myeloid leukemia (AML) and is intended to be ap-
plied in a clinical phase I/IIa trial. Thus, the main challenges for the production- and
formulation development are to produce a sufficient amount of the active pharma-
ceutical ingredient (API) with very high quality and to ensure long-term stability
of the product.
Good manufacturing practice (GMP)-compliant production processes are usually de-
veloped and performed by the pharmaceutical industry. The special aspect of this
thesis is the realization of GMP-compliant late-stage development of a protein-based
pharmaceutical drug at a small spin-off company operating at an university campus.
As a first step, specifications for critical quality attributes (CQA) were established
and justified. If mandatory requirements from regulatory authorities existed for
certain CQAs, these specifications were adopted for the development process. If no
specific requirements were demanded, commonly applied specifications were adopted
from similar production processes. If commonly applied specifications were not feasi-
ble, specifications were deducted from experimental characterizations. One example
for this approach is the determination of the tolerable amount of product-related
impurities such as aggregates, light chain dimers and light chains in the final pro-
duct formulation. The required amount of the API for a clinical phase I/IIa trial
including all necessary validations was discussed and determined theoretically.
The second task was to find an economic approach for the development of a pro-
duction process which fulfills the previously developed specifications and complies
with GMP requirements. At the beginning of process development, a suitable Chi-
nese hamster ovary (CHO)-based expression cell line, a so-called primary seed bank
(PSB), was generated and a scalable standard fermentation protocol was successfully
adopted. A variety of purification applications was tested for their suitability to
fulfill the previously determined specifications. In conclusion, a production process
consisting of affinity chromatography using KappaSelect followed by anion exchange-
and hydrophobic interaction chromatography and nanofiltration was developed. The
small-scale model (scale 1:100) of the process fulfills the requirements for product
quality and quantity and complies with GMP requirements.
A preliminary protein formulation buffer for the purified bispecific antibody was
selected using thermodynamic and kinetic stability studies in carefully chosen test
formulations. The evaluation of the melting temperature and the extent of aggrega-
tion of the API after a distinct time period of thermal stress resulted in a formulation
buffer consisting of Histidine, Trehalose and Tween® 20. This buffer indicates sta-
bility and a long shelf-life of bispecific antibody NF-CUN297Q.
The performed process- and preliminary formulation development are central prere-
quisites for GMP-compliant production. Bispecific antibody NF-CUN297Q produced
with this GMP-process and formulated in the developed buffer will be suitable for
application in a clinical phase I/IIa trial for the treatment of AML. This is an impor-
tant prerequisite for the successful proof of safety and efficacy of this pharmaceutical
drug.
Zusammenfassung
In den letzten beiden Jahrzehnten hat die Anwendung von monoklonalen Anti-
ko¨rpern die Behandlungsmo¨glichkeiten von diversen Krebsarten deutlich verbessert.
Verglichen mit niedermolekularen Wirkstoffen ist der Produktionsprozess fu¨r diese
proteinbasierten Wirkstoffe allerdings sehr viel anspruchsvoller. Dies gilt insbeson-
dere fu¨r komplexe Proteine wie bispezifische Antiko¨rper.
Das Ziel dieser Arbeit bestand darin, einen Produktionsprozess und eine vorla¨ufige
Proteinformulierung fu¨r den bispezifischen FLT3ˆCD3 Antiko¨rper NF-CUN297Q zu
entwickeln. Der Antiko¨rper ist zur Behandlung der akuten myeloischen Leuka¨mie
(AML) vorgesehen und soll in naher Zukunft in einer klinischen Phase I/IIa
Studie erprobt werden. Die Hauptherausforderung der Prozess- und Formulierungs-
entwicklung ist somit die Produktion einer ausreichenden Menge von biologisch
aktivem Wirkstoff mit sehr hoher Reinheit, sowie die Sicherstellung einer langen
Haltbarkeit.
Die Entwicklung und Durchfu¨hrung von good manufacturing practice (GMP)-
konformen Produktionsprozessen wird u¨blicherweise durch die pharmazeutische
Industrie durchgefu¨hrt. Der besondere Aspekt dieser Arbeit bestand darin, die
GMP-konforme Spa¨tphasenentwicklung eines protein-basierten Wirkstoffes in einem
kleinen Biotechnologieunternehmen auf einem universita¨ren Campus durchzufu¨hren.
Zuna¨chst wurden Spezifikationen fu¨r kritische Qualita¨tsmerkmale (critical quality
attributes = CQA) festgelegt und begru¨ndet. Wurden Spezifikationen fu¨r bestimmte
CQA von regulatorischen Beho¨rden vorgegeben, so wurden diese u¨bernommen. Falls
keine verbindlichen Vorgaben existierten, so wurden u¨bliche Spezifikationen von ver-
gleichbaren Produktionsprozessen u¨bernommen. Falls auch die U¨bernahme u¨blicher
Spezifikationen nicht praktikabel war, so wurden eigene Spezifikationen anhand
von experimentell erhobenen Daten gesetzt. Ein Beispiel fu¨r diesen Ansatz ist die
Ermittlung der maximal zula¨ssigen Konzentration von produktspezifischen Verun-
reinigungen wie Aggregaten, dem Dimer der leichten Kette und der leichten Kette
im finalen Produkt. Die erforderliche Menge von biologisch aktivem Wirkstoff fu¨r
eine klinische Phase I/IIa Studie inklusive aller notwendigen Validierungen wurde
theoretisch ermittelt.
Die zweite Aufgabe bestand darin, einen gu¨nstigen und effizienten Ansatz fu¨r die
Entwicklung eines Produktionsprozesses zu finden, welcher daru¨berhinaus die zuvor
festgelegten Spezifikationen erfu¨llt und GMP-konform durchfu¨hrbar ist. Zu Beginn
der Prozessentwicklung wurde eine geeignete Chinese hamster ovary (CHO)-basierte
Expressions-Zelllinie, eine sogenannte primary seed bank (PSB), generiert und ein
Standard-Fermentationsprotokoll erfolgreich adaptiert. Anschließend wurde eine
Reihe von Aufreinigungsmethoden auf ihre Eignung hinsichtlich des Erreichens der
zuvor festgelegten Spezifikationen getestet. Der resultierende Aufreinigungsprozess
setzt sich aus den drei chromatographischen Methoden Affinita¨tschromatographie
mittels KappaSelect, Anionenaustausch- und hydrophober Interaktionschromatogra-
phie, sowie einer Nanofiltration zusammen. Ein small-scale model des Produktions-
prozesses (Maßstab 1:100) wurde entwickelt und erfu¨llt die Anforderungen an die
Produktqualita¨t und -quantita¨t. Daru¨berhinaus ist der Produktionsprozess GMP-
konform durchfu¨hrbar.
Fu¨r den gereinigten bispezifischen Antiko¨rper wurde anschließend eine vorla¨ufige
Proteinformulierung entwickelt. Hierzu wurden thermodynamische und kinetische
Stabilita¨tsstudien in sorgfa¨ltig ausgewa¨hlten Testformulierungen durchgefu¨hrt. Die
Schmelzpunktbestimmung und die Bestimmung des Aggregatanteils nach kontinuier-
licher thermischer Belastung fu¨hrten zu einem Formulierungspuffer, welcher sich aus
Histidin, Trehalose und Tween® 20 zusammensetzt. Dieser Puffer gewa¨hrleistet Sta-
bilita¨t und eine lange Haltbarkeit des bispezifischen Antiko¨rpers NF-CUN297Q.
Die durchgefu¨hrte Prozessentwicklung und die vorla¨ufige Formulierungsentwicklung
sind zentrale Vorraussetzungen fu¨r die GMP-konforme Produktion des bispezi-
fischen Antiko¨rpers. Der mit dem entwickelten Prozess GMP-konform hergestellte
formulierte bispezifische Antiko¨rper NF-CUN297Q ist zur Anwendung in einer klini-
schen Phase I/IIa Studie geeignet. Somit ist eine wesentliche Voraussetzung fu¨r den
Nachweis der Sicherheit und Wirksamkeit dieses Wirkstoffes erfu¨llt.
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1.1 General introduction
1.1.1 Therapeutic monoclonal antibodies
Already in the late 19th century, Paul Ehrlich proposed the potential existence of
so-called “magic bullets” capable of selectively targeting a disease-causing organism
and releasing a specific toxin. With the development of hybridoma technology by
Ko¨hler and Milstein in 1975, the generation of “magic bullets” comprising antibod-
ies against defined target antigens became tangible (Ko¨hler and Milstein, 1975).
Nowadays, monoclonal antibodies (mAbs) play an important role in the treatment
of cancer, autoimmune and inflammatory diseases. With a revenue of 75 billion
US-dollars in 2013, antibody-related therapeutics are responsible for half of the sales
of all biological products (Ecker et al., 2015). Blockbusters with the highest revenue
include Adalimumab, Etanercept and Infliximab directed against tumor necrosis fac-
tor α (TNFα). Those drugs have been developed for the treatment of autoimmune
and inflammatory diseases. Rituximab directed against CD20, Trastuzumab, which
binds to human epidermal growth factor receptor 2 (HER2/neu), and Bevacizumab
directed against the vascular epidermal growth factor (VEGF) contribute to the
treatment of various cancers types. In addition, numerous new products are cur-
rently evaluated in clinical trials and expect approval by regulatory authorities.
Human antibodies are globular proteins, which can be subdivided into five struc-
turally similar subclasses: IgA, IgD, IgE, IgG and IgM. Immunoglobulin G1 (IgG1)
is the most abundant subclass in serum and almost all monoclonal antibody ther-
apeutics are based on this structure. Therefore, the following description refers to
the IgG1-subclass.
The different functions of antibodies can be allocated to different parts of the
molecule. The antigen-binding site is located at the N-terminus of each Fab-
fragment (fragment antigen binding), whereas the effector functions are triggered
via the C-terminal Fc-fragment (fragment crystallizable) (see figure 1.1 A). When
the Fc-fragment binds to its receptors, antibody dependent cell-mediated cytotox-
icity (ADCC) via the type III Fcγ-receptors (FcγRIII; CD16) on Natural killer
(NK)-cells or antibody-dependent cellular phagocytosis (ADCP) via type I Fcγ-
receptors (FcγRI; CD64) on monocytes and macrophages or type II Fcγ-receptors
(FcγRII; CD32) on neutrophil granulocytes is induced. The Fc-part is also capable
of activating the complement system resulting in complement dependent cytotox-
icity (CDC). Two Fab- and one Fc-fragment are connected via a highly flexible
hinge region to form the symmetrical “Y”-like shape of antibodies (see figure 1.1
A). IgG1-antibodies consist of two identical heavy chains of about 50 kDa each
and two identical light chains of about 25 kDa each (Fleischman et al., 1963). Di-
merization of two heavy chains is stabilized via two disulfide bonds in the hinge
region. Dimerization of heavy and light chain is stabilized via a disulfide bond
between the hinge region and the C-terminus of the light chain. Each chain can
be subdivided into immunogobulin domains consisting of about 110 amino acids
arranged via seven or nine strands to a compact β-barrel structure including one
intramolecular disulfide bond (Edmundson et al., 1976). The heavy chain is sub-
divided into four domains, whereas the light chain is subdivided into two domains.
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Each chain comprises one variable domain at the N-terminus (VL for the light
chain and VH for the heavy chain). Those domains consist of three hypervariable
complementary determining regions (CDR) embedded into four framework regions
(FR). The other immunoglobulin domains can be regarded as constant (CL for the
light chain and CH1, CH2 and CH3 for the heavy chain). CL associates to CH1 and
stabilizes dimerization of heavy and light chain. CH2 is the effector domain, which
binds to Fcγ-receptors on immune cells and to complement factor C1q. CH3 stabi-
lizes dimerization of the heavy chains and binds to the neonatal Fc-receptor (FcRn).
Monoclonal antibodies are usually of mouse origin, which also holds true for some of
the first therapeutic antibodies. Due to immunogenic reactions of patients against
those murine antibodies, different molecule sections were replaced by human IgG1-
structures (see figure 1.1). In a first approach, the variable domains remain from
murine origin, whereas the constant domains are human-derived (Morrison et al.,
1984). One prominent example for these chimerized antibodies is Rituximab. A
further advancement was the generation of humanized antibodies, which consist
of murine CDRs in human antibody framework regions (Jones et al., 1986) (for
example Trastuzumab). Finally, the problems associated with murine mAb sections
were completely circumvented by production of fully human antibodies. Those
antibodies are generated via phage-display or via immunization of mice with human
antibody genes (McCafferty et al., 1990; Marks et al., 1991). One example for this
approach is Adalimumab.
A) B) C) D)
Fab
Fc-part
Figure 1.1: IgG-Antibodies with decreasing murine part ratios for reduction of im-
munogenic reactions
A: fully murine IgG antibody; Fab = Fragment antigen binding; Fc = Fragment crystallizable; B:
chimerized antibody with variable murine domains and constant human domains; C: humanized
antibody with murine complementary determining regions in a human antibody framework; D:
human IgG antibody
1.1.2 Improvement strategies for monoclonal antibodies
Due to the fact that mAbs were exhibiting only limited success in the treatment of
various diseases, different improvement strategies were proposed.
As originally suggested by the “magic bullet” concept, one possibility for improve-
ment of efficacy is the generation of antibody-drug conjugates (ADC). For example
the α-CD33-mAb Gemtuzumab-Ozogamicin (Mylotarg®) for treatment of AML is
conjugated to the toxin Calicheamicin. However, this antibody was never approved
by EMA (European medicines agency) and the approval by the Food and drug ad-
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ministration (FDA) was withdrawn because of severe side effects in 2010.
An alternative approach to improve efficacy of mAbs is via the optimization of the
Fc-part. A higher affinity towards Fcγ-receptors can be achieved by the exchange
of distinct amino acids in the CH2-domain (Shields et al., 2001; Lazar et al., 2006).
Another approach to increase affinity of the Fc-part to its receptors is to modify
antibody glycosylation (Uman˜a et al., 1999).
A third possibility to improve antibody efficacy is to generate bispecific antibodies.
The main rationale for this approach is to recruit T-cells as effector cells; T-cells do
not express Fc-receptors and must therefore be recruited via an antibody-fragment
directed against an activating T-cell epitope. Nowadays a huge repertoire of differ-
ent bispecific antibody formats is proposed (Nun˜ez-Prado et al., 2015). If T-cell
recruitment is intended, the integration of a functional Fc-part in bispecific anti-
bodies should be avoided due to the possibility of Fcγ-receptor positive cells and
T-cells attacking each other via Fcγ-receptor/CD3-mediated activation. However,
the approved antibody Catumaxomab (Removab®), a rat-mouse hybrid antibody
directed against the epithelial adhesion molecule (EpCam) and CD3, still comprises
a functional Fc-part. The high cytokine release induced by this antibody might
be the result of this mechanism. The second bispecific antibody approved to date
(11/2015) is Blinatumomab (Blincyto®), a bispecific single-chain fragment variable
(scFv) antibody directed against CD19 on tumor cells and CD3 on T-cells for the
treatment of B-ALL (Bargou et al., 2008; Ribera et al., 2015). The mode of action
of T-cell recruiting bispecific antibodies is explained in figure 1.2.
1.1.3 Acute myeloid Leukemia and the target antigen FLT3
Leukemias are malignant diseases of the hematopoietic system and were first de-
scribed by Rudolf Ludwig Karl Virchow in 1845. Leukemic diseases can be charac-
terized by an accumulation of leukocyte precursor cells in bone marrow and blood.
All cell lineages of the hematopoietic system can be affected, resulting in anemia,
leukopenia or thrombocytopenia (NCI, 2013). Leukemic diseases may have a variety
of different causes, which can be subdivided into endogenous (e.g. genetic predispo-
sition) and exogenous causes (e.g. radiation, smoking, chemicals).
Leukemias can be subdivided into acute and chronic subtypes. Acute leukemias are
characterized by malignant proliferation of cells in early differentiation stages. This
results in a severe lack or absence of mature white blood cells. Chronic leukemias
are characterized by malignant proliferation of cells in late differentiation stages.
Furthermore, leukemias can be subdivided into myeloid and lymphoid subtypes ac-
cording to the origin of malignant cells. Myeloid leukemias derive from granulocyte-,
macrophage- or monocyte precursors, whereas lymphoid leukemias derive from B-
or T-cell precursors (Medicinenet, 2015).
Acute myeloid leukemia (AML) is a relatively rare disease with 4 new cases per
100,000 people each year. The incidence increases with age, median age at diagnosis
is 67 and 5-year survival rate is 25.9% (NIH, 2015).
First-line treatment of AML usually consists of chemotherapy and can be divided
into two phases: induction and consolidation therapy. The goal of induction therapy
is to achieve a complete remission by reducing the number of leukemic cells to an
undetectable level; the goal of consolidation therapy is to eliminate any residual
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tumor cell
deathimmediate
In the presence of tumor cells,
bispeci!c antibodies crosslink
activating receptors on T cells.
     Activated T cells
induce tumor cell lysis.
delayed
tumor cells
Activated T cells
proliferate and enlarge
the pool of e"ector cells.
Cytokines activate
other immune e"ectors.
T cells are not activated in
the absence of tumor cells.
Figure 1.2: Mode of action of bispecific α-CD3 antibodies
The bispecific antibody binds to target molecules on tumor cells and at the same time to activating
receptors expressed on T-cells. The cross-linkage of the receptors on the T-cell leads to T-cell
activation and, during the immediate response, to direct killing of tumor cells by T-cells. During
the delayed response, the activation of T-cells leads to T-cell proliferation and thereby to an
enlarged pool of T-effector cells. In addition, activated T-cells secrete pro-inflammatory cytokines,
which recruit other immune cells. Both mechanisms boost the inflammatory anti-tumor response
and strongly contribute to the killing of tumor cells. (© Synimmune GmbH)
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disease. Induction therapy starts with a treatment cycle of Cytarabine and an
Anthracycline (most often Daunorubicin). Consolidation therapy starts with high-
dose Cytarabine. For patients with high risk of relapse, autologous or allogeneic
stem cell transplantation is recommended (DGHO, 2015).
Experimental treatment options with biologicals included antibodies directed
against CD33 or the IL-3-receptor (CD123). The approval for α-CD33-antibody
Gemtuzumab-Ozogamicin was withdrawn because of severe side effects, as stated
earlier. CD33 is a pan-myeloid marker, which is also expressed on benign monocytes
(Griffin et al., 1984). CD123 was also investigated as treatment option for AML
(Jin et al., 2009), but the antigen is also expressed on dendritic cells and mast cells
(Dahl et al., 2004).
Perhaps the most promising target for immunotherapy of AML is fms-like tyro-
sine kinase 3 (FLT3), a type III receptor tyrosine kinase also known as CD135.
FLT3 is almost exclusively expressed on the surface of multipotent hematopoietic
progenitors in the bone marrow (Matthews et al., 1991). Expression of FLT3 was de-
tected on the surface of malignant cells in 70-100% of AML cases (Birg et al., 1992;
Drexler, 1996; Rosnet et al., 1996). The FLT3-molecule consists of five extracellular
immunoglobulin-like domains, a short transmembrane domain and a cytoplasmatic
region consisting of an ATP-binding domain and a phosphotransferase domain.
After binding the natural FLT3 ligand, the receptor homodimerizes and the cell
receives signals for survival, proliferation and differentiation (Lyman and Williams,
1995; Gabbianelli et al., 1995). 30% of AML patients exhibit an internal tandem
duplication mutation of FLT3 (ITD). This mutation results in permanent activa-
tion and signal transduction of the receptor resulting in unregulated proliferation
of affected cells (Yokota et al., 1997).
1.1.4 The bispecific antibody NF-CUN297Q
Bispecific FLT3ˆCD3 antibody NF-CUN297Q was developed for the treatment of
AML at the Department of Immunology of the University of Tu¨bingen (Durben,
2012; Durben et al., 2015). The format of the antibody is termed FabSc (see figure
1.3). This notation addresses the fact that the molecule consists of a Fab-fragment
and a single-chain fragment variable (scFv) antibody fragment. The Fab-fragment
is identical with the Fab-fragment of 4G8SDIEM, a chimeric mAb directed against
FLT3, which was previously developed at the Department of Immunology (Hof-
mann et al., 2012). The single chain fragment is derived from the humanized
α-CD3-antibody UCHT1 in VL-VH-orientation. The connection between Fab and
scFv-fragment consists of the hinge-region and CH2-domain-backbone of IgG1. In
order to circumvent dimerization of two heavy chains, two site-directed mutagenesis’
were performed in the hinge region; C226S and C229S. In addition, the CH3 domain
was excluded from the molecule. For prevention of glycosylation, the site-directed
mutagenesis N297Q was performed in the CH2 domain. In mAbs, the carbohydrates
at position N297 are covered between two heavy chains. In the FabSc-format, heavy
chains are not paired and carbohydrates would be exposed; mutagenesis N297Q
prevents glycosylation and therefore reduces the likelihood of immunological reac-
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tions. In order to prevent binding to Fcγ-receptors, the following modifications were
performed in the CH2 domain: E233P; L234V; L235A; ∆G236; D265G; A327Q and
A330S. The CH2 domain was extended by the first three amino acids of the CH3
domain (G341, Q342 and P343) to ensure a correct tertiary structure. The notation
NF-CUN297Q results from N-terminal FLT3-antigen, C-terminal single-chain derived
from UCHT-1 with site-directed mutagenesis N297Q. The amino acid sequence of
NF-CUN297Q can be found in appendix 5.2 at page 138.
The disadvantages of the FabSc-format compared to IgG-derived mAbs are the
reduced productivity and the fact that Protein A is not suitable for initial purifica-
tion. The last issue can be solved using other affinity media such as KappaSelect.
The advantages of the FabSc-format compared to the bispecific scFv-format are the
somewhat longer serum half-life, a higher productivity and a reduced tendency to
aggregate (Durben et al., 2015). The latter is very important to prevent unspecific
activation of T-cells due to cross-linkage of CD3.
C226S
C229S
X N297Q
CH3:
3 amino acids
from IgG1
Fab from
4G8SDIEM
scFv from
UCHT1
CH2 from
IgG1
Figure 1.3: The bispecific antibody NF-CUN297Q
red: murine part; green: human part; The X in the CH2 domain represents the site-directed
mutagenesis’ E233P; L234V; L235A; ∆G236; D265G; A327Q and A330S.
1.2 Background and context of the thesis
The monoclonal α-FLT3 antibody 4G8 was generated at the Department of Inter-
nal Medicine (II) of the University clinic of Tu¨bingen (Rappold et al., 1997). The
chimerized and Fc-optimized version 4G8SDIEM (WO/2011/076922) and the bispe-
cific antibody NF-CUN297Q (WO/2013/092001) were generated and initially char-
acterized at the Department of Immunology (University of Tu¨bingen) (Hofmann
et al., 2012; Durben et al., 2015). 4G8SDIEM will be applied in the minimal resid-
ual disease (MRD) state of AML. In contrast to that, the bispecific antibody will
be applied in a progressive state of the disease.
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The spin-off company Synimmune GmbH was founded for good manufacturing prac-
tice (GMP)-compliant development, clinical evaluation and commercialization of
these two promising antibodies. The company with ten full time employees was
funded by the German ministry of education and science (Bundesministerium fu¨r
Bildung und Forschung); Grant number GO-Bio 03/6070.
Synimmune GmbH was responsible for process- and formulation development, GMP-
production, quality control and preparation of clinical trials. The development tasks
were performed in close collaboration with the Department of Immunology (Uni-
versity of Tu¨bingen). GMP-production was performed at the GMP-facility of the
university clinic in Tu¨bingen.
The production process for 4G8SDIEM was adopted from a standard production
protocol for monoclonal antibodies. The antibody was formulated in a standard
formulation buffer for monoclonal antibodies.
Because of the different antibody format of NF-CUN297Q (FabSc-format), these ap-
proaches used for production of 4G8SDIEM were not feasible for the bispecific anti-
body. Thus, the challenge of this thesis was to define quality and quantity objectives
(specifications) for the bispecific antibody, which fulfill the requirements for a clinical
phase I/IIa trial. In addition, an economic approach for process- and formulation
development had to be found and successfully performed.
The special aspect of this thesis is the realization of good manufacturing practice
(GMP)-compliant late-stage development of a protein-based pharmaceutical drug
at an university-related setting. GMP-compliant production processes are usually
developed and performed by the pharmaceutical industry.
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1.3 Process development objectives for clinical
phase I/IIa trial
“The goal of manufacturing process development for the drug substance1 is to es-
tablish a commercial manufacturing process capable of consistently producing drug
substance of the intended quality.” states ICH2-Guideline Q11 “Development and
Manufacture of Drug Substances” (ICH-Q11, 2012). Not only for commercial pro-
cesses, but also for clinical application in a phase I/IIa trial, quality objectives
for biotechnological products such as NF-CUN297Q must be defined. Those quality
objectives (specifications) play a major role in the conduction of the development
process.
Regulatory authorities use the term “critical quality attributes” (CQA) to charac-
terize a product in terms of quality and therefore patient safety. ICH-Guideline
Q11 defines CQAs in the following way: “A CQA is a physical, chemical, biological,
or microbiological property or characteristic that should be within an appropriate
limit, range, or distribution to ensure the desired product quality. Potential drug
substance CQAs are used to guide process development. The list of potential CQAs
can be modified as drug substance knowledge and process understanding increase.”
(ICH-Q11, 2012).
One of the main difficulties of process development is to define CQA-specifications
for the future drug substance and drug product3. In most cases, regulatory autho-
rities do not dictate specified values, but demand high quality and scientific and
risk-evaluated justification of specifications (ICH-Q6B, 1999). Thus, the task is to
develop a process capable of producing large amounts of high-quality product after
developing justified specifications for a scientifically based product-release by the
qualified person. ICH-Guideline Q11 subdivides CQAs in properties or characteris-
tics that affect identity, purity, biological activity and stability of the active pharma-
ceutical ingredient (API). The following description refers to biologicals which are
produced in chinese hamster ovary (CHO)-cells.
1.3.1 Product Identity
The identity of the product must be verified in order to minimize the risk of confusion
with similar products. Identity of biologicals can be verified with various methods. A
SDS-PAGE and isoelectric focusing electrophoresis may be performed and the results
should be compared to theoretical values. In addition, the biological properties can
be used for identification. Binding of mAbs to their target antigen can be analyzed
via flow cytometric analysis.
1Bulk of formulated active pharmaceutical ingredient (API) in formulation buffer
2International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use; a project which combines regulatory requirements from Europe,
USA and Japan
3A finished dosage form of formulated active pharmaceutical ingredient (API) in formulation
buffer
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1.3.2 Product Purity
Product purity CQAs can be subdivided into product-related and process-related
impurities.
Product-related impurities are aggregated or fragmentary parts of the molecule.
Due to their API-specific properties, they should be characterized elaborately. In
mAbs, aggregates, light chain dimers or monomeric light chains might occur.
Due to the fact that biologicals are produced in living cells such as chinese hamster
ovary (CHO)-cells, process-related impurities such as host cell proteins (HCP) and
host cell DNA (HCDNA) might be present in the final product. If mAbs are pu-
rified via biospecific interaction chromatography, leached affinity ligands from the
purification process such as Protein A or KappaSelect can be found in the final
product. Another example for process-related impurities are endotoxins, which
are an indicator for contamination with gram-negative bacteria. Other possible
contaminants include viruses or transmissible spongiform encephalopathy (TSE)
proteins, so-called prions. In contrast to product-related impurities, process-related
impurities do not need to be characterized because a CHO-based fermentation
followed by biospecific interaction chromatography can be regarded as well known.
1.3.2.1 Product-related impurities
Aggregates / Multimers
Protein aggregation is a common phenomenon during production of biologicals, but
the mechanism of aggregation is still poorly understood (Wang, 2005). Aggregates1
can be subdivided into soluble/unsoluble, covalent/non-covalent, reversible/non-
reversible, native/denatured types (Cromwell et al., 2006). At the beginning of
aggregate formation, antibodies may partially be unfolded, leading to exposure of
more hydrophobic regions of the molecule which promotes intermolecular interac-
tions leading to aggregation (Kiese et al., 2008).
Aggregates increase immunogenicity of the API and might lead to reduced efficacy
due to enhanced generation of neutralizing antibodies (Ahmadi et al., 2015).
Due to the fact that aggregates are more hydrophobic than monomers, aggregate
removal can be achieved via implementation of hydrophobic interaction chromato-
graphy (HIC) (Lu et al., 2009; Suda et al., 2009).
Common specifications for aggregates in biotechnological products range below 5%
(Chon and Zarbis-Papastoitsis, 2011), an aggregate content below 1% is more favor-
able due to possible immunogenic reactions and should be pursued.
Due to the fact that the biological properties of aggregates might be API-specific,
further characterization is advised. The aggregate content can be monitored via size
exclusion chromatography (SEC) or field flow fractionation (FFF). The performance
of flow cytometric analysis on cells presenting the target antigens or potency assays
might be suitable methods for biological characterization.
1the term aggregate will be applied for multimers as well
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Fragments
The presence of the antibody fragments light chain dimer (LCD) and light chain (LC)
in the cell culture supernatant of mAbs has long been known (Knittler et al., 1995).
This might be the result of a faster translation of the light chain gene compared
to the longer heavy chain gene (Schlatter et al., 2005). In addition, the reducing
conditions inside the endoplasmatic reticulum may result in formation of light chain
dimers from free light chains (Knittler et al., 1995). This contamination is not criti-
cal, as long as the mAbs are purified via Protein A, which binds the heavy chain of a
mAb. When using KappaSelect as affinity ligand for antibody fragments, LCD/LC
are purified along with the monomeric IgG. There is not much known about the
effects of LCD/LC in patients except for the fact that they might have a negative
influence on renal function (Matsuura et al., 1999).
For evaluation of theoretical properties on chromatographic media such as ion-
exchange resins, the experimental determination of the isoelectric point (IEP) might
be helpful.
Due to the fact that the biological properties of these mAb-fragments are API-
specific, further characterization is highly recommended. The LCD/LC content can
be monitored via size exclusion chromatography (SEC) or field flow fractionation
(FFF). The performance of flow cytometric analysis on cells presenting the target
antigens or potency assays might be suitable methods for biological characterization.
In contrast to light chains, the presence of free Heavy chains in the cell culture su-
pernatant is not likely because heavy chains do not fold correctly in the absence of
light chains and remain bound to the immunoglobulin binding protein in the endo-
plasmatic reticulum (Schlatter et al., 2005; Vanhove et al., 2001). Unfolded heavy
chain polypeptides are subjected to degradation by the proteasome (Fagioli et al.,
2001).
1.3.2.2 Process-related impurities
Host cell proteins (HCP)
Potential risks associated with HCP-contamination are toxicity, immunogenicity and
influence on efficacy of the API. Induced α-HCP-antibodies may also react to en-
dogenous human protein homologs. Furthermore, HCPs can act as adjuvant to
increase the rate of formation of anti-API antibodies (de Zafra et al., 2015).
The following properties can be utilized for reduction of HCP content: molecular
size can be exploited with ultra- and diafiltration (UF/DF) and isoelectric point
(IEP)-distribution can be utilized for purification via ion-exchange chromatography.
10% of CHO host cell proteins are smaller than 25 kDa, 40% distribute from 25 to
50 kDa, 35% can be found in the range of 50 to 75 kDa and 10% distribute in the
range of 75 to 100 kDa. 30% of proteins have an IEP lower than 5. 35% of the IEPs
distribute in the range of 5 to 6, 15% in the range of 6 to 7 and 20% of the HCPs
have an IEP greater than 7 (Jin et al., 2010).
Commonly accepted specifications for CHO HCPs in biotechnological products are
below 100 parts per million (ppm) (Chon and Zarbis-Papastoitsis, 2011).
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Host cell DNA (HCDNA)
The FDA describes the risk of Host cell DNA as follows: “Residual DNA might be
a risk to your final product because of oncogenic and/or infectivity potential. There
are several potential mechanisms by which residual DNA could be oncogenic, includ-
ing the integration and expression of encoded oncogenes or insertional mutagenesis
following DNA integration. Residual DNA also might be capable of transmitting
viral infections if retroviral proviruses, integrated copies of DNA viruses, or extra-
chromosomal genomes are present.” (FDA-Guidance for Industry, 2010). Due to
the relatively low IEP with ď 5, DNA can efficiently be removed from proteins with
high IEPs such as mAbs via ion-exchange chromatography. Commonly accepted
specifications for CHO HCDNA in biotechnological products are below 10 ng/dose
(Chon and Zarbis-Papastoitsis, 2011; WHO-Biologicals, 2010).
Leached affinity ligand
Biospecific interaction chromatography (also known as affinity chromatography) is
usually performed as initial purification step for mAbs. The most widely used affin-
ity ligands for mAb purification are Protein A and G, a potential alternative for
antibody fragments is Protein L or camel body-derived KappaSelect. Despite the
fact that the protein ligand is covalently linked to its resin, leaching might occur
upon acidic elution of the API. The potential risk of affinity ligand contamination
in the final product is the same as for HCPs.
For evaluation of theoretical properties on chromatographic media such as ion-
exchange resins, the experimental determination of the isoelectric point (IEP) might
be helpful. Commonly accepted specifications for protein ligand in biotechnological
products are below 10 ppm (Chon and Zarbis-Papastoitsis, 2011).
Endotoxins
Endotoxins such as lipopolysaccharides (LPS) are released after disruption of the
cell wall of gram-negative bacteria and can therefore be used as surrogate readout
for contamination of the product with gram-negative bacteria.
Endotoxins act as pyrogens and can induce inflammation or severe septic shocks
(Opal, 2010). Due to the relatively low IEP of ď 5, LPS can easily be removed
from proteins with high IEP such as mAbs via ion-exchange chromatography (see
HCDNA). Demanded specifications are 5 IU/h/kg (Ph.Eur. 7.0 part 2.6.14. “Bacte-
rial endotoxins”).
Viral and TSE safety
Viral contamination of the API may be the result of contaminated cell lines or raw
materials. One potentially hazardous virus is the Lymphocytic Choriomeningitis
Virus (LCMV) which infects hamster and human cells. Enveloped viruses are usu-
ally pH-sensitive and larger than 30 nm and can be inactivated or removed via low
pH-values and nanofiltration respectively. Non-enveloped viruses exhibit isoelectric
points of 3 to 7 and can therefore be removed effectively from mAbs with high IEPs
by ion exchange chromatography (Michen and Graule, 2010). The capacity to clear
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infectious viruses within a production process is assessed via validation of virus
removal on a small-scale model (ICH-Q5A (R1), 1999).
The European medicines agency (EMA) states that a conversion of the demanded
sterility assurance level (SAL) of 10´6 for sterile products to viral safety is justifiable
(EMA-CPMP/BWP/268/95, 1996)
Transmissible spongiform encephalopathy (TSE) might occur via transmission
of prions of animal origin into the product. Prions are suspected to be a possible
cause for Creutzfeldt–Jakob disease. All raw materials must be produced animal-
component free. Analytical techniques for identification of prions do not exist so far
(10/2015) and therefore their absolute absence is demanded (EMA-2011/C-73/01,
2011).
1.3.3 Biological activity and stability of the product
The preservation of biological activity is a main issue during production and purifica-
tion of the API. Binding properties of mAbs can be monitored via flow cytometric
analysis on cells presenting the target antigens. In the case of CD3-specific anti-
bodies such as NF-CUN297Q, T-cell proliferation can be monitored via specific cell
proliferation assays. Efficacy can be monitored with potency assays. In general, the
most effective way to preserve the activity of the API is to avoid harsh conditions
such as extreme pH-, conductivity- or temperature conditions.
Stability studies for biologicals are essential to assess sensitivity to factors that might
cause aggregation and degradation. Those processes might have a negative influence
on biological activity and therefore product safety. A high stability is directly linked
to a long shelf-life.
As stated in ICH-Guideline Q5C, determination of expiration date should be based
on real-time/real-temperature studies (ICH-Q5C, 1995). Nevertheless, the use of
accelerated stability studies with increased temperature is common. These studies
should be performed with carefully chosen test buffers and can be performed as part
of the formulation development.
1.3.4 Required amount of active pharmaceutical ingredient
(API)
The required amount of API for clinical application or market demands depends on
the efficacy and safety profiles of the API and must be defined.
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1.4 Strategies to achieve development objectives
1.4.1 Molecular biology and Cell banking
In order to address viral safety, the parental cell line must be analyzed according
to ICH-Guideline Q5A to verify the absence of viral contaminants (ICH-Q5A (R1),
1999). The most commonly used parental cell line is a Chinese hamster ovary (CHO)
cell line. In order to address TSE-safety, the plasmid used for transfection must be
produced animal-component free.
The generation of a primary seed bank (PSB) must be performed under controlled
conditions in an access-controlled laboratory. All activities related to the generation
of the PSB should be documented. The handling of other cell culture, bacteria or
viruses is prohibited. Storage temperature must be recorded periodically. The PSB
should be thawed periodically to verify the suitability for production (EU-GMP-Part
2, 2005). Origin, history and production of parental cell lines must be documented
(ICH-Q5D, 1997). The PSB is the direct precursor of the master cell bank (MCB)
and the working cell bank (WCB). The MCB/WCB must be produced under GMP-
compliant conditions. Raw materials must be documented and must be animal
component-free (EMA-2011/C-73/01, 2011).
1.4.2 Fermentation
In order to prevent microbial or viral contamination, process scale fermentation
must be performed in a clean room (EU-GMP-Part 1, 2003). In order to address
TSE-safety in process scale fermentation, cell culture medium must be animal compo-
nents free. The following parameters should be recorded periodically and controlled
as appropriate in order to ensure a reproducible and robust process: cell density
and viability, temperature, gas composition, glucose, glutamine and pH. Antibody
concentration should be monitored in the late-phase of fermentation.
1.4.3 Chromatographic purification strategies
The classical approach for separation of biopharmaceutical products from impuri-
ties is to apply chromatographic techniques. The first partition chromatography
was performed by Martin and Synge in 1952 and can be regarded as precursor of
today’s chromatographic techniques (Martin, 1952). Nowadays, a typical purifica-
tion protocol for mAbs starts with biospecific interaction chromatography (affinity
chromatography) for purification of the API from the cell culture supernatant. The
degree of purity achieved after this purification step is usually not sufficient for
biopharmaceuticals (Tugcu et al., 2008). This initial purification is followed by
so-called polishing methods such as ion exchange chromatography or hydrophobic
interaction chromatography.
1.4.3.1 Biospecific interaction chromatography (Affinity chromatography)
The most commonly used chromatography medium for initial purification of mAbs
is Protein A. If this ligand is not applicable, several alternatives such as Protein
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G, Protein L or KappaSelect can be evaluated (Hnasko and McGarvey, 2015). The
advantage of these affinity media is their high selectivity and capacity for mAbs,
which makes them the ideal tool for initial purification from cell culture supernatant.
With the application of affinity chromatography, the HCP and HCDNA content can
be reduced very effectively. This purification strategy has no direct influence on the
aggregate content. Protein A and G can reduce the content of light chain dimer
(LCD) and light chain (LC), whereas Protein L and KappaSelect purify LCD/LC
along with the monomeric IgG. Elution is performed at low pH and might have an
influence on biological activity, this should be investigated.
1.4.3.2 Ion exchange chromatography (IEX)
Ion-exchange chromatography is a very effective polishing approach for the removal
of process- and product-related impurities.
Anion exchange chromatography (AIEX) is characterized by a cationic ligand
on the chromatographic resin. When a protein sample is applied to an equilibrated
column with a certain pH, all impurities with IEPs below this pH exhibit a negative
net charge and therefore bind to the resin. All impurities with higher IEPs than the
applied pH exhibit a positive net charge, do not bind and flow through the column.
Figure 1.4 shows a compendium of the distribution of IEPs of process-related im-
purities (or better: isoelectric areas for the sum of molecules) from chapter 1.3.2.2
starting at page 12.
Cation exchange chromatography (CIEX) is characterized by an anionic ligand
on the chromatographic resin. When a protein sample is applied to an equilibrated
column with a certain pH, all impurities with IEPs below this pH exhibit a negative
net charge, do not bind and therefore flow through the column. All impurities with
higher IEPs than the applied pH exhibit a positive net charge and bind to the resin.
Most of the impurities exhibit acidic IEPs, thus a basic IEP of the desired molecule
is favorable for ion-exchange chromatography. The IEPs of the leached affinity
ligand or antibody fragments such as LCD or LC must be determined experimentally
for a prediction of retention properties on ion-exchange resins. Aggregates can be
separated from the monomer as well; due to their larger size, they carry more charged
residues than the monomer. In conclusion, in a buffer with a pH lower than the IEP
of the monomer, the aggregate exhibits an IEP which is apparently higher. In
contrast, in a buffer with a pH higher than the IEP of the monomer, the aggregate
exhibits an IEP which is apparently lower.
The conductivity should be low to maintain ionic interactions. The length of ionic
interactions (debye length k´1) depends on the electrolyte concentration according
to equation 1.1.
k´1 “
c
ǫrǫ0RT
2F 2C0
(1.1)
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k´1 debye length
ǫ0 permittivity of free space
ǫr dielectric constant
R universal gas constant
T absolute temperature in kelvins
F Faraday constant
C0 concentration of the electrolyte (the conductivity dependents di-
rectly on this concentration)
However, if conductivity is too low, the risk of aggregation increases. As long as
no extreme pH- or conductivity-values are applied, the biological activity should be
unaffected in ion exchange chromatography.
HCP
HCDNA
Viruses
Endotoxins
pH 1 2 3 4 5 6 7 8 9
Figure 1.4: Isoelectric points (IEP) of process-related impurities
Process-related impurities exhibit different isoelectric points (or better: isoelectric areas for the sum
of molecules). These properties can be utilized for separation of these process-related impurities
from the active pharmaceutical ingredient (API) via ion-exchange chromatography. Especially
when the IEP of the API is high, the separation can be very efficient. HCP = Host cell proteins;
HCDNA = Host cell DNA
1.4.3.3 Hydrophobic interaction chromatography (HIC)
Hydrophobic interaction chromatography (HIC) is an attractive tool for removal
of aggregates and molecule fragments, which are usually more hydrophobic than
the protein monomers and therefore bind stronger to the hydrophobic ligand of
the resin (Suda et al., 2009; Lu et al., 2009). No predictions about the properties
of process-related impurities are possible. However, hydrophobicity decreases with
difference of applied pH and IEP due to formation of charged residues, which are
hydrophilic. HIC is an entropy-dependent separation method. Thus, this method
is very temperature-sensitive. When proteins bind to the resin, entropy increases
due to the release of water molecules from the hydration shell. Effects on biological
activity must be evaluated, but in general HIC is not as harsh as reversed phase
chromatography due to the absence of organic solvents.
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1.4.3.4 Multimodal chromatography (MMC)
A combination of two different chromatographic techniques is termed multimodal
chromatography (MMC). The most common combination is the use of HIC and
CIEX1. A prediction of retention properties of the API and the impurities is ex-
tremely difficult and should be evaluated experimentally. This method is demanding,
but effective when sufficiently controlled.
1.4.4 Viral and TSE safety
The most important guideline addressing viral safety is ICH-Guideline (ICH-Q5A
(R1), 1999). The Guideline states: “Three principal, complementary approaches
have evolved to control the potential viral contamination of biotechnology products:
• selecting and testing cell lines and other raw materials, including media com-
ponents, for the absence of undesirable viruses which may be infectious and/or
pathogenic for humans;
• assessing the capacity of the production processes to clear infectious viruses;
• testing the product at appropriate steps of production for absence of contam-
inating infectious viruses.”
Master and working cell banks (MCB/WCB) must be tested for viral contamination
according to this ICH-Guideline and a meaningful certificate of origin is required for
raw materials. Testing of the drug product will be performed in the process valida-
tion phase of the clinical phase III process. End product testing is not required for
products of CHO-origin due to the fact that this cell line is regarded as well-known
(ICH-Q5A (R1), 1999).
In order to ensure viral safety in the production process, at least two purification
techniques, pH-inactivation and nanofiltration, are commonly used to remove en-
veloped viruses. pH-inactivation is usually performed after affinity chromatography
at pH 3.5 for 1 h and inactivates especially enveloped viruses efficiently (Brorson
et al., 2003). Nanofiltration is usually performed with a 20 nm filter and reduces
viral load. A suitable technique for removal of non-enveloped viruses is ion exchange
chromatography (Michen and Graule, 2010); due to the acidic IEP of viruses (see
figure 1.4) they can be separated from the API, especially when the IEP of the API
is basic (see section 1.4.3.2).
The capacity to clear infectious viruses within a production process is assessed via
validation of virus removal on a small-scale model at the end of the process develop-
ment phase (viral clearance study) (ICH-Q5A (R1), 1999). Within this validation,
viruses are spiked to different steps of the process to verify the removal properties.
The validation of virus removal of a certain relevant model virus must be justified.
Usually enveloped and non-enveloped viruses are included into the study.
No animal-derived raw material should be used in the process (except for the
use of the CHO-based production cell line). Thus, no TSE proteins would be
introduced into the process.
1when using the term MMC in this thesis, it refers to the combination of HIC and CIEX
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1.4.5 Formulation development
The choice of an appropriate storage buffer, i.e. formulation buffer, is a critical as-
pect for protein stability and therefore shelf-life.
Storage forms can be subdivided into liquid, lyophilized and frozen forms. The
liquid dosage form is the least stressful condition for the API and the effort of de-
velopment is relatively low. On the other hand, this is the storage form with the
shortest shelf-life. The lyophilized storage form ensures a very long shelf-life and the
storage conditions are not very stressful for the API. The effort to develop such a
dosage form is very high. The frozen storage form has a very long shelf-life, but the
conditions might be stressful for the protein. The effort to develop and store those
dosage forms is relatively high.
Diverse modifications might occur during storage of the API; oxidation and aggre-
gation is likely. The main challenge of formulation development is to develop a
buffer in which these kind of modifications occur to a very low extent and/or very
late. Suitable buffer components, pH, conductivity and osmolality are parameters
to consider. Sugars may be added as stabilizers and as protectants against stress-
ful influences. Surfactants such as Polysorbates (e.g. Tween® 20) may be added
as stabilizers as well. Additional formulation components may include amino acids,
inorganic salts and antioxidants.
As already mentioned earlier, ICH-Guideline Q5C states that determination of expi-
ration date should be based on real-time/real-temperature studies (ICH-Q5C, 1995).
Nevertheless, the use of accelerated stability studies for determination of thermody-
namic and kinetic stability of a protein in certain formulation buffers is common
(Weiss et al., 2009). The thermodynamic stability of the protein should be inves-
tigated using thermal shift assays such as differential scanning fluorimetry. The
kinetic stability of the protein can be investigated by determination of the aggre-
gate content after a distinct period of thermal stress.
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1.5 Aim and objective of the thesis
The purpose of this thesis was to develop a production process and a preliminary
protein formulation buffer for bispecific antibody NF-CUN297Q. The subsequent
GMP-compliant production is a prerequisite for a clinical phase I/IIa trial for the
treatment of AML.
The first task was to develop justifiable specifications for critical quality attributes
(CQA), which had to be identified, evaluated and, if required, further characterized
to define quality objectives. In addition, the required amount of the Active phar-
maceutical ingredient (API) had to be defined.
The second task was to find an economic approach for the development of a pro-
duction process which fulfills the previously determined specifications and complies
with GMP requirements. This task subdivides into development of a production
cell line, fermentation- and purification development.
The third task was to develop a preliminary protein formulation buffer for the
bispecific antibody to ensure stability.
The special aspect of this thesis is the realization of late-stage development of a
protein-based pharmaceutical drug at a small spin-off company operating at a uni-
versity campus for a First-in-man study. This development is usually performed by
the pharmaceutical industry.
Bispecific antibody NF-CUN297Q produced under GMP-conditions with the devel-
oped process must be suitable for application in a clinical phase I/IIa trial for the
treatment of AML.
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2.1 Material
2.1.1 Equipment
7500 Fast Real-Time PCR system Life technologies, Darmstadt
A¨KTA purifier 100 GE Healthcare, Mu¨nchen
CCD Camera Fusion SL Vilber Lourmat, Eberhardzell
Cell harvester Inotech Biosystems, Rockville, MD/USA
Centifuge 5417 C Eppendorf, Hamburg
Centrifuge Labofuge 400R Thermo Scientific, Waltham, MA/USA
Centrifuge Megafuge 1.0 Thermo Scientific, Waltham, MA/USA
CO2-Incubator Haereus Thermo Scientific, Waltham, MA/USA
Criterion™ Cell Electrophoresis Bio-Rad, Mu¨nchen
Electrophoresis power supply power pac
1000
Bio-Rad, Mu¨nchen
ELISA reader Spectra Max 340 Molecular Devices, Ismaning
FACS Calibur BD Biosciences, Heidelberg
Freezer -20 °C Liebherr, Biberach an der Riss
Freezer -80 °C Colora Messtechnik, Frankenthal
Gammacell 1000 elite MDS Nordion, Ottawa, Can
Gene Pulser® II Bio-Rad, Mu¨nchen
Incubator Cellstar Nunc, Wiesbaden
Laminar Airflow Cabinet Integra Biosciences, Biebertal
Liquid Nitrogen Tank Cryofreezer Cryo Anlagenbau, Wilnsdorf
Magnetic Stirrer MR 2002 Heidolph instruments, Schwabach
Microbeta2 Counter Perkin Elmer, Rodgau
Microscope Axiovert 135 Carl Zeiss Microscopy, Jena
Mini-PROTEAN Tetra Electrophoresis
System
Bio-Rad, Mu¨nchen
Multi Channel Pipette Abimed, Langenfeld
Multistepper StepMate Abimed, Langenfeld
Nanodrop™ 1000 Thermo Fisher Scientific, Schwerte
Orbital Shaker Celltron Infors HT, Bottmingen/Basel, CH
pH-/conductivity-meter Seven Multi Mettler-Toledo, Giessen
Pipetboy Pipetus Hirschmann Laborgera¨te, Eberstadt
Pipettes 2, 10, 20, 200, 1000 µL Gilson, Middleton, WI/USA
Refrigerator Liebherr, Biberach an der Riss
SevenMulti™ with pH- and Conductivity
Expansion Units
Mettler Toledo, Giessen
Scale AC 2115 Sartorius, Go¨ttingen
Scale LC 821 Sartorius, Go¨ttingen
Thermoblock Liebisch, Bielefeld
Thermocycler PTC-100 MJ Research, St.Bruno, CA
Thermoshaker ELISA Plates Biosan, Riga, LV
UHPLC Dionex™ UltiMate™ 3000 BioRS Thermo Scientific, Waltham, USA
Climate Cabinet Unichromat 3000 Uniequip Laborgera¨tebau, Planegg
Water Bath Assistent WTE 3185 Karl Hecht, Sondheim v.d. Rho¨n
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Water Bath Memmert Memmert, Schwabach
Wave Reactor Biostat Cultibag RM 20
Optical
Sartorius, Go¨ttingen
2.1.2 Glas and plastic supplies
Amicon Ultra-4 Centrifugal Filter Units
MWCO 30 kDa
Millipore, Schwalbach
Beakers (glass) Schott, Mainz
Beakers (plastic) Vitlab, Großostheim
Bottletop Filters (0.22 µm) Millipore, Schwalbach
Cell Culture Flasks 75 cm² Greiner Bio-One, Frickenhausen
Cell Culture Flasks 75 cm² TPP, Trasadingen, CH
Cell Culture Plates 6, 24, 48, 96well TPP, Trasadingen, CH
Cell Culture Plates 96well Greiner Bio-One, Frickenhausen
Combination Cap (Luer Lock) Fresenius Kabi, Bad Homburg
Combitips 1.25, 2.5, 5mL Eppendorf, Hamburg
Counting Chamber (Neubauer) Brand, Weinheim
Cryo Vials 2mL TPP, Trasadingen, CH
Cultibag RM 2, 20L optical Sartorius, Go¨ttingen
Discofix C-3 B-Braun, Melsungen
Electroporation Cuvettes 4mm PEQLAB Biotechnologie, Erlangen
ELISA Plates Nunc F96 Maxisorp Nunc, Langenselbold
Erlenmeyer Flasks (plastic) 125, 250, 500mL Thermo Fisher Scientific, Schwerte
FACS Tubes 0.5mL Sarstedt, Nu¨mbrecht
Fast Optical 96-well Reaction Plate Applied Biosystems, Singapore
HPLC Vials 300 µL Thermo Scientific, Waltham, MA/USA
Hypodermic Needles 18Gˆ1.5 inch BD Biosciences, Heidelberg
Infusion Extender (0.3 x 4.1mm) Oriplast, Neunkirchen
Measuring Cylinders (glass) Isolab Laborgera¨te, Wertheim
Nalgene™ Cryo 1 °C Freezing Container Thermo Fisher Scientific, Schwerte
Pasteur Pipettes Wilhelm Ulbrich, Bamberg
PCR Softtubes 0.5mL Biozym Scientific, Hessisch Oldendorf
PE Tubes 50mL Greiner Bio-One, Frickenhausen
Pipette Tips with Filters 10, 20, 200, 1000 µL Biozym Scientific, Hessisch Oldendorf
Pipette Tips with Filters 10, 20, 200, 1000 µL Starlab, Ahrensburg
Polypropylene (PP) Tubes 15mL TPP, Trasadingen, CH
Printet Filter Mats A PerkinElmer, Rodgau
Reaction Tubes 1.5, 2mL Eppendorf, Hamburg
Round Bottom Plates, 96well Greiner Bio-one, Frickenhausen
Round Bottom Tubes 5mL BD Falcon, Heidelberg
Serological Pipettes 1, 2, 5, 10, 25mL TPP, Trasadingen, CH
Serological Pipettes 1, 2, 5, 10, 25, 50mL BD Falcon, Heidelberg
Sterile Filters 0.22 µm, diameters 4, 13,
33mm
Millipore, Schwalbach
Syringes (plastic) 2, 5, 10, 20, 30, 50mL BD Biosciences, Heidelberg
Tubespin Bioreactor 50, 600mL TPP, Trasadingen, CH
Tubing 0.125/0.25 Inch (inner/outer diame-
ter)
Saint-Gobain Performance Plastics, Lindau
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Virus Filters Planova 15N, 20N, BioEX Asahi Kasei, Ko¨ln
2.1.3 Chemicals and reagents
[3H-methyl]-Thymidine Hartmann Analytic, Braunschweig
10 x IEF Anode Buffer Bio-Rad, Mu¨nchen
10 x IEF Cathode Buffer Bio-Rad, Mu¨nchen
10 x Tris/Glycine/SDS Buffer Bio-Rad, Mu¨nchen
Acetic acid Carl Roth, Karlsruhe
Ammoniumsulfate Merck, Darmstadt
β-Mercaptoethanol Carl Roth, Karlsruhe
Biocoll separating solution Biochrom, Darmstadt
Bovine Serum Albumin (BSA) Carl Roth, Karlsruhe
Calibration buffers for conductivity
12.88mS/cm, 1413 µS/cm
Mettler-Toledo, Giessen
Calibration buffers for pH 4.01, 7.00, 9.21 Mettler-Toledo, Giessen
Criterion™ Precast Gel IEF pH 3-10, 1.0mm Bio-Rad, Mu¨nchen
CDM4PERMAb™ GE Healthcare, Mu¨nchen
Citric Acid Sigma-Aldrich Chemie, Mu¨nchen
ClonaCell™CHO ACF Supplement (40x) Stemcell, Ko¨ln
Coomassie staining “Roti-blue 5x” Carl Roth, Karlsruhe
Coomassie R250 (Brilliant blue R) Life Technologies, Darmstadt
Copper sulfate (CuSO4) Carl Roth, Karlsruhe
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie, Mu¨nchen
Dulbecco’s Phosphate Buffered Saline
(DPBS)
Life Technologies, Darmstadt
Efficient Feed A and B Life Technologies, Darmstadt
Ethanol AppliChem, Darmstadt
FACS-Clean, FACS-Flow, FACS-Rinse BD Biosciences, Heidelberg
Fetal Calf Serum (FCS) Perbio Science, Bonn
Gel filtration standard (151-1901) Bio-Rad, Mu¨nchen
Geneticin sulfate (G 418) Biochrom, Berlin
Glycine Carl Roth, Karlsruhe
HEPES Carl Roth, Karlsruhe
Histidine Carl Roth, Karlsruhe
Hydrochloric acid 36% Merck, Darmstadt
IEF Sample Buffer Bio-Rad, Mu¨nchen
Iscove’s Modified Dulbecco’s Medium
(IMDM)
Lonza, Verviers, BE
Isoelectric Focusing Calibration Kit High
Range pI (pH 5 - 10.5)
GE Healthcare, Mu¨nchen
Isopropanol Carl Roth, Karlsruhe
Laemmli Sample Buffer Bio-Rad, Mu¨nchen
L-Glutamine 200mM Lonza, Verviers, BE
MEM non-essential amino acids C.C.Pro, Neustadt
Methanol Merck, Darmstadt
Mini-Protean TGX 10%-Gels Bio-Rad, Mu¨nchen
Monosodium dihydrogenphosphate Merck, Darmstadt
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PageRuler™ Prestained Protein Ladder Thermo Fisher Scientific, Schwerte
Penicillin Cambrex, Verviers, BE
pH-gradient Buffer A (pH 5.6) Thermo Fisher Scientific, Schwerte
pH-gradient Buffer B (pH 10.2) Thermo Fisher Scientific, Schwerte
Phosphoric acid 85% AppliChem, Darmstadt
Phytohemagglutinin Life Technologies, Darmstadt
Roswell Park Memorial Institute Medium-
1640 (RPMI)
Life Technologies, Darmstadt
Sodium acetate Carl Roth, Karlsruhe
Sodium azide Merck, Darmstadt
Sodium chloride Merck, Darmstadt
Sodium pyruvate C.C.pro, Neustadt
Sodium succinate Fluka Chemie, Buchs
Sodium hydroxide 40% Carl Roth, Karlsruhe
Streptavidin-monoHRP BD Biosciences, Heidelberg
Streptavidin-polyHRP Immunotools, Friesoythe
Streptomycin Cambrex, Verviers, Belgien
Sulfosalicylic acid Carl Roth, Karlsruhe
TMB Microwell Peroxidase System (2-C) Medac, Wedel
Trehaloseˆ2H2O Carl Roth, Karlsruhe
Trichloroacetic Acid Carl Roth, Karlsruhe
Tris-Base Sigma-Aldrich Chemie, Mu¨nchen
Tris-HCl Sigma-Aldrich Chemie, Mu¨nchen
Trypan-Blue 0,4% Sigma-Aldrich Chemie, Mu¨nchen
Tween® 20 (Polysorbate 20) Merck, Darmstadt
Tween® 80 (Polysorbate 80) Merck, Darmstadt
Ultima Gold™ High Flashpoint LSC-cocktail PerkinElmer, Rodgau
Water for injection (Ampuwa®) Fresenius Kabi, Bad Homburg
2.1.4 Chromatography columns and media
Hiload™ -16/60-Superdex™ 200 pg GE Healthcare, Mu¨nchen
Hiprep™ -26/10-Desalting Column GE Healthcare, Mu¨nchen
Hiscreen™ -4.7mL-Capto MMC GE Healthcare, Mu¨nchen
Hiscreen™ -4.7mL-Capto Q GE Healthcare, Mu¨nchen
Hiscreen™ -4.7mL-Capto SP ImpRes GE Healthcare, Mu¨nchen
Hiscreen™ -4.7mL-Phenyl Sepharose High
Performance
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Butyl Sepharose 4 Fast Flow GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Butyl Sepharose High Perfor-
mance
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Butyl-S Sepharose 6 Fast
Flow
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Capto MMC GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Capto Q GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Capto S GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Capto SP ImpRes GE Healthcare, Mu¨nchen
HiTrap™ -1mL-KappaSelect GE Healthcare, Mu¨nchen
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HiTrap™ -1mL-Octyl Sepharose 4 Fast Flow GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Phenyl Sepharose 6 Fast Flow
(high sub)
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Phenyl Sepharose 6 Fast Flow
(low sub)
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Phenyl Sepharose High Per-
formance
GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Protein L GE Healthcare, Mu¨nchen
HiTrap™ -1mL-Protein G GE Healthcare, Mu¨nchen
KappaSelect, 25mL GE Healthcare, Mu¨nchen
CaptureSelect IgG-CH1 Affinity Matrix Life Technologies, Darmstadt
MediaScout® Columns 10mL Atoll, Weingarten
Tricorn 5/20 columns GE Healthcare, Mu¨nchen
MAbPac™ SCX-10 RS, 5 µm BioLC™
2.1x50mm
Thermo Scientific, Waltham, MA/USA
Superdex™ 200 Increase 10/300 GL GE Healthcare, Mu¨nchen
TOSOH TSK-Gel® G3000 SWXL 7,8x300;
5 µm
Tosoh Biosciences, Darmstadt
2.1.5 Buffers and media
2.1.5.1 Cell culture
IMDM-complete medium IMDM
10% FCS (heat inactivated 1 h 56 °C)
4mM L-Glutamine
100U/ml Penicillin
100 µg/ml Streptomycin
1 x Sodium pyruvate
1 x MEM-NEAA
50 µM β-Mercaptoethanol
RPMI-complete medium RPMI
10% FCS (heat inactivated 1 h 56 °C)
4mM L-Glutamine
100U/ml Penicillin
100 µg/ml Streptomycin
1 x Sodium pyruvate
1 x MEM-NEAA
50 µM β-Mercaptoethanol
Cryopreservation medium 4 °C 45% fresh cell culture medium
45% conditioned medium (supernatant of
centrifuged cells)
10% DMSO
CDM4PERMAb + 4mM L-Glutamine CDM4PERMAb
4mM L-Glutamine
Efficient Feed B + 40mM L-Glutamine Efficient Feed B
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40mM L-Glutamine
Trypan blue solution 0.1% Trypan blue in DPBS
2.1.5.2 Chromatography
Buffer recipies adjusted to 20 °C ˘ 2 °C
KappaSelect
0.1M Glycine 0.1M Glycine
(pH 2.5) in water (bidest)
adjust pH with HCl (36%)
Anion exchange chromatography (AIEX)
50mM Tris 45mM Tris Base
(pH 9.3 Cond. 0.5mS/cm) 5mM Tris-HCl
in water (bidest)
50mM Tris 5mM Tris Base
(pH 7.2 Cond. 4mS/cm) 45mM Tris-HCl
in water (bidest)
50mM Tris 18.45mM Tris Base
(pH 8.0 Cond. 3mS/cm) 31.55mM Tris-HCl
in water (bidest)
50mM Tris 18.45mM Tris Base
(pH 8.0 Cond. 80mS/cm) 31.55mM Tris-HCl
1M NaCl
in water (bidest)
150mM Tris 145mM Tris Base
(pH 9.60) 5mM Tris-HCl
in water (bidest)
Cation exchange chromatography (CIEX)
20mM Phosphate 20mM NaH2PO4
(pH 6.22) adjust pH with NaOH (10M)
in water (bidest)
20mM Phosphate 20mM NaH2PO4
(pH 8.5) adjust pH with NaOH (10M)
in water (bidest)
20mM Phosphate 20mM NaH2PO4
(pH 7.3 Cond. 3.0mS/cm) adjust pH with NaOH (10M)
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adjust Cond. With NaCl (1M)
in water (bidest)
20mM Phosphate 20mM NaH2PO4
(pH 7.3 Cond. 80mS/cm) adjust pH with NaOH (10M)
1M NaCl
in water (bidest)
20mM Phosphate 20mM NaH2PO4
(pH 7.3 Cond. 150mS/cm) adjust pH with NaOH (10M)
2M NaCl
in water (bidest)
20mM Phosphate 20mM NaH2PO4
(pH 7.3 Cond. 15mS/cm) adjust pH with NaOH (10M)
123mM NaCl
in water (bidest)
150mM HEPES 150mM HEPES
(pH 8.00) adjust pH with NaOH (10M)
in water (bidest)
Hydrophobic interaction chromatography (HIC)
1M Ammonium sulfate / 50mM Tris 1M Ammonium sulfate
(pH 8.00 Cond. 130mS/cm) 18.45mM Tris Base
31.55mM Tris-HCl
in water (bidest)
50mM Tris 18.45mM Tris Base
(pH 8.00 Cond. 3.0mS/cm) 31.55mM Tris-HCl
in water (bidest)
50mM Tris 81.3mM Ammonium sulfate
(pH 8.00 Cond. 18.5mS/cm) 18.45mM Tris Base
31.55mM Tris-HCl
in water (bidest)
1M Ammonium sulfate 1M Ammonium sulfate
(Cond. 130mS/cm)
Multimodal chromatography (MMC)
100mM Acetate / 50mM Phosphate / 100mM Sodium acetate
20mM Succinate 50mM NaH2PO4
(pH 5.0) 20mM Sodium succinate
adjust pH with HCl (36%)
100mM Acetate / 50mM Phosphate / 100mM Sodium acetate
20mM Succinate 50mM NaH2PO4
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(pH 8.5) 20mM Sodium succinate
adjust pH with NaOH (10M)
25mM Phosphate 25mM NaH2PO4
(pH 7.00 Cond. 4.3mS/cm) adjust pH with NaOH (10M)
in water (bidest)
25mM Phosphate 25mM NaH2PO4
(pH 7.00 Cond. 80mS/cm) adjust pH with NaOH (10M)
1M NaCl
in water (bidest)
25mM Phosphate 25mM NaH2PO4
(pH 7.00 Cond. 20mS/cm) adjust pH with NaOH (10M)
173mM NaCl
in water (bidest)
25mM Phosphate 25mM NaH2PO4
(pH 7.00 Cond. 63mS/cm) adjust pH with NaOH (10M)
687mM NaCl
in water (bidest)
2.1.5.3 SDS-PAGE
Coomassie staining solution 20 % Roti Blue 5x
20% Methanol
60% water (bidest.)
Destain solution water (bidest.)
Laemmli Sample Buffer (non-reduced) Laemmli Sample Buffer
Laemmli Sample Buffer (reduced) 10% β-Mercaptoethanol
in Laemmli Sample Buffer
Electrophoresis buffer 10% 10 x Tris/Glycine/SDS Buffer
in water (bidest.)
2.1.5.4 ELISA
Wash buffer 0.05% Tween® 20
in DPBS
Blocking solution 0.05% Tween® 20
10% BSA
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in DPBS
Dilution buffer 2.5% BSA
in DPBS
Stop solution 1M Phosphoric acid
2.1.5.5 Isoelectric focusing electrophoresis
Fixation solution 4% Sulfosalicylic acid
12.5% Trichloroacetic acid
30% Methanol
in water (bidest.)
Conditioning solution 4% Sulfosalicylic acid
27% Isopropanol
30% Acetic acid
in water (bidest.)
Staining solution 4% Sulfosalicylic acid
27% Ethanol
10% Acetic acid
0.04% Coomassie R250 (Brilliant blue R)
0.5% CuSO4
in water (bidest.)
Destaining solution 4% Sulfosalicylic acid
40% Methanol
10% Acetic acid
in water (bidest.)
2.1.5.6 Flow cytometric analysis
FACS buffer 0.01% NaN3
1% FCS (heat inactivated)
in DPBS
2.1.6 Plasmids
Plasmid pGH2-1353 (see figure 2.1) was designed for transfection of 25-CHO-S cells
to express antibody NF-CUN297Q. Design and synthesis of the plasmid was per-
formed by Dr. Ludger Grosse-Hovest, head of R&D at Synimmune GmbH and En-
telechon GmbH respectively. The DNA sequence coding for the bispecific antibody
was codon-usage-optimized for hamster cells. The Plasmid was produced under
animal-component-free conditions.
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Figure 2.1: Plasmid chart of expression vector pGH2-1353 The plasmid backbone of the
11022 bp plasmid pGH2-1353 is based on the plasmid pUC-Neo shown as an black inner arch. pUC-
Neo carries a beta-lactamase operon (bla; Ampicillin resistance), an origin of replication (pUC-ori),
and a neomycin resistance cassette. The expression of the neomycin resistance gene (APH(3’)-II)
is controlled by the SV40 promoter and polyA-region. The expression of the light and heavy chain
of the bispecific antibody fragment is independently controlled by the human Cytomegalovirus
Major Immediate-Early Promoter-Enhancer element (hCMV-MIE) and the termination signal of
the bovine growth horme (BGH). 4G8-light = cDNA for the variable and constant domain of the
light chain of antibody 4G8; 4G8-heavy = cDNA for the variable, constant CH1, modified hinge
and modified CH2 domain of antibody 4G8; CD3-scFv = variable heavy and light chain domains
of antibody UCHT1 linked by a Glycin-Serine linker. Restriction enzyme sites for uniquely cut-
ting enzymes and the sites of the fusion of restriction enzyme sites used for cloning, are indicated.
Design and synthesis of the plasmid was performed by Dr. Ludger Grosse-Hovest, head of R&D at
Synimmune GmbH and Entelechon GmbH respectively. (© Synimmune GmbH)
2.1.7 Antibodies
Antibodies used for this thesis are listed in table 2.11.
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Table 2.11: Antibodies
Notation Specificity Species Conjugate Source of supply
GaH-Fc human Fc part goat (polyclonal) none Dianova, Hamburg
GaH-Fc-PE human Fc-part goat (polyclonal) R-Phycoerythrin Dianova, Hamburg
GaM-IgG-Biot mouse IgG goat (polyclonal) Biotin Dionova, Hamburg
NF-CUN297Q (SP2/0) FLT3 x CD3 mouse/human none M. Durben, Tu¨bingen
NP-C16N297Q (SP2/0) PSMA x CD16 mouse/human none F. Vogt, Tu¨bingen
NP-CUN297Q (SP2/0) PSMA x CD3 mouse/human none F. Vogt, Tu¨bingen
MaH-κL-PE human κ light chain mouse (monoclonal) R-Phycoerythrin Biolegend, San Diego, USA
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2.1.8 Cell lines
Table 2.12: Cell lines
Name Description Source of supply
25-CHO-S ovarian cancer cell line of chinese hamster (CHO-K1) Celonic AG, Basel, CH
Jurkat human T-cell lymphoma D. Schendel, Mu¨nchen
NALM-16 human acute lymphoblastic leukemia DSMZ, Braunschweig
2.1.9 Kits
Table 2.13: Kits
Kit Supplier
ADCC Reporter Bioassay, Core Kit Promega, Mannheim
CaptureSelect™ Kappa Select Leakage ELISA Kit Life technologies, Darmstadt
CHO HCP ELISA Kit, 3G (F550) Cygnus technologies,
Southport, NC/USA
PrepSEQ® Residual DNA Sample Preparation Kit Life technologies, Darmstadt
PROTEOSTAT® Thermal Shift Stability Assay Kit Enzo Life Sciences, Lo¨rrach
ResDNASEQ® Quantitative CHO DNA Kit Life technologies, Darmstadt
2.1.10 Software
Table 2.14: Software
Software Supplier
CellQuestPro Becton-Dickinson, Heidelberg
Chromeleon 7.2 Thermo Scientific, Braunschweig
Modde 10.0 Umetrics, Frankfurt
MS Office Microsoft, Unterschleißheim
PLA-2.1 Stegmann Sytems, Rodgau
Sigma Plot V12.0 SPSS, Mu¨nchen
TeXnicCenter 2.02 ToolsCenter.org (Open Source Project)
Unicorn 5.11/5.31 GE Healthcare, Mu¨nchen
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2.2 Methods
2.2.1 Cell culture
All cell lines and human peripheral blood mononuclear cells (PBMC) were culti-
vated at 37°C, 5% CO2 and 90% rel. humidity. For cultivation of CHO cells basal
medium CDM4PERMAb supplemented with 4mM L-Glutamine and feed medium
(Efficient Feed B) supplemented with 40mM L-Glutamine were used. NALM-16
cell line and human PBMC were cultivated in IMDM-complete medium; Jurkat cell
line was cultivated in RPMI-complete medium.
2.2.1.1 Thawing of cryopreserved cells
CHO cells: One cryo vial containing cryopreserved cells was thawed in a water bath
at 37 °C. Subsequently, the cell suspension was transferred into a 15mL PP tube.
10mL of cold (4 °C) basal medium was added slowly (approximately 1min.). The
suspension was centrifuged (210ˆ g for 5min.) and the supernatant was discarded.
The cells were resuspended in 25mL pre-warmed (37 °C) basal medium and were
transferred into a 125mL disposable Erlenmeyer flask. After 24 h of cultivation, cell
culture medium was exchanged by centrifugation (210ˆ g for 5min.) by 25mL of
new pre-warmed (37 °C) basal medium.
NALM-16 and Jurkat cells: One cryo vial containing cryopreserved cells was thawed
in a water bath at 37 °C. The cell suspension was transferred into a 75 cm² cell culture
flask with 10mL of pre-warmed (37 °C) cell culture medium.
2.2.1.2 Isolation of human PMBC
PMBC were extracted from heparinized blood from human donors (mandatory
premise: ethics approval). 12.5mL blood was diluted with 12.5mL DPBS and
carefully applied to 12.5mL “biocoll separating solution”. The preparation was cen-
trifuged at 670ˆ g for 30min. without brake. PBMC were extracted with a 10mL
serological pipette and the same volume of DPBS was added. The PBMC solution
was centrifuged at 210ˆ g for 10min. and PBMC were resuspended in 25mL DPBS.
The cells were washed two times with 25mL DPBS via centrifugation at 210ˆ g for
10min. and were subsequently resuspended in IMDM-complete medium to obtain
desired cell density.
2.2.1.3 Viable Cell count
Viability of cells was assessed by trypan blue staining. Trypan blue solution was
added to cell suspension in a 96-well-plate in a ratio of 1:2. Subsequently, the amount
of viable cells was determined with a Neubauer counting chamber and an inverse
microscope. The amount of viable cells per large square multiplied with 104 and the
dilution factor results in the viable cell density per mL cell culture medium.
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2.2.1.4 Cultivation and standard fermentation protocol for antibody
production
CHO cells were cultivated in suspension cell culture in disposable Erlenmeyer flasks
on a shaker with 150 rpm (rotation diameter d = 2.5 cm). In expansion phase, viable
cell density was maintained between 0.5 and 3.0 x 106 viable cells per mL. In late-
logarithmic phase at 3 - 6 x 106 viable cells per mL, 10% (V/V) feed medium was
added to maintain a high cell density in stationary growth phase of 6 – 8 x 106
viable cells per mL. In intervals of 2 days, additional 10% (V/V) feed medium was
added to the cell culture. Cells were harvested when cell viability fell below 80%
after three feed additions. Cells were cultivated in Erlenmeyer flasks (V = 125mL,
250mL and 500mL) and Tubespin bioreactors (V = 600mL).
NALM-16 and Jurkat cells were cultivated in cell culture flasks (A = 75 cm²). Viable
cell density was maintained between 0.5 and 2.0 x 106 viable cells per mL.
2.2.1.5 Fermentation in a 10 L wave-reactor
Cultivation of CHO-cells was performed in a Cultibag RM 2L and 20L optical.
Inoculum for Cultibag RM 2L optical was cultivated according to standard fermen-
tation protocol for antibody production until expansion phase. 3 x 108 viable cells
in expansion phase were inoculated into 300mL basal medium in a Cultibag RM 2L
optical. Cultivation conditions were 37 °C, 5% CO2, rocking angle of 6° and rocking
rate of 20 rpm. In expansion phase, cell viability was maintained between 0.5 and
3.0 x 106 viable cells per mL. Expansion phases were 300mL to 900mL in Cultibag
RM 2L optical and 900mL to 2000mL to 3750mL and to 6700mL in Cultibag RM
20L optical. In late-logarithmic phase of 3 - 6 x 106 viable cells per mL, 10% (V/V)
feed medium was added to maintain a high cell density in stationary growth phase
of 6 – 8 x 106 viable cells per mL. In intervals of 2 days, additional 10% (V/V)
feed medium was added to cell culture. Cells were harvested when cell viability fell
below 80% after three feed additions.
2.2.1.6 Cell harvesting
Cell culture supernatant was centrifuged twice at 6000ˆ g for 30min. Subsequently,
the supernatant was filtered through a 0.22 µm filter and sodium azide was added
to a final concentration of 0.02%. pH was adjusted to 7 – 8 with 40% NaOH.
2.2.1.7 Cryopreservation
Cell suspension containing 107 cells was centrifuged (210ˆ g for 5min.). Cells were
resuspended in 1mL cold cryopreservation medium (4 °C) and transferred to a 2mL
cryo vial. The cryo vial was transferred to a Nalgene™ Cryo 1 °C Freezing Container
and stored at -80 °C. 2 days to 2 months later the cryo vial was transferred to the
vapor phase of liquid nitrogen (-140 °C).
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2.2.1.8 Stable Transfection of Chinese hamster ovary (CHO) cells for
antibody production
For stable transfection via electroporation 2 x 107 25-CHO-S cells were washed three
times with 25mL of fresh, cold (4 °C) basal medium (centrifugation at 210ˆ g for
5min.). Cells were resuspended in 200 µL fresh basal medium (4 °C) and transferred
to a cuvette for electroporation which was pre-cooled on ice. 10 µg of linearized
plasmid DNA was added to the suspension. Electroporation was performed with U
= 230V and C = 975 µF. Subsequently, the cell suspension was transferred to 12mL
pre-warmed cell culture medium and a 1:2 serial dilution until 1:128 was performed.
50 µL was pipetted into each well of 96-well-plates. 24 h later 50 µL of cell culture
medium containing 2mg/mL selection antibiotic G418 was added to each well. Two
to four weeks later, the supernatant of growing cells was assessed in an ELISA for
the presence and concentration of produced antibody. High-producer clones were
expanded to 3mL in 6-well-plates and subsequently diluted to 1 cell per well in a
96-well plate containing basal medium with 1 x ClonaCell™CHO ACF Supplement.
Two to four weeks later, the supernatant of growing monoclonal cells was assessed in
an ELISA for the presence and concentration of produced antibody. High-producer
clones were expanded to 3mL in 6-well-plates and subsequently diluted to 1 cell per
well in a 96-well plate containing basal medium with 1 x ClonaCell™CHO ACF Sup-
plement. Two to four weeks later, the supernatant of growing cells was assessed in
an ELISA for the presence and concentration of produced antibody. High-producer
clones were expanded to 3mL in 6-well-plates and subsequently to 10mL in TPP-
Bioreactors (V = 50mL) until standard cultivation was performed.
2.2.2 Purification
2.2.2.1 pH- and conductivity-measurement of buffers
For pH and conductivity-measurement, a SevenMulti™ with pH and conductivity
expansion units was used. The device was used according to manufacturer’s instruc-
tions.
2.2.2.2 Liquid chromatography system A¨KTA purifier 100
The Fast protein liquid chromatography (FPLC) system A¨KTA purifier 100 was op-
erated with control software Unicorn 5.11 according to manufacturer’s instructions.
The operation temperature for the chromatography applications was set to 21 ±
1 °C in a climate cabinet.
Prior to use, chromatography columns were equilibrated with at least three column
volumes of indicated buffer A. Standard detection methods were the measurement of
optical absorbance at λ = 280 nm (OD280) and conductivity as well as the measure-
ment of the system pressure before the column. The eluted peaks were fractionated
by peak detection (OD280) and collected into 5mL round bottom tubes.
Biospecific interaction chromatography (affinity chromatography) for initial pu-
rification from cell culture supernatant (pH 7-8) included chromatographic resins
such as Protein A, G and L, CaptureSelect IgG-CH1 and KappaSelect. Polishing
applications included Anion exchange chromatography (AIEX), Cation exchange
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chromatography (CIEX), Hydrophobic interaction chromatography (HIC) and Mul-
timodal chromatography (MMC). A detailed list of the applied columns and resins
can be found in table 2.1.4 at page 26.
Columns with a bed volume of V = 1mL and bed height of h = 2.4 cm were used
for Determination of dynamic binding capacity at 10% breakthrough for
affinity media (DBC10%) and for Evaluation of polishing strategies. If not
stated differently, the columns were operated with a flow rate of 1mL/min. and
are referred as “Hitrap™ 1mL columns”. A 5mL sample loop was used for sample
application.
For characterization and separation of the monomer and the product-related impu-
rities, a “Hiload™ -16/60-Superdex™ 200 pg” Size-exclusion chromatography (SEC)-
column was used. This column was operated with a flow rate of 1.2mL/min. A
5mL sample loop was used for sample application.
Two scalable models of the production process with process-realistic flow rates
and protein loading capacity were used: the buffer verification model and the
small-scale model. The buffer verification model was used to verify previously
evaluated chromatography conditions. The small-scale model was used to simulate
a scaled-down production process in the scale of 1:100. This means, that instead of
100 L cell culture supernatant only 1 L is purified and the volume of the small-scale
columns is „ 10mL instead of 1 L. The column dimensions of the production process
and the two process models are found in table 2.15.
The linear flow rates in the production process are standard values according to
manufacturer’s instructions (see table 2.15). For abidance of process-realistic flow
rates, the following premises must be applied for both process models:
The chromatography columns of the buffer verification model are equipped with the
half bed height of the process scale columns. Thus, in order to keep residence time
constant, the linear flow rate must be decreased by the factor of two (see equations
2.1 and 2.2). The chromatography columns of the small-scale model are equipped
with the same bed height as the process scale columns. Therefore, the linear flow
rate must be kept constant to achieve the same residence time .
residence time [h] “
bed height [cm]
linear flow rate [cm/h]
(2.1)
linear flow rate [cm/h] “
volumetric flow rate [mL/h]
cross sectional area of column [cm²]
(2.2)
The 1L KappaSelect column of the production process purifies a maximum of
12950mg KappaSelect binding protein (KSBP) per production batch (see discus-
sion part 4.2 at page 116). This results in 60.9mg KSBP for the buffer verification
model and 121.7mg KSBP for the small-scale model when the protein load is scaled
according to column volumes. After application of a security factor, the applied
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amount of protein was 70.5mg for the buffer verification model and 130mg for the
small-scale model. Column dimensions, flow rates and protein binding properties
for process scale, buffer verification model and small-scale model are summarized
in table 2.15. The small-scale model was only applied for KappaSelect, AIEX and
HIC.
For the buffer verification model, a 150mL superloop was used for sample applica-
tion. For the small-scale model, a direct load via the system pumps was performed
for sample application.
Table 2.15: Column dimensions, flow rates and protein binding properties of Process
scale, Buffer verification model and Small-scale model; The small-scale model was only
applied for KappaSelect, AIEX and HIC; The applied amount of KappaSelect binding protein to
the process scale KappaSelect column will be discussed in discussion part 4.2 at page 116; AC =
Affinity Chromatography; AIEX = Anion exchange chromatography; CIEX = Cation exchange
chromatography; HIC = Hydrophobic interaction chromatography; MMC = Multimodal chroma-
tography
Process Buffer verification Small-scale
Characteristics scale model model
Column volume [mL] 1000 4.7 9.4
Bed height [cm] 20 10 20
Cross sectional area [cm²] 50 0.466 0.466
Appl. of KSBP
theory [mg] 12950 60.9 121.7
Appl. of KSBP
with security factor [mg] N/A 70.5 130
Lin. flow rate [cm/h]
AC: KappaSelect 400 200 400
AIEX/CIEX/MMC 150 75 150 (only AIEX)
HIC: Phenyl HP 120 60 120
Vol. flow rate [mL/min.]
AC: KappaSelect 333.33 1.55 3.11
AIEX/CIEX/MMC 125 0.59 1.18 (only AIEX)
HIC: Phenyl HP 100 0.47 0.94
2.2.2.3 Nanofiltration
Nanofiltration was performed with the support of “Asahi Kasei” Corporation. Three
tangential flow filters were tested: Planova™ 15N, Planova™ 20N and Planova™
BioEx with filtration surface of 0.001m² each. A filtration device was set up accord-
ing to figure 2.2.
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Figure 2.2: Filtration procedure - Nanofiltration
A tangential flow filtration (TFF) was performed. Filtration liquid was placed into the pressure
vessel and was filtrated into the receiving vessel with 98 kPa trans-membrane pressure (TMP) for
Planova™ 15/20N and with 330 kPa TMP for Planova™ BioEx.
Prior to use, all filters were flushed with 20mL water for injection with a maxi-
mum of 98 kPa trans-membrane pressure (TMP) with compressed nitrogen and a
leakage test was performed (bubble point test, see below). Subsequently, filters
were flushed with 20mL DPBS with a maximum of 98 kPa. Antibody solution was
placed into the pressure vessel and was filtrated with indicated maximum TMP of
filters: Planova™ 15N and 20N with a maximum TMP of 98 kPa and Planova™
BioEx with a maximum TMP of 330 kPa. Filtration was performed with constant
pressure. The filtrated volume was assessed with a measuring cylinder every 10min.
for Planova™ 15/20N and every 5min. for Planova™ BioEx. The required filtration
volume was calculated for each filter individually. After use, all filters were flushed
with 20mL water for injection with a maximum of 98 kPa TMP and a leakage test
(bubble point test) was performed.
Bubble point test:
After flushing the test filters with water for injection, the pressure vessel was filled
with nitrogen gas and a pressure of 98 ± 5 kPa was applied to the filtration mem-
brane. For the next 20 sec., the filter membrane was visually inspected for emerging
nitrogen bubbles. The test is regarded as passed if no bubbles emerge.
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2.2.3 Characterization of the active pharmaceutical ingredi-
ent and product-related impurities
2.2.3.1 Determination of antibody concentration
For determination of antibody concentration, the protein absorbance at 280 nm was
used. According to the Beer-Lambert law, the concentration can be calculated with
the equation for molar extinction (see 2.3). A useful conversion is equation 2.4 for
specific extinction, which results in a concentration in [g/L].
E “ lg
ˆ
I0
I
˙
“ ǫ ˚ c ˚ d (2.3)
E “ E0.1%1 cm ˚ c
1
˚ d (2.4)
E0.1%1 cm “ ǫ{M (2.5)
E molar extinction
I0 reference intensity
I sample intensity
ǫ molar extinction coefficient [L/(mol*cm)]
c concentration [mol/L]
d path length [cm]
E0.1%1 cm specific extinction [L/(g*cm)]
c
1
concentration [g/L]
M molar mass [g/mol]
The specific extinction for antibody solutions of a concentration of 1 g/L and a path
length of 1 cm is 1.37 L/(g*cm).
2.2.3.2 ELISA for antibody concentration
Coating reagent:
GaH-Fc; dilution 1:1000 in DPBS
Biotinylated reagent:
GaM-IgG-Biot; dilution 1:10.000 in dilution buffer
Standard solution:
NF-CUN297Q (SP2/0); dilution according to work list in DPBS
50 µL of diluted capture antibody was applied to each well of an ELISA Plate “Nunc
F96 Maxisorp” and incubated over night at 4 °C. The content of the wells was dis-
carded and 100 µL of blocking solution was added to each well. After an incubation
period of 1 h at room temperature, the content of the wells was discarded and the
plate was washed three times with wash buffer. 50 µL of standard or sample was
added to each well indicated on work list. After 1 h of incubation at room temper-
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ature, the content of the wells was discarded and the plate was washed four times
with wash buffer. Detection antibody was diluted in dilution buffer and 50 µL was
added per well. After 1 h of incubation at room temperature, the content of the wells
was discarded and the plate was washed four times with wash buffer. Steptavidin-
polyHRP was diluted 1:10000 in dilution buffer and 100 µL was added to each well.
After 30min. incubation at room temperature, the content of the wells was discarded
and the plate was washed six times with wash buffer. The 1:1-mixture of “TMB
Microwell Peroxidase System (2-C) solution” was prepared and 100 µL was added to
each well. The plate was incubated for 5min. in the dark and 50 µL of 1M Phospho-
ric acid was added. OD450 was measured with an ELISA plate reader. A standard
curve was calculated using 4-Parameter logistic-fit-analysis.
2.2.3.3 Isoelectric focusing electrophoresis
Samples were diluted 1:2 in “IEF Sample Buffer”. 1 to 5 µg protein was applied to
each well of “Criterion™ Precast Gel IEF pH 3-10, 1.0mm”. 20 µL of reconstituted
“Isoelectric Focusing Calibration Kit High Range pI (pH 5 - 10.5)” was applied to the
gel as a IEP standard. Running buffer for the anode was 1:10 diluted “10 x Anode
Buffer”. Running buffer for the cathode was 1:10 diluted “10 x Cathode Buffer”.
Operating conditions were U = 100V for 60min., U = 250V for 60min. and U =
500V for 30min. in an electrophoresis cell. Gel was fixed with Fixation solution
for 30min. followed by conditioning with Conditioning solution for 5min. Gel was
stained with ‘Staining solution for 2 h and destained with Destaining solution for
1 h. The gel was photographed using a CCD camera.
2.2.3.4 SEC / UHPLC
Size exclusion chromatography (SEC) was performed using a UHPLC-system
“Dionex™ UltiMate™ 3000 BioRS” equipped with two columns: “TOSOH TSK-
Gel G3000 SWXL 7,8x300; 5 µm” or “Superdex 200 Increase 10/300 GL”. The
Superdex column was introduced later and elicits better resolution of antibody
aggregates, monomers and fragments. A maximum of 10 µg or 50 µL of sample was
applied per run. The system was operated at 500 µL/min. with DPBS. Proteins
were detected via OD at λ = 220 nm (OD220). Chromatograms were compared to
an external gel filtration standard (Bio-Rad). Data acquisition and analysis was
performed via control software Chromeleon 7.2.
2.2.3.5 CIEX / UHPLC
Cation Exchange chromatography was performed using a UHPLC-system “Dionex™
UltiMate™ 3000 BioRS” equipped with column “MAbPac SCX-10 RS, 5 µm”. 10 µL
sample containing 10 µg protein was diluted 1:2 in water and again 1:3 in “pH
gradient buffer A (pH 5.60)”. A maximum of 60 µL of diluted sample was applied
per run. The system was operated at 500 µL/min with “pH gradient buffer A (pH
5.60) and B (pH 10.2)”. Proteins were detected via OD at 280 nm. Data acquisition
and analysis was performed via control software Chromeleon 7.2.
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2.2.3.6 SDS-PAGE
Samples were diluted 1:2 in “laemmli sample buffer”. When performing a SDS-
PAGE with reducing conditions, 10% β-mercaptoethanol was added. Samples were
incubated at 75 °C for 5min. in a thermo cycler. 2 µg of sample was applied to each
well of a “Mini-PROTEAN® TGX™ 10%-Gel“. 5 µL of “PageRuler™ Prestained
Protein Ladder” was applied to the gel as protein standard. Operating conditions
were U = 200V for 30min. in an electrophoresis cell with Tris/Glycine/SDS buffer.
Gels were stained in coomassie staining solution for 1 h followed by destain solution
for 2 h.
2.2.4 Process-related impurities
2.2.4.1 Host cell protein ELISA for CHO cells
A commercially available ELISA kit was used: “CHO HCP ELISA kit, 3G (F550)”.
All required solutions were supplied with the kit. ELISA was performed according
to the manufacturer’s instructions.
Pre-coated 96-well plates were incubated with 100 µL anti-CHO:HRP and 50 µL
sample or standard for 2 h at 180 rpm on a microtiter plate shaker. The content of
the wells was discarded and the plate was washed five times with washing solution.
100 µL TMB substrate was added and after an incubation period of 30min., 100 µL
stop solution was added. OD450 was measured with an ELISA plate reader. A
standard curve was calculated using 4-Parameter logistic-fit-analysis.
2.2.4.2 ELISA for determination of leached KappaSelect ligand
A commercially available ELISA kit was used: “CaptureSelect™ Kappa Select Leak-
age ELISA Kit”. The manufacturer’s instructions were modified (see below).
Coating reagent:
Goat IgG anti-KappaSelect affinity ligand; dilution 1:200 in DPBS
Biotinylated reagent:
Biotinylated Goat IgG anti-KappaSelect affinity ligand; dilution 1:200 in dilution
buffer
Standard solution:
CaptureSelect™ human Ig kappa affinity ligand, dilution according to work list in
protein-L purified NF-CUN297Q polished via AIEX-medium CaptoQ.
50 µL of diluted coating reagent was applied to each well of an ELISA Plate
“Nunc F96 Maxisorp” and incubated over night at 4 °C. The content of the wells
was discarded and the wells were washed five times with wash buffer. Subsequently
250 µL of blocking solution was added to each well and the plate was incubated
at room temperature for 30 min. on a microtiter plate shaker. The content of the
wells was discarded and the plate was washed one time with wash buffer. Standard
and samples were incubated at 95 °C for 15min. and centrifuged at 12,000ˆg for
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5min. 100 µL of standard or samples was added to each well indicated on work list.
After 1 h of incubation at room temperature, the content of the wells was discarded
and the plate was washed five times with wash buffer. Detection antibody was
diluted in dilution buffer and 100 µL was added per well. After 1 h of incubation
at room temperature, the content of the wells was discarded and the plate was
washed five times with wash buffer. Steptavidin-monoHRP was diluted 1:2500 in
dilution buffer and 100 µL was added to each well. After 30min. of incubation at
room temperature, the content of the wells was discarded and the plate was washed
five times with wash buffer and two times with water (bidest.). The 1:1-mixture of
“TMB Microwell Peroxidase System (2-C) solution” was prepared and 100 µL was
added to each well. The plate was incubated for 5min. in the dark and 50 µL of
1M Phosphoric acid was added. OD450 was measured with an ELISA plate reader.
A standard curve was calculated using 4-Parameter logistic-fit-analysis.
2.2.4.3 Host cell DNA quantitative PCR for CHO cells
Two commercially available kits were used: “PrepSEQ® Residual DNA Sample
Preparation Kit” and “ResDNASEQ® Quantitative CHO DNA Kit”
DNA extraction:
DNA extraction was performed according to manufacturer’s instructions. Samples
were diluted according to work list in DPBS containing additional 0.35M NaCl.
Protein residues are lysed via Protein K. DNA is concentrated via magnetic parti-
cles and eluted for analysis.
QPCR:
Quantitative PCR (QPCR) and evaluation was performed according to manufac-
turer’s instructions. QPCR war performed on a 7500 Fast Real-Time PCR system.
2.2.5 Biological activity
2.2.5.1 Flow cytometric analysis
Target cells NALM-16 or Jurkat were cultivated with high viability. Cells were
washed three times in FACS buffer (centrifugation at 670ˆ g for 3min.) and resus-
pended to a cell density of 106 cells/mL in FACS buffer. 100 µL of suspension was
transferred to each well of a round bottom plate, centrifuged (670ˆ g for 3min.)
and incubated with 50 µL of antibody solution for 30min. at 4 °C. Cells were
washed three times with FACS buffer (see above) and incubated with secondary
antibody linked to a chromophore for 30min. at 4 °C. Cells were washed three times
(see above) and resuspended in 200 µL FACS buffer and transferred to FACS tubes
0.5mL.
Flow cytometry was performed on a “FACSCalibur flow cytometer”. Data acqui-
sition and evaluation was performed using “CellQuestPro software”. Binding of
NF-CUN297Q to FLT3 was investigated using NALM-16 cells and binding to CD3
was investigated using Jurkat cells. The bispecific antibody was detected using
GaH-Fc-PE or MaH-κL-PE antibodies.
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2.2.5.2 Inactivation of target cells
Target cells were inactivated via radiation with 120Gy using a 137Cs source in a
“Gammacell 1000 elite” irradiation chamber.
2.2.5.3 T-cell proliferation Assay
T-cell proliferation induced by the FLT3ˆCD3 antibody was measured using a [3H]-
Thymidine incorporation assay. 105 PBMC in 50 µL IMDM-complete medium were
seeded into each well of a 96-well plate. 105 inactivated target cells NALM-16 in
50 µL IMDM-complete medium were added to each well. Subsequently, the antibody
was diluted in IMDM-complete medium and 50 µL of each dilution was added to
wells indicated on work list. The 96-well plate was incubated for 72 h and then
pulsed with 0.5 µCi/well [3H]-Thymidine. After 20 h cells were harvested on Printet
FiltermatA and precipitated radioactivity was determined in a liquid scintillation
counter.
2.2.5.4 Potency Assay (Promega)
This Assay was performed to determine the potency of NF-CUN297Q and product-
related impurities. A commercially available kit was used: “ADCC Reporter Bioas-
say, Core Kit”. The Potency assay was performed according to the manufacturer’s
instruction with NALM-16-cells as target cells. The effector to target ratio was 1:2
(30,000 NALM-16 and 60,000 effector cells per assay).
The effector cells of this kit are Jurkat cells transfected with a Fc-receptor which
triggers the NFAT-activation path. A luciferase gene is linked to the NFAT-gene
and is co-expressed with NFAT. When adding luciferin and Adenosintriphosphate
(ATP), activation can be measured via luminescence intensity.
NF-CUN297Q does not work via classical ADCC because it does not bind to Fc-
receptors. However, Jurkat cells are T-cell-derived cells and therefore express a
T-cell-receptor and CD3, which also utilizes the NFAT-activation pathway. Thus,
this assay can be used to assess NF-CUN297Q activity.
Analysis and calculation of EC50-values was performed via “PLA-software 2.1”.
2.2.6 Stability and formulation development
Experiments for optimization of product stability were planned, performed and eval-
uated in an Design of experiment-approach (Fisher, 1990). The usual one factor at a
time-approach was not suitable due to the fact that the investigated factors influence
each other and the responses. Data analysis was performed via software “Modde
10.0”.
2.2.6.1 Differential scanning fluorimetry
This assay is applied to determine the melting temperature Tm1, or half-maximal
denaturation temperature, of NF-CUN297Q in a certain buffer. A commercially avail-
able kit was used for this assay: “ProteoStat® Thermal Shift Stability Assay Kit”
Fluorescence of the dye at 610 nm is induced when bound to hydrophobic residues
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of a protein. Thus, the protein of interest is stressed by increasing temperature
which induces unfolding and therefore presentation of hydrophobic residues. Suit-
able formulation buffers contribute to a higher resistance of a protein to temperature-
induced unfolding. The experiments were performed in a “7500 Fast Real-Time PCR
system”. One part “10 x assay buffer” was diluted in 9 parts water for injection. One
part “1000 x ProteoStat® TS Detection Reagent” was diluted in 99 parts “1 x Assay
buffer”. For each reaction 22.5 µL NF-CUN297Q [1mg/mL] in a certain buffer was
mixed with 2.5 µL 10 x ProteoStat® TS Detection Reagent. The following reaction
plates were used: “Fast optical 96-well reaction plate”. Temperature was increased
from 25 °C to 100 °C with 1 °C/min. Fluorescence was assessed at 610 nm. Fluo-
rescence was plotted against temperature (see figure 2.3). The maximum of the
first derivative of this plot represents the temperature, where half of the protein is
unfolded and is referred to as melting temperature Tm1.
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Figure 2.3: Differential scanning fluorimetry - Example formulation buffer
Buffer composition: NF-CUN297Q [1mg/mL] in 20mM Histidine pH 6.2, 0.075% Tween
® 20,
50 g/L Trehalose, 75mM NaCl; Tm1 = 70.1 °C
2.2.6.2 Thermal stress test
This assay was used to determine the amount of aggregation of a protein in a cer-
tain buffer resulting from long-term constant thermal stress. Study temperature
was 40 °C for a time period of one week for formulation screening experiment and
for four weeks for formulation optimization experiment. Samples were stressed in
an incubator “cellstar” and determination of aggregate and monomer content was
assessed via “Sec / UHPLC” with column “Superdex 200 Increase 10/300 GL”.
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An expression cell line and a fermentation protocol were developed for the efficient
production of bispecific antibody NF-CUN297Q. Subsequently, product-related im-
purities were identified and characterized. Process-related impurities were not char-
acterized because the CHO-based production process followed by biospecific interac-
tion chromatography can be regarded as well-known. Different purification strategies
were evaluated for their suitability of effectively separating the active pharmaceuti-
cal ingredient (API) from product- and process-related impurities. A purification
process was developed and the purification was verified with a so-called small-scale
model (1:100) of the production process. The performance of nanofilters was evalu-
ated to find a suitable filter for the production process. Finally, a suitable protein
formulation buffer was developed, which indicates high stability and a long shelf-life
of bispecific antibody NF-CUN297Q.
3.1 Cell line - Primary seed bank
The parental cell line 25-CHO-S, a CHO-K1 cell line adapted to suspension cell cul-
ture, was stably transfected with plasmid pGH2-1353 and selection was performed
using the aminoglycoside antibiotic G418. Plasmid pGH2-1353 was designed for
transfection of 25-CHO-S cells for expression of bispecific antibody NF-CUN297Q.
High-producer clones were identified by ELISA for antibody concentration at semi-
confluent growth in 96-well plates. After sequential subcloning and two single cell
cloning procedures, clone “T1/16/6-B5//E2/P2-G5/P1-A6” (designated “L2A6”)
was chosen for the generation of a primary seed bank (PSB). A production titer
of 35mg/L KappaSelect binding protein (KSBP) was obtained in the cell culture
supernatant of shaker flasks. For characterization of KSBP see results part 3.3.1 at
page 50.
Separate reports were generated for the plasmid construction (by Dr. Ludger Große-
Hovest) and for the generation of a PSB (by Gregor Neumann). The presentation
of those reports would exceed the scope of this thesis. The reports are administered
by Dr. Ludger Große-Hovest, Head of R&D at Synimmune GmbH.
3.2 Fermentation
Basal cell culture medium CDM4PERMAb and a fed-batch protocol for antibody
production was adopted from the fermentation process of 4G8SDIEM, the first
product of Synimmune GmbH. In the late-logarithmic growth phase of PSB-clone
“L2A6”, 10% (V/V) feed medium Efficient feed B supplemented with 40mM L-
Glutamine was added to cell suspension. 2 and 4 days later, additional 10% (V/V)
Efficient feed B supplemented with 40mM L-Glutamine was added.
This procedure resulted in a KSBP concentration of 165mg/L (with 55% monomer
content) in cell culture supernatant produced in shaker flasks. In addition, in a
10L wave-reactor fermentation a KSBP-titer of 110mg/L (with 55% monomer) was
achieved. This concentration is sufficient for production of the bispecific antibody
as discussed in chapter 4.2 at page 116.
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3.3 Development of a purification procedure
3.3.1 Identification and Characterization of product-related
impurities
After purification of bispecific antibody NF-CUN297Q from cell culture supernatant
with KappaSelect affinity chromatography medium, 4 Peaks appear in an elution
profile of size-exclusion chromatography (SEC)-separation on “Hiload™ -16/60-
Superdex™ 200 pg”’ (see figure 3.1). The proteins of the 4 Peaks were termed
KappaSelect binding protein (KSBP).
P1 as the first peak is assumed to be an aggregate. P2 as the largest peak is assumed
to be the monomer and P3 and P4 seem to be light chain dimer (LCD) and light
chain (LC), respectively (Knittler et al., 1995; Schlatter et al., 2005). In order to
verify these assumptions, SDS-PAGE and an isoelectric focusing electrophoresis was
performed. In addition, the proteins were further characterized by flow cytometric
analysis on cells expressing the antigen of interest. Finally, a T-cell proliferation
assay and a potency assay were performed to proof the absence of any biological
activity of the product-related impurities P1, P3 and P4.
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Figure 3.1: Product-related impurities - Preparative SEC-separation
A¨KTA Purifier 100
Column: Hiload™ -16/60-Superdex™ 200 pg;
Protein (KSBP): 5mg in 2mL;
Buffer: DPBS
Flow rate: 1.20mL/min
P1: Aggregate; P2: Monomer; P3: LCD; P4: LC
3.3.1.1 SDS-PAGE
The theoretical molecular weight of the monomer, LCD and LC was calculated with
the online bioinformatics resource portal “Expasy” (http://web.expasy.org/compute
pi/ (date of request: 01.07.2015)). For amino acid sequence of NF-CUN297Q see
chapter 5.2 at page 138. For calculation of the molecular weight (MW) of the
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monomer, the heavy and light chain sequences were plotted in series. For calcula-
tion of the MW of LCD, the LC sequence was plotted twice. A calculation of the
MW of the aggregate is not possible. Theoretical and experimentally determined
MW of KSBP are summarized in table 3.1
At the SDS-PAGE gel under unreduced condition (see figure 3.2 A), P1 is hardly
visible. This may be due to the fact that this aggregate is too large to migrate into
the gel. The apparent molecular weight of P2 is 23 kDa heavier than the calculated
weight of the monomer, the MW for P3 and P4 are in the range for LCD and for
LC.
At the SDS-PAGE gel under reduced condition (see figure 3.2 B), P1 shows bands
at 70 and 30 kDa, which might represent heavy and light antibody chains indicating
that the aggregate consists at least partly of aggregated monomer. P2, P3 and P4
exhibit the correct sizes for heavy and light chains respectively. Thus, the reduced
samples indicate that P1 is an aggregate, P2 is the monomer, P3 is LCD and P4
is LC. The reason why LC appears to be smaller under unreduced conditions can
be explained by the presence of one intramolecular disulphide bond per antibody
domain. This results in an incomplete unfolding of the protein and therefore a
smaller apparent size. In conclusion, the nature of the product-related impurities
has been clearly defined.
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Figure 3.2: Product-related impurities - SDS-PAGE
SEC fractions of figure 3.1 at page 50 (P1-4) and purified KSBP (Pre); A = unreduced condition;
B = reduced condition; molecular weights of the samples are summarized in table 3.1; marker:
“PageRuler™ Prestained Protein Ladder”
3.3.1.2 Isoelectric focusing electrophoresis
Theoretical isoelectric points (IEPs) were calculated with the online bioinformat-
ics resource portal “Expasy” (http://web.expasy.org/compute pi/ (date of request:
01.07.2015)). For amino acid sequence of NF-CUN297Q see appendix part 5.2 at page
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Table 3.1: Product-related impurities - SDS-PAGE
Molecular weight of SEC fractions of figure 3.1 at page 50 (P1-4) in kDa; experimental and theo-
retical data of KappaSelect binding protein (KSBP)
Unreduced condition Reduced condition
Fraction Theoretical Experimental Theoretical Experimental
P1 = Aggregate N/A N/A N/A „ 70/30
P2 = Monomer 87 „ 110 63.8/23.4 „ 70/30
P3 = LCD 46.7 „ 40 23.4 „ 30
P4 = LC 23.4 „ 20 23.4 „ 30
138. For calculation of the IEP of the monomer, the heavy and light chain sequences
were plotted in series. For calculation of the IEP of LCD, the LC sequence was plot-
ted twice.
Experimental IEPs were determined using isoelectric focusing electrophoresis (see
figure 3.3). The IEP of the aggregate could not be determined, this may be due
to the fact that the aggregate is too large to migrate into the gel. Experimentally
determined IEPs for the monomer, LCD and LC accord with the calculated IEPs
(see table 3.2).
Those results confirm the nature of the product-related impurities. The knowledge
of the IEP of the monomer and the product-related impurities is important for eval-
uation of purification strategies, especially for ion exchange chromatography (IEX).
P4P3P2P1
8.45
9.30
6.55
5.85
8.15
8.45
6.55
5.85
8.15
 IEP  IEP
Figure 3.3: Product-related impurities - Isoelectric focusing electrophoresis - deter-
mination of isoelectric points (IEP)
SEC fractions of figure 3.1 at page 50 (P1-4); IEPs of the samples are summarized in table 3.2;
marker: “Isoelectric Focusing Calibration Kit High Range pI (pH 5 - 10.5)”
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Table 3.2: Product-related impurities - Isoelectric focusing electrophoresis - calcu-
lated IEP
IEPs of SEC fractions of figure 3.1 at page 50; experimental and theoretical data of KappaSelect
binding protein (KSBP)
Theoretical Experimental
Fraction IEP IEP
P1 = Aggregate N/A N/A
P2 = Monomer 8.5 „ 8.5
P3 = LCD 6.2 „ 6.2
P4 = LC 6.2 „ 6.2
3.3.1.3 Flow cytometric analysis
Flow cytometric analysis of the aggregate, monomer, LCD and LC was performed
on NALM-16 cells for the FLT3 specificity and on Jurkat cells for the CD3 speci-
ficity.
Figure 3.4 A and B show that only the monomer binds to FLT3 and CD3 at low
concentrations (starting at 100 ng/mL). Aggregates, LCD and LC only bind at high
concentrations (starting at 10 µg/mL). At very high concentrations, the aggregate
exhibits enhanced binding to CD3 and especially to FLT3. LCD binds with a
slightly higher affinity to FLT3 and CD3 than LC.
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Figure 3.4: Product-related impurities - Flow cytometric analysis
Titration of SEC fractions of figure 3.1 at page 50 on A) NALM-16 (FLT3`) and B) Jurkat
(CD3`) cells; Aggregate (); Monomer (˝); LCD (Ĳ); LC (İ); Isotype 1 = NP-CUN297Q (SP2/0)
50 µg/mL; Isotype 2 = NP-C16N297Q (SP2/0) 50 µg/mL; Reference = NF-CUN297Q (SP2/0)
50 µg/mL; Detection: MaH-κL-PE
3.3.1.4 T-cell proliferation assay
The T-cell proliferation assay was performed with the aggregate, monomer, LCD
and LC and was divided into two experiments. The first experiment was performed
with freshly isolated PBMC of a healthy donor and target cells NALM-16 (see figure
3.5 A). This experiment was performed to see if and to what extent product-related
impurities induce proliferation of T-cells in the presence of target cells expressing
FLT3. The second experiment was performed with PBMC to see if and to what
extent product-related impurities induce proliferation of T-cells in the absence of
target cells (see figure 3.5 B). No activation should be detectable in the absence of
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target cells.
In the first experiment, it can be seen that only the monomer induces a strong dose-
dependent proliferation of PBMC at lower concentrations (starting at 1 ng/mL).
Aggregates, LCD and LC only induce proliferation of PBMC at higher concentra-
tions (starting at 100 ng/mL). In the second experiment, again only the monomer
induces proliferation of PBMC (starting at 4 ng/mL). Aggregates, LCD and LC only
induce proliferation of PBMC at higher concentrations (starting at 400 ng/mL); they
exhibits only very weak biological activity.
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Figure 3.5: Product-related impurities - T-cell proliferation assay
Titration of SEC fractions of figure 3.1 at page 50 with 100,000 target cells / 100,000 PBMC per
well (A) and without target cells / 100,000 PBMC per well (B); Aggregate (); Monomer (˝);
LCD (Ĳ); LC (İ); N = NALM-16; P = PBMC; PHA = 10 µg/mL phytohemagglutinin
3.3.1.5 Potency Assay (Promega)
The aggregate, monomer, LCD and LC were titrated in a potency assay to determine
the potency compared to a reference standard (NF-CUN297Q (SP2/0)). In figure 3.6
A and B it can be seen that the aggregate, LCD and LC are two to three log-values
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less potent than the monomer and the reference. EC50-values were calculated and
compared to the potency of an appropriate reference (see table 3.3). The aggregate
exhibits a EC50 of 99.4 ng/mL, which corresponds to a potency of 0.8% compared
to reference. The monomer exhibits almost the same EC50 as the reference which
corresponds to a relative potency of 90%. EC50 of LCD and LC could not be
calculated because no plateau-phase was reached. Thus, the aggregate, LCD and
LC exhibit only weak biological activity.
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Figure 3.6: Product-related impurities - Potency assay (Promega)
Titration of SEC fractions of figure 3.1 at page 50; Aggregate (); Monomer (˝); LCD (Ĳ); LC
(İ); Reference (✽) = NF-CUN297Q (SP2/0); E:T = 2:1; E = modif. Jurkat; T = NALM-16
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Table 3.3: Product-related impurities - Potency Assay - EC50-values of KSBP; Ref 1
corresponds to Aggregate and Monomer experiment, whereas Ref 2 corresponds to LCD and LC
experiment
EC50 [ng/mL] % of Ref
Aggregate 99.3 0.8
Monomer 0.9 90
LCD N/A N/A
LC N/A N/A
Ref 1 0.8 100
Ref 2 0.8 100
3.3.1.6 Summary and Conclusion
The product-related impurities of bispecific antibody NF-CUN297Q can be subdivided
into multimers and fragmentary parts of the antibody. Those impurities are puri-
fied along with the monomer when using KappaSelect as affinity chromatography
medium. The four KappaSelect binding proteins (KSBP) -aggregate, monomer,
light chain dimer (LCD) and light chain (LC)- were identified via SDS-PAGE and
isoelectric focusing electrophoresis. The product-related impurities exhibit almost
no biological activity, whereas the monomer binds towards FLT3 and CD3, activates
T-cells in a cell-proliferation assay and exhibits almost the same potency as a suit-
able reference standard. In addition, the monomer activates PBMC in the absence
of target cells to a small extent.
Despite the fact that a contamination with product-related impurities seems to be
uncritical due to their minimal biological activity, they should be removed from the
monomer for safety reasons and to minimize unintended immunological reactions.
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3.3.2 Evaluation of purification strategies
A variety of different purification strategies was evaluated for their suitability of sepa-
rating the active pharmaceutical ingredient (API) from product- and process-related
impurities. Different chromatographic techniques were applied and intensively dis-
cribed in the following part:
• Biospecific interaction chromatography - Affinity chromatography (AC) in
chapter 3.3.2.1 at page 59 f.
• Anion exchange chromatography (AIEX) in chapter 3.3.2.2 at page 61 ff.
• Cation exchange chromatography (CIEX) in chapter 3.3.2.3 at page 66 ff.
• Hydrophobic interaction chromatography (HIC) in chapter 3.3.2.4 at page 71
ff.
• Multimodal chromatography (MMC) in chapter 3.3.2.5 at page 78 ff.
In order to fulfill regulatory requirements, only chromatographic media with a so-
called regulatory support file were used. Those media are certified to be used under
Process development- and GMP-conditions.
The performance of affinity media was assessed in pilot experiments. A character-
ization of binding properties of bispecific antibody NF-CUN297Q towards different
affinity media was performed.
For the development of suitable polishing applications, the performance of the four
methods AIEX, CIEX, HIC, MMC was evaluated. Hitrap™ columns (V = 1mL)
were used for evaluation of conditions such as pH, conductivity and binding prop-
erties on an A¨KTA system. Analysis of the removal of product-related impurities
light chain dimer (LCD) and light chain (LC) was performed via SEC (Tosoh) /
UHPLC.
The next step was to verify the determined conditions in a so-called buffer ver-
ification model on Hiscreen™ columns (V = 4.7mL). At this step, criteria for
process realistic flow rates and protein-loading capacities were met (see discussion
part 2.2.2.2 at page 37).
Extended analysis of the polishing methods was performed in chapter 3.3.2.6 at page
83 ff. The analysis by size exclusion chromatography was improved by the use of a
column with better resolution than the Tosoh column; SEC (Superdex) / UHPLC.
With this method, the evaluation of aggregate-, LCD- and LC-content was possible.
Further analytical techniques included the evaluation of the monomer yield, SDS-
PAGE, flow cytometric analysis and a T-cell proliferation assay. The required effort
for performance of the methods was also included in the evaluation.
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3.3.2.1 Biospecific interaction chromatography - Affinity chromato-
graphy (AC)
A variety of different affinity chromatography media were evaluated for their binding
properties towards NF-CUN297Q. Protein A or Protein G did not allow binding at all
and other media such as “CaptureSelect IgG-CH1”, which binds to the CH1-domain
of antibodies, were exhibiting very low binding capacities. KappaSelect and Protein
L showed very good binding properties. Protein L binds to the framework regions
of the variable domain of the light chain. Therefore, an influence on the tertiary
structure of the complementary determining regions might be possible. KappaSelect
binds towards the constant domain of the light chain. Thus, KappaSelect was chosen
for further investigation.
An established method for determination of the binding capacity of a certain protein
to an affinity medium is the determination of the dynamic binding capacity at 10%
breakthrough (DBC10%). DBC10% is determined with previously purified protein in
DPBS with the same residence time as for the performance of the production process
scale. A linear flow rate of 400 cm/h is recommended for affinity chromatography
process applications with KappaSelect. For a column with a volume of 1 L and a
bed height of 20 cm, this linear flow rate results in a residence time of 3min. (see
equations 2.2 and 2.1 at page 38). Thus, this residence time was applied on a
Hitrap™ column; a CV of 1mL and a bed height of 2.4 cm results in a volumetric
flow rate of 0.33mL/min. Previously purified KSBP containing „ 6% aggregates,
„ 55% monomer, „ 22% LCD and „ 17%LC was applied onto the column (see
figure 3.7).
Marker M1 marks the condition where KSBP is applied onto the column. The OD280
at the marker M1 is 498mAU, the OD280 at marker M2 is 49.8mAU (10% of marker
M1). The volume between the two markers M1 and M2 multiplied with the feed
concentration represents the amount of KSBP where a 10% breakthrough through
the column can be observed. This amount is termed DBC10%. The volume between
the two markers is 11.8mL, the feed concentration was 1.57mg/mL. This results in
a DBC10% of 18.5mg KSBP per mL chromatography medium.
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M1 M2
Figure 3.7: Affinity Chromatography - DBC10% of KappaSelect binding protein
(KSBP) on KappaSelect; DBC10% = 18.5mg/mL resin
A¨KTA Purifier 100
Column: HiTrap™ -1mL-KappaSelect;
Protein (KSBP) conc.: 1.57mg/mL;
Buffer: DPBS
Flow rate: 0.33mL/min
Marker M1: OD280 of bypass mode = 498mAU; V = 2.4mL
Marker M2: OD280 at DBC10% = 49.8mAU; V = 14.2mL
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3.3.2.2 Anion Exchange Chromatography (AIEX)
A modern and commonly applied chromatography medium from GE Healthcare
was used for anion exchange chromatography. Capto Q is a strong anion exchange
resin based on quaternary ammonia structure (see figure 3.8).
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Figure 3.8: Capto Q - ligand
In order to remove as many HCPs, HCDNAs, Viruses and Endotoxins from the
active pharmaceutical ingredient (API) as possible, a slightly lower pH than the
isoelectric point (IEP) of the API should be applied. With this condition, the
mentioned impurities exhibit a negative net charge and bind to the resin, whereas
the monomer flows through the column without binding; the so-called flow-through
mode (FT mode). However, as a first step, a bind-elute mode with pH-gradient
elution was performed for assessment of a suitable pH-value for the FT mode. The
conductivity of the applied buffer should be as low as possible to increase the bind-
ing capacity of the resin. However, conductivity was not lowered below 2mS/cm to
avoid protein precipitation.
Bind-elute mode with pH-gradient Elution:
(see figure 3.9 at page 63)
The IEP of the monomeric antibody is 8.5, the IEP of LCD/LC is 6.2. Thus, a
slightly higher pH than the IEP of the monomer was used to bind the monomer
and LCD/LC. Binding-pH was 9.3. Subsequently, pH was decreased to 7.2 with a
gradient of 20 column volumes (CV). A suitable buffer ion for this pH-value is Tris
due to its pKa-value of 8.2. In addition, it is a cationic buffer ion and therefore
does not interfere with the AIEX-matrix.
The first peak of figure 3.9 A marks the monomer, the second peak marks LCD and
LC (verified via SEC Tosoh in figure 3.9 B). pH and conductivity right in between
the two peaks were determined (marker M) in order to apply this condition as
starting condition for the next experiment.
Condition: 50mM Tris pH 8.00, conductivity 3mS/cm
Flow-through mode:
(see figure 3.10 at page 64)
With the selected conditions (see above), the monomer should flow through the
column without binding and LCD/LC should bind. In order to verify the binding
of LCD/LC to the resin, buffer A containing 1M NaCl was used to elute LCD/LC.
This elution step will not be performed in process scale.
In contrast to theoretical assumptions, almost the whole KSBP passed through
in flow-through mode (FT mode) (Peak 1). Peak 2 consists of LCD and LC as
expected. Despite the fact that this method seems to be not suitable for removal of
62 CHAPTER 3. RESULTS
LCD and LC on a Hitrap™ column, is has to be taken into account that separation
properties are also dependent on flow rate and protein concentration. The sepa-
ration property can differ enormously under process-realistic flow rate and protein
load on a Hiscreen™ column. Due to the fact that the determined conditions are
very favorable for removal of process-related impurities (relatively high pH and low
conductivity), this method was applied in the buffer verification model.
Buffer verification model1:
(see figure 3.11 at page 65)
For the buffer verification model of AIEX, 11mL KappaSelect eluate in 0.1M
Glycine pH 2.5 containing the required 70.5mg KappaSelect binding protein (KSBP)
was used. This solution was shifted to the required conditions of pH 8.00 and con-
ductivity of 3mS/cm using 5mL 150mM Tris pH 9.60 and 4mL water for injection.
Thus, 20mL pH- and conductivity-adapted solution containing 70.5mg of KSBP
was applied onto a Hiscreen™ column with a flow rate of 0.59mL/min.
The first peak contains almost pure monomer, whereas the second and third peak
consist only of LCD and LC. The second peak probably occurs because of a change
of the buffer properties. Note that the buffer at Peak 1 consists of Glycine (which
does not buffer pH at the pH-value of 8), the monomer and the buffer ion Tris.
Buffer conditions at Peak 2 exhibits the same conductivity, but the buffer consists
only of Tris as buffer ion and LCD/LC. Thus, the buffer at Peak 2 has a higher
buffer capacity than buffer at Peak 1. Those little differences in buffer composition
probably lead to an elution of LCD/LC. In addition, due to the fact that a superloop
was used for sample application, pressure increases up to 0.5 bar after application
of the protein solution and flushing of the superloop. Thus, this may lead to a
premature elution property of LCD/LC as well.
Regardless of these considerations, the procedure is capable of clearly separating the
monomer from the contaminants. In addition, the premature elution of LCD/LC
does not matter, because only Peak 1 is fractionated, Peak 2 and 3 will not be
processed further during the production process. The third peak occurs because
of reduced binding capacity resulting from increased salt concentration and was
only applied to verify the binding of LCD/LC to the resin. This step will not be
performed in the production process.
1For explanation of flow rate and amount of KSBP see part 2.2.2.2 at page 37
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Figure 3.9: AIEX - Evaluation of buffer conditions - Bind-elute mode with pH-
gradient Elution
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto Q; Protein amount: 1mg;
Buffer A: 50mM Tris pH 9.3; Buffer B: 50mM Tris pH 7.2;
Gradient: 20CV; Flow rate: 1mL/min
Marker M: pH 8.00 Cond. 3.0mS/cm
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.10: AIEX - Evaluation of buffer conditions - flow-through mode and salt
gradient
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto Q; Protein amount: 1 mg;
Buffer A: 50mM Tris pH 8.0 Cond. 3.0mS/cm; Buffer B: 50mM Tris pH 8.0 Cond. 80mS/cm ;
Gradient: 20CV; Flow rate: 1mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.11: AIEX - Buffer verification model
A: A¨KTA Purifier 100
Column: Hiscreen™ -4.7mL-Capto Q;
Protein amount: 70.5mg in 20mL;
Buffer A: 50mM Tris pH 8.0 Cond. 3.0mS/cm; Buffer B: 50mM Tris pH 8.0 Cond. 80mS/cm ;
Gradient: -; Flow rate: 0.59mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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3.3.2.3 Cation exchange chromatography (CIEX)
A modern and commonly applied chromatography medium from GE Healthcare
was used for cation exchange chromatography. Capto SP ImpRes is a strong cation
exchange resin based on sulfopropyl structure (see figure 3.12).
Resin
Figure 3.12: Capto SP ImpRes - ligand
As in AIEX, in order to remove as many HCPs, HCDNAs, Viruses and Endotoxins
from the API as possible, a pH slightly below the IEP of the API should be applied.
With this condition, the mentioned impurities exhibit an anionic net charge and do
not bind to the resin, whereas the antibody binds to the resin; the so-called bind-
elute mode (BE mode). For conductivity, the same rules as for AIEX can be applied.
Bind-elute mode with pH-gradient Elution:
(see figure 3.13 at page 68)
The IEP of the monomeric antibody is 8.5, the IEP of LCD/LC is 6.2. Thus, a
slightly lower pH than the IEP of LCD/LC was used to bind the monomer and
LCD/LC. Binding-pH was 6.22. Subsequently, pH-value was increased to 8.5 with
a gradient of 20 column volumes (CV). A suitable buffer is Phosphate due to its
pKa-value of 7.2. In addition, it is an anionic buffer ion and therefore does not
interfere with the CIEX-matrix.
LCD/LC flow through the column. pH and conductivity were determined immedi-
ately before Peak 2 (see marker M), which represents the monomer. The determined
condition was applied as starting condition for the next experiment.
Condition: pH 7.3, conductivity 3mS/cm
Bind-elute mode with salt-gradient Elution:
(see figure 3.14 at page 69)
With the selected conditions (see above), LCD/LC flow through the column while
the monomer binds to the resin. For elution of the monomer, an increase of con-
ductivity is more favorable than an increase of pH because it is less stressful for the
monomer and easier to control in process scale.
After binding of the monomer to the resin with buffer A, conductivity was slowly
increased by a gradient of 20 CV to an elution buffer containing buffer A and 1M
NaCl. The following suitable elution condition was determined (marker M):
Condition: 20mM Phosphate pH 7.3, conductivity 15mS/cm (adjusted with NaCl)
Buffer verification model1:
(see figure 3.15 at page 70)
As in the AIEX-experiment, KappaSelect eluate in 0.1M Glycine pH 2.5 was used as
starting material. 11mL of this eluate contained the required 70.5mg KappaSelect
1For explanation of flow rate and amount of KSBP see part 2.2.2.2 at page 37
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binding protein (KSBP).
This solution was shifted to the desired conditions of pH 7.30 and conductivity of
3mS/cm using 7mL 150mM HEPES pH 8.0 and 12mL water for injection. Thus,
30mL pH- and conductivity-adapted solution containing 70.5mg KSBP was applied
onto a Hiscreen™ column with a flow rate of 0.59mL/min.
The verification of buffer conditions worked out well. Peak 1 represents LCD/LC,
Peak 2 is the monomer. Peak 3 is not verifiable via SEC.
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Figure 3.13: CIEX - Evaluation of buffer conditions - Bind-elute mode with pH-
gradient Elution
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto SP ImpRes; Protein amount: 1mg;
Buffer A: 20mM Phosphate pH 6.22;
Buffer B: 20mM Phosphate pH 8.5;
Gradient: 20 CV; Flow rate: 1mL/min
Marker M: pH 7.4 Cond. 3.5mS/cm
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.14: CIEX - Evaluation of buffer conditions - Bind-elute mode with salt-
gradient Elution
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto SP ImpRes; Protein amount: 1mg;
Buffer A: 20mM Phosphate pH 7.3 Cond. 3.0mS/cm;
Buffer B: 20mM Phosphate pH 7.3 Cond. 80mS/cm ;
Gradient: 20 CV; Flow rate: 1 mL/min
Marker M: pH 7.3 Cond. 15mS/cm
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.15: CIEX - Buffer verification model
A: A¨KTA Purifier 100
Column: Hiscreen™ -4.7mL-Capto SP ImpRes;
Protein amount: 70.5mg in 30mL;
Buffer A: 20mM Phosphate pH 7.30 Cond. 3mS/cm;
Buffer B: 20mM Phosphate pH 7.30 Cond. 15mS/cm;
Buffer C: 20mM Phosphate pH 7.30 Cond. 150mS/cm ;
Gradient: -; Flow rate: 0.59mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
3.3. DEVELOPMENT OF A PURIFICATION PROCEDURE 71
3.3.2.4 Hydrophobic interaction chromatography (HIC)
A prediction of suitability of a certain hydrophobic chromatography medium for
a distinct application is not possible. Thus, a variety of different chromatography
media was evaluated for their suitability to separate the monomer from product-
related impurities. Figure 3.16 arranges different media according to their relative
hydrophobicity and average resolution. The following media were applied: “Butyl
Sepharose 4 fast flow”, “Butyl Sepharose High performance”, “Butyl-S Sepharose 6
fast flow”, “Octyl Sepharose 4 fast flow”, “Phenyl Sepharose 6 fast flow (high sub)”,
“Phenyl Sepharose 6 fast flow (low sub)” and “Phenyl Sepharose high performance”.
Butyl Sepharose High Performance
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Capto Octyl
Capto Butyl
Capto Phenyl (high sub)
Octyl Sepharose 4 Fast Flow
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Figure 3.16: HIC ligands and media
Resolving power and ydrophobicity of various HIC media based on elution studies of the six model
proteins: ovalbumin, α-chymotrypsinogen, ribonuclease, lactoferrin, lysozym, α-amylase.
(© GE Healthcare)
Bind-elute mode with salt-gradient Elution:
(see figure 3.17 at page 73-75)
On HIC media, proteins bind at high-salt conditions and elute at low-salt condi-
tions. Hydrophobic proteins bind tighter than hydrophilic proteins. Thus, KSBP
were bound by application of high salt buffer A. Conductivity was decreased by
application a gradient (20 CV) to low salt buffer B resulting in an individual elution
profile. Peaks were not assessed in SEC-analysis.
For the column with the best resolution, Phenyl Sepharose High Performance
(Phenyl HP), the conductivity between the two peaks was determined (marker M)
and used as starting condition for an experiment in flow-through mode.
Condition: 50mM Tris pH 8.00 conductivity 18.5mS/cm.
Flow-through mode:
(see figure 3.18 at page 76)
With the selected conditions (see above), the monomer flows through the column
while LCD/LC bind to the resin. The elution with decreased salt concentration at
the end of the experiment was applied to verify the binding of LCD/LC to the resin,
this elution step will not be performed in the production pro
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Buffer verification model1:
(see figure 3.19 at page 77)
As in the AIEX-experiment, KappaSelect eluate in 0.1M Glycine pH 2.5 was ap-
plied as starting material. 11mL of this eluate contained the required 70.5mg
KappaSelect binding protein (KSBP). This solution was shifted to the required
conditions of pH 8.00 and conductivity of 18.5mS/cm using 4.5mL 150mM Tris
pH 9.60 and 1.5mL 1M (NH4)2SO4. Thus, 17mL pH- and conductivity adapted
solution containing 70.5mg KSBP was applied onto a Hiscreen™ column with a flow
rate of 0.47mL/min.
The first peak represents almost pure monomer, whereas the second and third peak
consist of only LCD and LC. The second peak probably occurs because of a change
of the buffer properties similar to the AIEX-experiment. In addition, the same
pressure condition was occurring. This might be the reason why the larger molecule
LCD leaches (Peak 2) and the smaller molecule LC still sticks to the column. Those
complex interactions were avoided in further experiments by using a sample pump
instead of a superloop for sample application.
Nevertheless, these interactions do not impact the process itself. Only Peak 1 is
fractionated, Peaks 2 and 3 will not be processed further in production process. The
third peak occurs because of reduced binding capacity resulting from decreased salt
concentration and was only applied to verify the binding of LCD/LC to the resin.
This elution step will not be performed in production process.
1For explanation of flow rate and amount of KSBP see part 2.2.2.2 at page 37
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A) HiTrap™ -1mL-Butyl Sepharose 4 Fast Flow
B) HiTrap™ -1mL-Butyl Sepharose High Performance
C) HiTrap™ -1mL-Butyl-S Sepharose 6 Fast Flow
HIC - Media screening - Bind-elute mode with salt-gradient Elution 1/3
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D) HiTrap™ -1mL-Octyl Sepharose 4 Fast Flow
E) HiTrap™ -1mL-Phenyl Sepharose 6 Fast Flow (high sub)
F) HiTrap™ -1mL-Phenyl Sepharose 6 Fast Flow (low sub)
HIC - Media screening - Bind-elute mode with salt-gradient Elution 2/3
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G) HiTrap™ -1mL-Phenyl Sepharose High Performance
M
Figure 3.17: HIC - Media screening - Bind-elute mode with salt-gradient Elution 3/3
A¨KTA Purifier 100
Column: see A) to G);
Protein amount: 1mg;
Buffer A: 1M Ammonium sulfate/ 50mM Tris pH 8.00 Cond. 130mS/cm;
Buffer B: 50mM Tris pH 8.00 Cond. 3.0mS/cm ;
Gradient: 20CV; Flow rate: 1mL/min
Marker M: pH 8.00 Cond. 18.5mS/cm
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Figure 3.18: HIC - Evaluation of buffer conditions - Flow-through mode
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Phenyl Sepharose High Performance; Protein amount: 1mg;
Buffer A: 50mM Tris pH 8.00 Cond. 18.5mS/cm ;
Buffer B: 50mM Tris pH 8.00 Cond. 3.0mS/cm ;
Gradient: 20 CV; Flow rate: 1mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7,8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.19: HIC - Buffer verification model
A: A¨KTA Purifier 100
Column: Hiscreen™ -4.7mL-Phenyl Sepharose High Performance;
Protein amount: 70.5mg in 17mL;
Buffer A: 50mM Tris pH 8.00 Cond. 18.5 mS/cm
Buffer B: water (bidest.)
Gradient: -; Flow rate: 0.47mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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3.3.2.5 Multimodal Chromatography (MMC)
A modern and commonly applied chromatography medium from GE Healthcare was
used for multimodal chromatography. Capto MMC is a chromatography resin with
a multimodal CIEX/HIC-ligand (see figure 3.20).
Resin 
Figure 3.20: Capto MMC - ligand
As in AIEX and CIEX, in order to remove as many HCPs, HCDNAs, Viruses and
Endotoxins from the API as possible, a pH slightly below the IEP of the API
should be applied. With this condition, the mentioned impurities exhibit an anionic
net charge and do not bind to the resin, whereas the antibody binds to the resin;
the so-called bind-elute mode (BE mode). Due to their hydrophobic properties,
multimodal media are much more salt tolerant than CIEX-media.
Bind-elute mode with pH-gradient Elution:
(see figure 3.21 at page 80)
The IEP of the monomeric antibody is 8.5, the IEP of LCD/LC is 6.2. Thus, a
slightly lower pH than the IEP of LCD/LC was used to bind the monomer and
LCD/LC. Binding-pH was 5.0. Subsequently, pH-value was increased to 8.5 with
a gradient of 20 column volumes (CV). The following buffers were recommended
by manufacturer GE Healthcare: 100mM Acetate / 50mM Phosphate / 20mM
Succinate pH 5.0 (buffer A) and pH 8.5 (buffer B).
The first peak marks the LCD and LC, the second peak represents the monomer.
pH and conductivity right in between the two peaks were determined (marker M)
in order to apply this condition as starting condition for the next experiment.
Condition: pH 7.0 conductivity 17mS/cm.
Bind-elute mode with salt-gradient Elution:
(see figure 3.22 at page 81)
The selected condition (see above) was slightly altered. Buffer ion was Phosphate
in order to simplify the buffer and conductivity was decreased to 4.3mS/cm to in-
crease the binding capacity of the monomer. With these conditions, LCD/LC flow
through the column while the monomer binds to the resin. As in CIEX, the increase
of conductivity is more favorable for elution of the monomer than an increase of
pH because this condition is less stressful for the monomer and easier to control in
process scale.
After binding of the monomer to the resin with buffer A, conductivity was increased
by a gradient of 20 CV to an elution buffer containing buffer A and 1M NaCl. The
following suitable application and elution conditions were determined (markers M1
an M2):
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Application: 25mM Phosphate pH 7.00, conductivity 17mS/cm
Elution: 25mM Phosphate pH 7.00, conductivity 63mS/cm
Because of the high conductivity required for elution, it can be concluded that the
monomer exhibits a high binding affinity towards the resin.
Buffer verification model1:
(see figure 3.23 at page 82)
As in the AIEX-, CIEX- and HIC-experiments, KappaSelect eluate in 0.1M Glycine
pH 2.5 was used. 21mL of this eluate contained the required 70.5mg KappaSelect
binding protein (KSBP). This solution was shifted to the required condition of
pH 7.00 and conductivity 20mS/cm using 24mL 75mM Phosphate pH 8.0 and
18mL 0.2M NaCl. Thus, 65mL of pH- and conductivity adapted solution con-
taining 70.5mg of KSBP was applied onto a Hiscreen™ column with a flow rate of
0.59mL/min.
The verification of buffer conditions did not show the expected results. Peak 1 rep-
resents LCD/LC and to some extent the monomer, Peak 2 represents the monomer.
As already mentioned, the binding affinity of the monomer towards the resin is
very high. However, because of the huge amount of monomer in the flow-through
fraction, the binding capacity is low at the same time. This is a disadvantage of this
method. Further optimization would be required, if this method would be applied.
1For explanation of flow rate and amount of KSBP see part 2.2.2.2 at page 37
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Figure 3.21: MMC - Evaluation of buffer conditions - Bind-elute mode with pH-
gradient Elution
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto MMC; Protein amount: 1mg;
Buffer A: 100mM Acetate / 50mM phosphate / 20mM Succinate pH 5.0;
Buffer B: 100mM Acetate / 50mM phosphate / 20mM Succinate pH 8.5;
Gradient: 20 CV; Flow rate: 1mL/min
Marker M: pH 7.0 Cond. 17.0mS/cm
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain; Peak at 23.75min. results from intrinsic absorption of Succinate at 220 nm
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Figure 3.22: MMC - Evaluation of buffer conditions - Bind-elute mode with salt-
gradient Elution
A: A¨KTA Purifier 100
Column: HiTrap™ -1mL-Capto MMC; Protein amount: 1mg;
Buffer A: 25mM Phosphate pH 6.98 Cond. 4.3mS/cm;
Buffer B: 25mM Phosphate pH 6.98 Cond. 80mS/cm ;
Gradient: 20 CV; Flow rate: 1 mL/min
Marker M1: pH 7.00 Cond. 20mS/cm
Marker M2: pH 7.00 Cond. 63mS/cm
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 3.23: MMC - Buffer verification model
A: A¨KTA Purifier 100
Column: Hiscreen™ -4.7mL-Capto MMC;
Protein amount: 70.5mg in 65mL;
Buffer A: 25mM Phosphate pH 7.3 Cond. 20mS/cm;
Buffer B: 25mM Phosphate pH 7.3 Cond. 63mS/cm;
Gradient: -; Flow rate: 0.59mL/min
B: UHPLC BioRS 3000
Column: SEC TOSOH TSK-Gel® G3000SWXL 7.8x300; 5 µm
Analysis of load (Pre) and fractions of A; Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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3.3.2.6 Extended analysis
In the following, the buffer verification models of the 4 methods (AIEX, CIEX, HIC
and MMC) were compared according to the following criteria. KappaSelect binding
protein (KSBP) was analyzed before and after each polishing method.
Purity, yield and process effort:
• SEC Superdex (improved SEC analysis) for evaluation of the content of aggre-
gates, monomer, LCD and LC in KSBP
• Evaluation of monomer yield
• SDS-PAGE for characterization of KSBP
• Evaluation of the required effort to perform the polishing method
Biological activity
• Flow cytometric analysis on FLT3- and CD3-positive cell lines
• T-cell proliferation assay
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Purity, Monomer yield and required effort to perform the method
SEC Superdex (improved SEC analysis):
The four polishing methods were compared with SEC (Superdex) analysis (see
figures 3.24 to 3.27) . The peak evaluation results from Chromeleon 7.2 software
are summarized in table 3.4
AIEX is an effective method for reduction of the aggregate content. The enrichment
of the monomer and LCD/LC removal is not very effective.
CIEX is enriching aggregates. The enrichment of monomer and removal of LCD/LC
is very effective.
HIC is a very effective method for reduction of the aggregate content. In addition,
the enrichment of monomer and the removal of LCD/LC is efficient.
MMC is also an effective method for reduction of the aggregate content, enrichment
of monomer and removal of LCD/LC.
Thus, in regard to this analytical evaluation, AIEX, HIC and MMC are suitable for
polishing of the active pharmaceutical ingredient (API). CIEX is not suitable due
to its aggregate-enriching properties.
Mon
LCD LCPre
Post
Mon
Figure 3.24: Buffer verification model - SEC (Superdex) - AIEX
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of load (Pre) and polishing application (Post); Mon = Monomer, LCD = Light chain
dimer, LC = Light chain
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Figure 3.25: Buffer verification model - SEC (Superdex) - CIEX
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of load (Pre) and polishing application (Post); Mon = Monomer, LCD = Light chain
dimer, LC = Light chain
Pre
Post
Mon
Mon
LCD LC
Figure 3.26: Buffer verification model - SEC (Superdex) - HIC
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of load (Pre) and polishing application (Post); Mon = Monomer, LCD = Light chain
dimer, LC = Light chain
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Figure 3.27: Buffer verification model - SEC (Superdex) - MMC
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of load (Pre) and polishing application (Post); Mon = Monomer, LCD = Light chain
dimer, LC = Light chain
Table 3.4: Buffer verification model - Extended analysis - SEC Superdex
KSBP analysis pre and post each polishing application
Sample Aggregate [%] Monomer [%] LCD [%] LC [%]
Pre AIEX 4.4 55.5 23.7 16.0
Post AIEX 0.8 91.3 4.2 3.0
Pre CIEX 1.3 51.5 22.1 24.7
Post CIEX 3.8 93.1 1.2 1.0
Pre HIC 3.7 56.3 24.5 14.8
Post HIC 0.6 94.7 2.2 1.5
Pre MMC 3.2 56.7 23.5 16.2
Post MMC 0.8 98.6 0.3 0.3
Monomer Yield:
Yield was determined by multiplying protein concentration with the monomer
content (determined via SEC Superdex) before and after application of a chromato-
graphic technique. The monomer yield is 89% for AIEX, 98-100% for CIEX, 90%
for HIC and only 75% for MMC. The low yield for MMC was already seen in the
purification chromatogram 3.23 at page 82; relevant amount of monomer was found
in the flow-through fraction.
SDS-PAGE:
SDS-PAGE shows analogue bands compared to SEC-analysis (see figure 3.28). No
additional or missing bands are visible (except for the fact that the aggregate
fraction is missing on SDS-PAGE because of the heat-treatment of the samples in
SDS-PAGE preparation). In regard to this analytical evaluation, all techniques are
suitable for polishing of the API.
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Figure 3.28: Buffer verification model - SDS-PAGE
Analysis of load (Pre) and polishing application (Post); A = unreduced condition; B = reduced
condition; marker: “PageRuler™ Prestained Protein Ladder”
Required effort to perform the method:
Method effort is low for AIEX and HIC, because these methods can be performed
in flow-through mode (FT mode). MMC requires a medium method effort due to
the application of a bind-elute mode (BE mode). The effort for CIEX is very high
due to the application of a BE mode and relatively high back pressure due to a
small bead size (40 µm), this results in a low flow rate.
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Biological activity:
Flow cytometric analysis on FLT3- and CD3-positive cell lines:
Flow cytometric analysis of monomer-normalized KSBP before and after each
polishing method was almost identical for all four polishing methods compared
to reference NF-CUN297Q (SP2/0) (see figures 3.29 and 3.30). In regard to this
analytical evaluation, all techniques are suitable for polishing of the API.
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Figure 3.29: Buffer verification model - Flow cytometric analysis - NALM-16 cells
Titration of monomer-normalized samples pre (‚) and post (˝) polishing application on NALM-16
cells; Isotype = NP-CUN297Q (SP2/0) 10 µg/mL; Ref = NF-CUN297Q (SP2/0) 10 µg/mL; Detec-
tion: GaH-Fc-PE
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Figure 3.30: Buffer verification model - Flow cytometric analysis - Jurkat cells
Titration of monomer-normalized samples pre (‚) and post (˝) polishing application on Jurkat
cells; Isotype = NP-C16N297Q (SP2/0) 10 µg/mL; Ref = NF-CUN297Q (SP2/0) 10 µg/mL; Detec-
tion: GaH-Fc-PE
T-cell proliferation assay:
Titration of monomer-normalized KSBP obtained in the T-cell proliferation assay
before and after each polishing method was almost identical for all four polishing
methods compared to reference NF-CUN297Q (SP2/0) (see figure 3.31). In regard to
this analytical evaluation, all techniques are suitable for polishing of the API.
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Figure 3.31: Buffer verification model - T-cell proliferation assay
Titration of monomer-normalized samples pre (‚) and post (˝) polishing application; Reference
(Ź) = NF-CUN297Q (SP2/0); E:T = 1:1; N = NALM-16; P = PBMC; PHA = 10 µg/mL phyto-
hemagglutinin
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3.3.2.7 Summary and Conclusion
The results for the extended analysis are summarized in table 3.5.
AIEX is an effective method for the enrichment of monomer, results in high monomer
yield and no loss of biological activity is observed. Furthermore, this technique
promises good theoretical properties for the removal of process-related impurities;
the relatively high pH-value of 8 and the low conductivity of 3mS/cm are very
favorable for this application (see part 1.4.3 at page 15).
CIEX is not a suitable method due to the aggregate-enriching properties.
HIC is a very effective method for the enrichment of monomer and reduction of
LCD/LC content and especially for the reduction of aggregate content. Monomer
yield is high and no loss of biological activity can be observed.
MMC is not a suitable method due to a very low monomer yield.
The combination of AIEX and HIC is suitable because of the different separa-
tion mechanisms of these methods. The advantage of this combination is the
effective removal of process-related impurities via AIEX and the effective removal
of product-related impurities (especially aggregates) via HIC. Those methods were
applied for the development of a small-scale model, a 1:100-scale model of the
planned production process scale.
Table 3.5: Summary of extended analysis for buffer verification model of AIEX, CIEX,
HIC and MMC
AIEX CIEX HIC MMC
Aggregate [%] (SEC) 0.8 3.8 0.6 0.8
Monomer [%] (SEC) 91.3 93.1 94.7 98.6
LCD/LC [%] (SEC) 7.2 2.2 3.7 0.6
Monomer Yield [%] 89 98-100 90 75
SDS-PAGE Analogue bands to SEC
Method effort Low Very high Low Medium
Flow cytometric analysis Same binding pre and post method
T-cell proliferation assay Same proliferation pre and post method
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3.3.3 Development of a small-scale model of the production
process
At the end of chapter 3.3.2, it was concluded that the combination of polishing
methods AIEX (Capto Q) and HIC (Phenyl HP) is reasonable and suitable. For
simulation of a production process, a small-scale model (1:100) must be developed.
The theoretical background for performance of the methods such as scaling of
columns and flow rates is explained in part 2.2.2.2 at page 37.
In order to verify the suitability of the combination of KappaSelect, AIEX (Capto
Q) and HIC (Phenyl HP), three purifications with two different batches of super-
natant were performed. For verification of process limitations, one purification was
performed with 90%, one with 110% and one with 135% load of the intended
130mg of KSBP (see 2.2.2.2 at page 37).
In the buffer verification models of chapter 3.3.2, AIEX was performed in FT mode
with a 50mM Tris buffer pH 8.00 conductivity 3mS/cm, HIC was performed in FT
mode with a 50mM Tris buffer pH 8.00 conductivity 18.5mS/cm (adjusted with
(NH4)2SO4). Thus, the easiest way to combine these two polishing applications is to
perform the AIEX method first, then add the required amount of 1M (NH4)2SO4
to increase conductivity to 18.5mS/cm and then perform the HIC method.
The three verification batches were named AH1.1, AH1.2 and AH1.3. “AH1” repre-
sents the first possible combination of AIEX and HIC (see above). The ennumeration
behind this abbreviation represents the batch number. For each batch, samples were
collected after each column to perform analytical evaluation (in-process controls 1-3
(IPC-1-3)).
The following analytical evaluation was performed for IPCs of the three verification
batches:
• SEC (Superdex) / UHPLC and monomer yield
• SDS-PAGE
• Analytical CIEX / UHPLC
• Flow cytometric analysis on FLT3- and CD3-positive cell lines
• T-cell proliferation assay
• Potency Assay (Promega)
• Process related impurities (HCP-, HCDNA-, LKS-removal)
For purification chromatograms and parameters see appendix part 5.3.1 at page 139
ff. and table 5.2 at page 139. A compendium of results for IPCs can be found in
the appendix (see table 5.3 at page 143).
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3.3.3.1 SEC (Superdex) / UHPLC and Monomer yield
(see appendix figure 5.4 at page 144, table 5.4 at page 145 and summarizing figure
3.32 at page 93)
With process AH1, it was possible to reduce the aggregate content from 6.6% via
4.4% to 0.3%. The main aggregate clearance was achieved via HIC. Monomer
content rises from 53.9% to 97.2% and LCD/LC content declines from 39.3% to
1.8%. The main LCD/LC clearance was achieved via AIEX.
Monomer yield was calculated from tables 5.2 at page 139 and 5.3 at page 143 with
the following equation (amount in [mg]):
Monomer yield [%] “
IPC-2 amount Monomer
AIEX appl. amount Monomer
˚
IPC-3 amount Monomer
HIC appl. amount Monomer
˚100
(3.1)
Monomer yield declines with rising KSBP-load. 100% KSBP load corresponds to
130mg KSBP (see chapter 2.2.2.2 at page 37). Monomer yield is 91.5% at 90%
maximum load to 77% at 135% maximum load (see figure 3.32 D).
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Figure 3.32: Small-scale model - (SEC Superdex)
A-C: Content of product-related impurities detected via SEC Superdex; D: calculation of monomer
yield; 100% KSBP load corresponds to 130mg KSBP; verification batches AH1.1-3
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3.3.3.2 SDS-PAGE
(see appendix figure 5.7 at page 146)
SDS-PAGE analysis exhibits analogue bands compared to SEC-analysis for all three
verification batches. No additional or missing bands are visible (except for the fact
that the aggregate fraction is missing on SDS-PAGE because of the heat-treatment
in SDS-PAGE preparation).
3.3.3.3 Analytical CIEX / UHPLC
(see appendix figure 5.8 at page 146)
All three chromatograms of verification batches exhibits almost the same elution
profile consisting of one main peak, two acidic variants, one acidic shoulder of the
main peak and two basic variants.
3.3.3.4 Process related impurities
(see figure 3.33)
With small-scale process AH1, it was possible to reduce the HCP content from
almost 6000 ppm via 52 ppm to 20.8 ppm and HCDNA content from 670 ppm to less
than 1.5 ppm. The main HCP- and HCDNA-clearance post affinity chromatography
was achieved via AIEX.
The removal of process-related impurity “leached KappaSelect” (LKS) could not be
evaluated due to a very high background and a false-low signal of the ELISA. After
incubation at 95 °C, LCD/LC are not denatured and still bind to the KappaSelect
ligand resulting in a false low signal of the ELISA. In IPC-3, the LCD/LC content is
still 1.8% and might therefore still result in a false-low signal of the ELISA. Solely a
theoretical consideration on removal efficiency of the process could be performed; an
isoelectric focusing electrophoresis of the KappaSelect ligand (from ELISA kit) was
performed to predict the property of the KappaSelect ligand on AIEX (see figure
3.34 at page 95). IEP of KappaSelect-ligand is lower than 5.85 and can therefore in
theory be removed very effectively via AIEX.
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Figure 3.33: Small-scale model - Removal of Process-related impurities
Concentration of process-related impurities detected via ELISA (HCP) and QPCR (HCDNA);
concentrations normalized to monomer; verification batches AH1.1-3
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Figure 3.34: Isoelectric focusing electrophoresis - KappaSelect ligand
Ligand from KappaSelect ELISA kit; marker: “Isoelectric Focusing Calibration Kit High Range
pI (pH 5 - 10.5)”
3.3.3.5 Flow cytometric analysis
(see appendix figure 5.9 at page 147 and 5.10 at page 148)
All titration curves of monomer-normalized KSBP of IPC-1 to 3 exhibit the same
progression for all verification batches on NALM-16 (FLT3`) and on Jurkat cells
(CD3`) and are comparable to reference standard (NF-CUN297Q (SP2/0)).
3.3.3.6 T-cell proliferation assay
(see appendix figure 5.11 at page 149)
All titration curves of monomer-normalized KSBP of IPC-1 to 3 exhibit the same pro-
gression for all verification batches. The reference standard (NF-CUN297Q (SP2/0))
exhibits a slightly weaker cell-proliferation inducing property. This may be due to
the fact that the reference standard was already two years old and stored in DPBS
instead of a suitable formulation buffer.
3.3.3.7 Potency Assay (Promega)
(see appendix figure 5.12 at page 150 and table 3.6 at page 96)
For this experiment, only IPC-3 of batches AH1.1 to AH1.3 were compared to ref-
erence NF-CUN297Q (SP2/0). Overall EC50 of the three batches is 3.0 ˘ 0.2 ng/mL,
which corresponds to only 33.3% ˘ 0.8% relative potency compared to reference.
NF-CUN297Q seems to lose potency during purification via process AH1.
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Table 3.6: Small-scale model - Potency Assay (Promega) - Calculation of EC50-values
of IPC-3 for batches AH1.1-3
EC50 [ng/mL] % of Ref
Experiment 1
AH1.1 2.8 32
AH1.2 2.7 33
Ref 0.9 100
Mean AH1.1/2 2.75 ˘ 0.05 32.5 ˘ 0.5
Experiment 2
AH1.1 3.2 34
AH1.3 3.2 34
Ref 1.1 100
Mean AH1.1/3 3.2 ˘ 0 34 ˘ 0
Experiment 1 and 2
mean AH1.1/2/3 3.0 ˘ 0.2 33.3 ˘ 0.8
3.3.3.8 Summary and Conclusion
Aggregates and LCD/LC are very effectively removed via process AH1 resulting in a
monomer yield of 90%. For all three batches purified, SDS-PAGE, SEC (Superdex),
analytical CIEX / UHPLC were almost identical. HCP and HCDNA are very ef-
fectively removed especially via AIEX. LKS is theoretically removed very efficiently
via AIEX as well. Biological activity decreases during purification, this can only be
observed in the potency assay (Promega).
Despite some loss of potency and incomplete analytical evaluation, the small-scale
model AH1 exhibits excellent results and is suitable for up-scaling.
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3.3.4 Nanofiltration
The purpose of this test was to find a suitable filter for the reduction of potential
viral contamination for a production process. Because of previous experience with
“Asahi Kasei”-Nanofilters in the production process of the first product of Syn-
immune GmbH, 4G8SDIEM, filtration performance was solely evaluated on “Asahi
Kasei”-filters. For performance of a process realistic small-scale-experiment, the
technical objectives for the production process must first be defined. As discussed
in 4.2.2 at page 117, maximum monomer content per batch is 6050mg with a con-
centration of 1mg/mL. With addition of a safety factor of 5%, 6300mg antibody
monomer with a concentration of 1mg/mL are to be filtrated. The formulation
buffer for this experiment was DPBS.
The following filters were tested: Planova™ 15N, Planova™ 20N and Planova™
BioEx.
Process development scientists of “Asahi Kasei” proposed a 1:120 small-scale model
for Planova™ 15N and Planova™ 20N and a 1:100 small-scale model for Planova™
BioEx. Parameters for filtration are listed in table 3.7
Experimental procedure:
As first step, each filter was flushed with 20mL water for injection. A leakage test
was performed and was negative for all three filters. Subsequently, the filters were
flushed with 20mL DPBS and filtration was performed according to the parameters
in table 3.7 and 3.8. A post-use-leakage test was performed and was negative for all
three filters.
Table 3.7: Nanofiltration - Parameters for filtration
Filtration volume in process 6.3 L
Filter area process filters 0.120m² (15N,20N) 0.100m² (BioEx)
Filtration volume downscale model 52.5mL (15N, 20N), 63mL (BioEx)
Filter area downscale filters 0.001m²
Maximal TMP 98 kPa (15N, 20N), 330 kPa (BioEx)
Mode of filtration isobar
Concentration of antibody solution 1.03mg/mL
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Table 3.8: Nanofiltration - Filtration procedure
Filter Planova™ 15N 20N BioEX
Filtrated volume - 45 49.4 49.8
void volume [mL]
Filtrated Monomer [mg] 46.35 50.88 51.29
% of required filtration volume 88.3% 97% 81.4%
according to setpoint
Table 3.9: Nanofiltration - Results of filtration
Filter Planova™ 15N 20N BioEX
Filtration time [h] 1.25 0.75 0.42
Average flux [L/h/m²] 44 73.33 132
Product recovery [mg] 44 51.15 45.1
Product recovery (rel) 95% 100% 88%
0 10 20 30 40 50 60 70 80
0
20
40
60
80
100
Planova 15N
Planova 20N
Planova BioEx
t [min.]
%
 o
f 
fi
lt
ra
ti
o
n
 v
o
lu
m
e
Figure 3.35: Nanofiltration
Results:
Filtration can be performed in less than 1.5 h with all three filters. Thus, all fil-
ters would be suitable for nanofiltration in production process. However, product
recovery is an issue for Planova BioEx with only 88%. Recovery of Planova 20N is
slightly higher than in Planova 15N (100% instead of 95%) and the filtration time
is much shorter (0.75 h instead of 1.25 h). In conclusion, the use of the following
nanofilter will be recommended for production process:
Planova™ 20N; area: 0.120m²
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3.4 Formulation development
A suitable protein formulation buffer increases thermodynamic and kinetic stability
as well as shelf-life of the active pharmaceutical ingredient (API). The following
parameters were predetermined for formulation development:
• Development of a liquid dosage form
• Antibody concentration of 1mg/mL
In 2011, Warne et al. stated that the effort for the development of protein for-
mulations for Phase-I-biopharmaceuticals can be reduced drastically by using a
platform approach (Warne, 2011). Based on formulations of approved drugs, those
investigators tried narrowing down reasonable combinations of buffer compositions
and properties.
When analyzing pH of formulations of approved antibody therapeutics (see ex-
amples in table 3.10), it can be seen that a mild acidic pH is common and the main
buffer ions are Histidine or Phosphate. Histidine was used as buffer component
for NF-CUN297Q due to its pKa-value of 5.97 (instead of 7.2 for Phosphate). Thus,
Histidine exhibits a higher buffer capacity in mild acidic environment; it is also
recommended as starting buffer by Warne et al. in buffers from pH 5.60 to 6.80.
The addition of a protectant against the influence of several stress factors such as
ultra-/diafiltration or freeze-thaw-cycles is recommended. Saccharose is quite com-
mon in lyophilized dosage forms. When using an acidic pH in liquid dosage forms,
Saccharose is an unfavorable choice due to glycolysis. This degradation reaction
can especially be observed in the presence of Imidazole (Farr and Heitz, 1974). A
reasonable alternative is Trehalose because of a more stable α-α-1,1-glycosidic bond
between the monosaccharides. Concentrations up to 100 g/L Trehalose are common
in formulations for monoclonal antibodies.
In order to maintain a physiological osmolality of roughly 300mOsm/kg, sodium
chloride is added to each test buffer if required. Usually, surfactants are added to
the protein formulation to reduce the risk of aggregate formation. The addition
of Tween® 20 or Tween® 80 is common in concentrations ranging from 0.01 to 0.2%.
The formulation development experiments were performed using a statistical strat-
egy termed “Design of experiments” (DoE) (Fisher, 1990). With this approach,
multiple factors (parameters) of an experiment are altered simultaneously and a
correlation to multiple responses (results) can be deducted and verified. This is an
established approach for process- and formulation development of biopharmaceuti-
cals.
Differential scanning fluorimetry (DSF) was used for determination of thermody-
namic stability of the API in a certain buffer. The half-maximal denaturation
temperature (melting temperature) of the monomer was determined with this
method. The thermal stress test was used for determination of kinetic stability
of the API. After incubation of the antibody solution at 40 °C for 1 or 4 weeks,
SEC (Superdex) / UHPLC analysis of the antibody in the respective buffer was
performed. The amount of aggregates and the amount of monomer normalized to
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the whole peak area were determined.
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Table 3.10: Formulation composition of selected monoclonal antibodies in liquid dosage form (FDA-Accessdata, 2015)
Drug Approval Conc. pH Buffer Isotonisation Sugar Surfactant
Rituximab 1997 10mg/ml 6.5 25mM Citrate 150mM NaCl none 0.07% Tween® 80
Daclizumab 1997 5mg/mL 6.9 70mM Phosphate 80mM NaCl none 0.02% Tween® 80
Palivizumab 1999 100mg/mL 6.0 25mM Histidine 10 mM NaCl none none
1.5mM Glycine
Adalimumab 2002 50mg/mL 5.2 15mM Phosphate 100mM NaCl 12 g/L Mannitol 0.1% Tween® 80
10mM Citrate
Tositumomab 2003 2.5mg/mL 7.2 10mM Phosphate 150mM NaCl 100 g/L Maltose none
18mM KOH
Cetuximab 2003 2mg/mL 7-7.4 15mM Phosphate 150mM NaCl none none
Natalizumab 2004 20mg/mL 6.1 15mM Phosphate 150mM NaCl none 0.02% Tween® 80
Bevacizumab 2005 25mg/mL 6.2 50mM Phosphate none 60 g/L Treh.*2H2O 0.04% Tween
® 20
Ranibizumab 2006 10mg/ml 5.5 10mM Histidine none 100 g/L Treh.*2H2O 0.01% Tween
® 20
Panitumumab 2006 20mg/mL 5.6-6.0 80mM NaOAc 100mM NaCl none none
Eculizumab 2007 10mg/mL 7.0 15mM Posphate 150mM NaCl none 0.022% Tween® 80
Golimumab 2009 100mg/mL 5.5 5.6mM Histidine none 41 g/L Sorbitol 0.015% Tween® 80
Ipilimumab 2011 5mg/mL 7.0 100 µM DTPA 100mM NaCl 10 g/L Mannitol 0.01 % Tween® 20
20mM Tris
Tocilizumab 2011 20mg/mL 6.5 15mM Phosphate none 50 g/L Saccharose 0.05% Tween® 80
Nivolumab 2014 10mg/mL 6.0 20 µM DTPA 50mM NaCl 30 g/L Mannitol 0.02% Tween® 80
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3.4.1 Formulation screening
In the formulation screening experiment, the screening buffers comprised the follow-
ing constant properties:
• 20mM Histidine
• Osmolality 300mOsm/kg
• Antibody concentration 1mg/mL
The experiment was performed with the following factors (parameters or variables)
as full factorial analysis (see figure 3.36):
• pH 5.60 to 6.80
• Tween® 20 or Tween® 80 from 0% to 0.15%
• Trehalose from 0 to 100 g/L1
Figure 3.36: Formulation screening: Design region
Performed experiments are marked in the corners and in the center of design region
The following responses (results) were investigated:
• Melting temperature determined via differential scanning fluorimetry (DSF)
Tm1
• Aggregate content after 1 week at 40 °C determined via SEC (Superdex) on
UHPLC
• Monomer content after 1 week at 40 °C determined via SEC (Superdex) on
UHPLC
1NaCl was added to maintain osmolality of 300mOsm/kg ranging from 150mM NaCl for 0 g/L
Trehalose to 0mM NaCl for 100 g/L Trehalose
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For evaluation of connections between factors and responses, the fitting method
“partial least squares” (PLS) was performed by software “Modde 10.0”. Results
are presented in heat maps, green is a favorable condition, red is an unfavorable
condition. The R2, Q2 and residual standard deviation (RSD) of each plot are noted
in the caption of the figures.
To evaluate the informative value of a model, the following statistical parameters
were considered:
• R2 (Coefficient of correlation) shows the model fit; 0.5 is a model with rather
low significance.
R2 “
the sum of squares of Y corrected for the mean, explained by the model
the total sum of squares of Y corrected for the mean
(3.2)
• Q2 shows an estimate of the future prediction precision. Q2 should be greater
than 0.1 for a significant model and greater than 0.5 for a good model.
Q2 “ 1´
the prediction residual sum of squares
the total sum of squares of Y corrected for the mean
(3.3)
• RSD (residual standard deviation)
3.4.1.1 Results for Tween® 20 buffers
The results are presented in table 3.11 and figures 3.37, 3.38 and 3.39. For response
Tm1, R
2 and Q2 are both higher than 0.5. RSD is with 0.32 relatively low.
For response “Aggregate content [%] at 40 °C for 1 week” R2 is higher than 0.5. Q2
is lower than 0.5. RSD is with 1.58 relatively low.
For response “Monomer content [%] at 40 °C for 1 week” R2 is higher than 0.5. Q2
is lower than 0.5. RSD is with 2.30 relatively low.
The calculated models are not fitted perfectly. Due to the fact that this experiment
is only the screening for a preliminary formulation, the results are evaluated anyway.
For response Tm1, the most favorable conditions are found at pH 5.6, Tween
® 20-
concentration of 0.15% and 100 g/L Trehalose with a melting temperature of Tm1
= 73 °C. The worst conditions are pH 5.6, no Tween® 20 and no Trehalose with
Tm1 = 67 °C.
For responses “Aggregate content [%] at 40 °C for 1 week” and “Monomer con-
tent [%] at 40 °C for 1 week” the most favorable conditions are found at pH 6.8, no
Tween® 20 and 100 g/L Trehalose with down to 0% aggregation and 98% monomer.
The worst conditions are found at high concentrations of Tween® 20 from pH 5.6
to 6.8. Trehalose has a positive effect on aggregation property, especially at lower
pH-values. The highest determined amount of aggregation was 5% and the lowest
amount of monomer was 93%.
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Table 3.11: Formulation screening - Buffer composition and responses for Tween® 20
buffers
Parameters Responses
pH Tween® 20 Trehalose Tm1 Aggregate Monomer
[%] [g/L] [°C] content [%] content [%]
40 °C 1 week 40 °C 1 week
5.6 0 0 66.8 4.04 93.53
6.8 0 0 67.2 0.21 98.06
5.6 0.150 0 69.0 5.15 91.92
6.8 0.150 0 68.0 6.32 91.75
5.6 0 100 71.8 1.01 95.17
6.8 0 100 70.4 0.20 97.32
5.6 0.150 100 73.2 3.45 91.43
6.8 0.150 100 71.0 5.33 92.00
6.2 0.075 50 70.0 0.61 97.47
6.2 0.075 50 70.1 1.38 96.77
6.2 0.075 50 70.1 1.65 96.38
Figure 3.37: Formulation screening - Tween® 20 - Melting temperature Tm1
Numbers and heat lines in the plot represent Tm1; R
2 = 0.99; Q2 = 0.62; RSD = 0.32
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Figure 3.38: Formulation screening - Tween® 20 - Aggregate content [%] after 1 week
at 40 °C Numbers and heat lines in the plot represent the aggregate content in % of protein;
R2 = 0.80; Q2 = 0.23; RSD = 1.58
Figure 3.39: Formulation screening - Tween® 20 - Monomer content [%] after 1 week
at 40 °C Numbers and heat lines in the plot represent the monomer content in % of protein;
R2 = 0.69; Q2 = 0.12; RSD = 2.30
3.4.1.2 Results for Tween® 80 buffers
The results are presented in table 3.12 and figure 3.40. For response “Aggregate con-
tent [%] at 40 °C for 1 week”, R2 and Q2 are both higher than 0.5. RSD is with 1.20
relatively low. The statistical significance of this model is very high and is evaluated.
A direct significant correlation of Tween® 80-concentration and the aggregation
property can be observed. As a consequence, all further experiments with buffers
containing Tween® 80 were omitted because this compound seems to induce aggre-
gation.
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Table 3.12: Formulation screening - Buffer composition and responses for Tween® 80
buffers
Parameters Responses
pH Tween® 80 Trehalose Tm1 Aggregate Monomer
[%] [g/L] [°C] content [%] content [%]
40 °C 1 week 40 °C 1 week
5.6 0 0 66.8 4.04 93.53
6.8 0 0 67.2 0.21 98.06
5.6 0.150 0 69.2 23.51 71.70
6.8 0.150 0 68.8 21.86 76.54
5.6 0 100 71.8 1.01 95.17
6.8 0 100 70.4 0.20 97.32
5.6 0.150 100 74.4 22.82 73.72
6.8 0.150 100 71.8 23.34 74.53
6.2 0.075 50 70.3 10.99 87.45
6.2 0.075 50 70.4 10.10 88.32
6.2 0.075 50 70.6 11.84 86.53
Figure 3.40: Formulation screening - Tween® 80 - Aggregate content [%] after 1 week
at 40 °C Numbers and heat lines in the plot represent the aggregate content in % of protein;
R2 = 0.99; Q2 = 0.73; RSD = 1.20
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3.4.1.3 Sweet spot analysis
The sweet spot analysis tool allows the combination and visual presentation of ac-
ceptance criteria for various responses. In order to determine a sweet spot area for
the Tween® 20 experiment, the following specifications were set for each response:
• Tm1: > 70°C
• Aggregate content after 1 week at 40 °C: 0-1% of whole peak area
• Monomer content after 1 week at 40 °C: > 95% of whole peak area
The sweet spot area is located in the area of pH 5.6 to 6.8 and Tween® 20-
concentration of 0 to 0.075% with 100 g/L Trehalose (see figure 3.41). The so-called
sweet spot is marked in green, two criteria met is marked in pale blue, one criterion
met is marked in dark blue and no criteria met is marked in white.
Figure 3.41: Formulation screening - Sweet spot analysis
The so-called sweet spot is marked in green, two criteria met is marked in pale blue, one criterion
met is marked in dark blue and no criteria met is marked in white
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3.4.2 Formulation optimization
Due to the fact that the sweet spot area of the formulation screening experiment
is still very large, an optimization experiment was performed with the following
constant properties for each optimization buffer:
• 20mM Histidine
• Osmolality 300mOsm/kg
• Antibody concentration 1mg/mL
• 100 g/L Trehalose
The experiment was performed with the following factors (parameters) as full fac-
torial analysis including star points in the central composite design face-centered
(CCF-design):
• pH 5.60 to 6.80
• Tween® 20 from 0% to 0.075%
The buffers investigated are marked on the sweet spot plot of the formulation screen-
ing experiment (see figure 3.42).
Figure 3.42: Formulation optimization - Design region deducted from the sweet spot
analysis of the formulation screening experiment
The following responses were investigated:
• Melting temperature determined via DSF (Tm1)
• Aggregate content after four weeks at 40 °C determined via SEC (Superdex)
on UHPLC1
1The assessment of aggregate and monomer content was performed after 4 weeks instead of 1
week because no difference in SEC-profiles was detectable.
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• Monomer content after four weeks at 40 °C determined via SEC (Superdex) on
UHPLC
For evaluation of connections between factors and responses, the fitting method
“partial least squares” (PLS) was performed by software “Modde 10.0”. Results are
depicted in heat maps. The R2, Q2 and residual standard deviation (RSD) of each
plot are noted in the caption of figure 3.43.
3.4.2.1 Results for Tween® 20 buffers
For calculation of the models, all relationships that were not statistically significant
were omitted from model fitting. This was done to increase the informative value
of the models.
For response Tm1 the omitted relationships were T20*T20 and T20*pH. For re-
sponses “Aggregate content [%] at 40 °C for 1 week” and “Monomer content [%] at
40 °C for 1 week” the omitted relationships included T20, T20*T20 and T20*pH.
For all responses the statistical parameters R2, Q2 meet their specifications and RSD
is relatively low. Despite of some weaknesses in the model fitting, the statistical
significance of these models is high enough for preliminary formulation studies.
For response Tm1, the best conditions were found at pH 5.8 and Tween
® 20-
concentration of 0.075%. The melting temperature at these conditions was Tm1
= 73.5 °C (see table 3.13 and figure 3.43). The worst condition was pH 6.8 / no
Tween® 20; the melting temperature was less than 71 °C.
For responses Aggregates [%] and Monomer [%] the best conditions are found at
pH-values higher than 6.2. The Tween® 20-concentration is irrelevant. Best values
for aggregation were less than 0.5% and more than 95% monomer. The worst
conditions are found at pH 5.6 with an aggregate content of more than 1.5% and
less than 90% monomer.
Table 3.13: Formulation optimization - Buffer composition and responses
Parameters Responses
pH Trehalose Tm1 Aggregate Monomer
[g/L] [°C] content [%] content [%]
40 °C 4 weeks 40 °C 4 weeks
5.6 0 72.2 0.97 90.70
6.8 0 70.2 0.32 96.29
5.6 0.0750 73.6 1.66 89.85
6.8 0.0750 71.4 0.39 95.71
5.6 0.0375 73.3 2.68 85.80
6.8 0.0375 71.4 0.38 95.76
6.2 0 72.8 0.28 94.69
6.2 0.0750 73.0 0.24 94.57
6.2 0.0375 72.8 0.34 94.36
6.2 0.0375 72.7 0.31 94.24
6.2 0.0375 72.9 0.24 94.52
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Figure 3.43: Formulation optimization - Melting temperature Tm1, Aggregate and monomer content [%] after 4 weeks at 40 °C
Tm1: R2 = 0.92; Q2 = 0.77; RSD = 0.34
Aggregates [%]: R2 = 0.76; Q2 = 0.57; RSD = 0.43
Monomer [%]: R2 = 0.86; Q2 = 0.76; RSD = 1.33
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3.4.2.2 Sweet spot analysis
In order to determine a sweet spot area for the formulation optimization experiment,
the following specifications were set for each response:
• Tm1: > 72°C
• Aggregate content after 4 weeks at 40 °C: 0-1% of whole peak area
• Monomer content after 4 weeks at 40 °C: > 95% of whole peak area
The sweet spot for these conditions is a narrow area in the range of pH 6.3 to 6.6
from 0 to 0.075% Tween® 20 (see figure 3.44).
6,8
Figure 3.44: Formulation optimization - Sweet spot analysis
The so-called sweet spot is marked in green, two criteria met is marked in pale blue, one criterion
met is marked in dark blue and no criteria met is marked in white
The analysis of the sweet spot plot results in a preliminary formulation buffer with
the following properties:
• 20mM Histidine pH 6.4
• 100 g/L Trehalose
• 0.05% Tween® 20
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The purpose of this thesis was to develop a production process and a preliminary
protein formulation buffer for the bispecific antibody NF-CUN297Q. The GMP-grade
active pharmaceutical ingredient (API) obtained from the production process is in-
dented for application in a clinical phase I/IIa trial for the treatment of AML.
A main issue of biopharmaceutical process development is to develope a process,
which is capable of producing an API with the required purity. In most cases,
regulatory authorities do not demand specified quality objectives but rather high
quality and scientific and risk-based justification of specifications for critical qual-
ity attributes (CQA) (ICH-Q6B, 1999). Another fact to consider is the required
amount of the API for a clinical phase I/IIa trial and for validation of all necessary
production steps and assays. The outcome of these quality and quantity objectives
is the prerequisite for process development.
The achievements of process development for bispecific antibody NF-CUN297Q will
be evaluated in terms of these objectives.
4.1 Determination of quality objectives
ICH-Guideline Q11 subdivides critical quality attributes (CQAs) in properties or
characteristics that affect identity, purity, biological activity and stability of the
active pharmaceutical ingredient (API) (ICH-Q11, 2012).
In the following part, the determined specifications for identity, biological activity
and stability of the API are discussed. Subsequently, specifications for product- and
process-related impurities as well as for viral- and TSE-safety are discussed.
Specifications for CQAs were adopted from mandatory authoritative requirements,
if existing. If no specific values are demanded, commonly applied specifications
were adopted. If commonly applied specifications were not feasible (e.g. for product-
related impurities), the determination of specifications was based on characterization
experiments. All determined specifications for the process- and formulation devel-
opment are summarized in table 5.5 at page 151.
4.1.1 Active pharmaceutical ingredient (API)
The monomeric bispecific antibody NF-CUN297Q can be identified via SDS-PAGE,
isoelectric focusing electrophoresis and flow cytometric titration. The results must
accord with theoretical values.
The purification process may influence the biological activity of the API. Thus, the
specifications for biological activity were set as follows.
Flow cytometric analysis: a comparable binding property to cells presenting the
antigens of interest compared to an appropriate reference and no loss of binding
activity during purification.
T-cell proliferation assay: a comparable proliferation-inducing property of T-
cells compared to an appropriate reference and no loss of activation properties
during purification.
Potency assay (Promega): a comparable activity of the purified API of three
batches.
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The unspecific activation of T-cells in the absence of target cells was already ob-
served in initial characterization experiments at the Department of Immunology
(Durben, 2012; Durben et al., 2015). The assumption that this activation could be
assigned to aggregates was not correct. The unspecific activation is triggered by
the monomer which may bind to FLT3 on monocytes and thereby activates T-cells
(Gabbianelli et al., 1995; Durben et al., 2015). This unintended biological activity
is an immanent property of the monomeric bispecific antibody and can therefore
not be reduced or removed.
Stability of an API must be ensured in all phases of clinical development and
shelf-life of the product should be at least one year. No real-time/real-temperature
studies in an appropriate formulation buffer were performed so far. However, sur-
rogate specifications for thermodynamic and kinetic stability can be deducted from
performed experiments and can be applied for formulation development: Melting
temperature Tm1 ą 72 °C, aggregate content ă 1% after four weeks at 40 °C and
monomer content ą 95% after four weeks at 40 °C. If and to what extent these
specifications correlate to a high stability and long shelf-life must be verified in
real-time/real-temperature studies. Those studies are not part of this thesis. If a
preliminary formulation buffer indicates sufficient stability, it should be suitable for
application in clinical phase I/IIa trials. A profound formulation development and
stability study should be performed for a clinical phase III trial.
4.1.2 Impurities
Specifications for the critical concentration of protein-based impurities such as ag-
gregates, light chain dimers (LCD), light chains (LC), Host cell proteins (HCP) and
Leached affinity ligands (LKS) were defined. These impurities are immunogenic
and might therefore lead to the generation of α-API antibodies in patients (de
Zafra et al., 2015; Romer et al., 2007). This might have a significant impact on
efficacy. Thus, the specifications for these protein-based impurities should be very
low in all phases of clinical development as well as for approved drugs (Chon and
Zarbis-Papastoitsis, 2011).
Because of their API-specific properties, the biological activity of the product-
related impurities aggregate, LCD and LC was characterized in order to develop
scientific and risk-based purity specifications. These impurities exhibited only
minimal biological activity. However, in order to increase safety and to minimize
unintended immunological or renal reactions, the acceptable aggregate and LCD
level was lowered to ă 1% and to ă 2% for LC (determined via SEC Superdex).
Specifications of process-related impurities were adopted from similar processes
with monoclonal antibodies, because the CHO-based production process followed
by biospecific interaction chromatography can be regarded as well-known. The
specification for HCP was set to ă 100 ppm, for Host cell DNA (HCDNA)1 to
ă 10 ppm and for leached affinity ligand to ă 10 ppm. Those threshold values are
generally regarded as safe (Chon and Zarbis-Papastoitsis, 2011; WHO-Biologicals,
1a commonly accepted specification for HCDNA content is 10 ng/dose; assuming a maximum
dose of 1mg/day, which is already overestimated (see 4.2 at page 116), a specification of 10 ng/mg
(10 ppm) was set. Because of the dose-overestimation, this is a safe specification.
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2010). The specification for the critical concentration of HCDNA was set very low
because of the possibility to transmit oncogenes or proviruses along with the DNA.
Despite the fact that a clinical confirmation of this mechanism has not been shown
so far (11/2015), the specifications for this impurity should be low in all phases of
clinical development because of the potential severe effects of a gene transmission.
In contrast to most other impurities, the influence of endotoxins on patients is very
well described. Thus, regulatory authorities issued mandatory specifications for this
impurity: 5 IU/h/kg (Ph.Eur. 7.0, 2015).
4.1.3 Viral and TSE safety
Another critical aspect is to ensure viral safety. Specifications for viral safety were
adopted from the European medicines agency (EMA): This regulatory authority
states that a conversion of the demanded sterility assurance level (SAL) of 10´6
for sterile products to viral safety is justifiable; the assurance level is the likelihood
of contamination risk per vial (EMA-CPMP/BWP/268/95, 1996). However, the
confirmation of this assurance level can only be obtained in viral clearance studies
with a small-scale model of the production process. That study is not part of this
thesis.
The risk of transmissible spongiform encephalopathy (TSE) proteins is still not
completely understood and therefore the specification from EMA is: “the absence
of any TSE-proteins” (EMA-2011/C-73/01, 2011). The presence of these proteins
should be completely avoided in all phases of clinical development as well as in drug
approval. No animal-derived raw material will be used in the process (except for the
use of the CHO-based production cell line). Thus, this specification will be fulfilled.
4.2 Determination of quantity objectives
4.2.1 Estimated dose, final product concentration and batch
size requirements
A realistic dose estimation for an active pharmaceutical ingredient (API) is impor-
tant for reliable process development. The batch size requirements for a planned
clinical trial can only be deducted from this estimation. Because of the fact that
no safety study with animals was conducted so far, the estimated dose can only
crucially be derived from similar drugs in clinical development. The most recently
FDA-approved bispecific antibody is Blinatumomab (FDA-Accessdata, 2015). In a
clinical phase II trial, patients received 15 µg/m²/day for 28 days, which is about
30 µg per day and 840 µg in 28 days (Clinicaltrials.gov, 2015).
The minimal reliable filling volume for the intended liquid dosage form is 0.5mL
per vial and concentration is to be set to 1mg/mL because previous observations
indicated that the protein is stable at this concentration. In conclusion, 500 µg of
NF-CUN297Q is available per vial.
Assuming a medication cycle of at most 28 days, one patient needs 28 vials and
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therefore 14mg API. Assuming a maximum of 50 patients per trial, 700mg API
will be required for a clinical phase I/IIa trial.
However, 94% of the vial content will be discarded with this liquid dosage form. The
development of a lyophilized dosage form would be more economic; Blinatumomab
contains 35 µg of lyophilized API per vial (BlinCyto, 2015). The development of
a lyophilized dosage form will not be performed for the clinical phase I/IIa trial
because of the higher development effort compared to a liquid dosage form. That
development could be pursued for a clinical phase III trial or for drug approval.
Calculation of the required API for additional regulatory requirements such as
safety studies, stability studies, a viral clearance study and validation of parts of
production and quality control is difficult to predict at this stage of process devel-
opment.
4.2.2 Technical limitations of the production process
KappaSelect binding proteins (KSBP) exhibit a DBC10% of 18.5mg/mL towards
the KappaSelect affinity resin. A range of 30 to 70% of this capacity will be applied
in production process in order to avoid a shift of the proportion of monomer to
LCD/LC; the latter residues exhibit a higher affinity towards the KappaSelect resin
due to their smaller molecular weight and same (LC) or twice as many binding sites
(LCD) compared to the monomer.
The smallest KappaSelect column connectable to an A¨KTA ready purification sys-
tem is a 1 L column (GE-Healthcare, 2015) which can bind 5550mg to 12950mg
KSBP at 30 - 70% of DBC10%.
In a test fermentation run, productivity in a 10L-wave-reactor was 110mg/L KSBP
consisting of approximately 55% NF-CUN297Q-monomer, 40% LCD/LC and 5% ag-
gregates. A 100L wave-reactor will be used in the production process. Therefore,
approximately 11,000mg KSBP comprising 6050mg NF-CUN297Q-monomer will be
produced. Thus, a purification process with a polishing recovery of at least 80%
produces 5000mg of polished NF-CUN297Q-monomer. In conclusion, two to three
batches should be sufficient for a clinical phase I/IIa trial including all regulatory
requirements.
4.3 Achievement of quality objectives
4.3.1 Molecular biology and Cell banking
A stably transfected Chinese hamster ovary (CHO)-based clone was generated for
permanent and reliable production of bispecific antibody NF-CUN297Q under serum-
free conditions. This primary seed bank (PSB)-clone is suitable for the generation of
a Master cell bank (MCB) and a Working cell bank (WCB) under GMP-conditions.
The MCB and WCB must be generated and tested according to ICH-Guidelines
Q5D and Q5A (ICH-Q5D, 1997) (ICH-Q5A (R1), 1999). This task is not part of
this thesis.
Quality objectives for the absence of microbial contamination, viral safety and
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Transmissible spongiform encephalopathy (TSE)-proteins were met. Separate re-
ports were generated for the plasmid construction (by Dr. Ludger Große-Hovest)
and for the generation of a PSB (by Gregor Neumann).
4.3.2 Fermentation
Fermentation in a university-related setting was only possible because disposable
fermentation equipment was available for lab- and verification scale of the fermen-
tation. Verification scale was a 10L-wave reactor. Development with stainless steel
equipment would not have been feasible.
As already discussed in 4.2.2 at page 117, the achieved production titer of 110mg/L
KappaSelect binding protein (KSBP) is sufficient for the intended production pro-
cess. Quality objectives for the absence of microbial contaminants and viral safety
will be fulfilled when the production process is performed under GMP-conditions
in a clean room. The fermentation will be performed with animal-component free
fermentation media and equipment. Therefore, the quality objectives for TSE-safety
will be fulfilled as well.
4.3.3 Purification
4.3.3.1 Affinity chromatography
KappaSelect binding proteins (KSBP) exhibit a DBC10% of 18.5mg/mL towards
KappaSelect affinity resin. This is an average capacity compared to manufacturers
data sheet (GE-Healthcare, 2012). GE Healthcare states that the DBC10% for Fab-
fragments is 15mg/mL. NF-CUN297Q has 1.75-times the weight of one Fab-fragment.
Thus, KappaSelect should theoretically bind 26.25mg NF-CUN297Q per mL Kappa-
Select resin. This capacity is propably reduced due to sterical reasons and therefore
the value of 18.5mg/mL is an average capacity. This DBC10% is sufficient as already
discussed in 4.2.2 at page 117.
The affinity chromatography was not further optimized in terms of removal of
product- and process-related impurities. A modification of washing conditions or
flow rates was not evaluated because the polishing process in small-scale model AH1
was sufficiently effective to allow removal of product- and process-related impurities.
4.3.3.2 Polishing applications
Usually, the purity achieved after initial purification is not sufficient for application
in a clinical phase I/IIa trial. Thus, additional chromatographic techniques were
evaluated for their suitability to purify the active pharmaceutical ingredient (API)
without affecting its biological activity. Those methods are termed “polishing ap-
plications”. This discussion part refers to the buffer verification models (see results
part 3.3.2.2 at page 61 ff.).
Anion exchange chromatography (AIEX):
When comparing the isoelectric points (IEPs) of the monomer and LCD/LC to
the IEPs of process-related impurities, it can be seen that a high pH (but lower
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than the IEP of the monomer) is favorable. In that way, all components with IEPs
below the applied pH bind to the positively charged resin, whereas the components
with higher IEPs such as the monomer and the aggregate flow through the column
(see figure 4.1). A pH-value of 8.00 and conductivity of 3.0mS/cm is therefore very
suitable for removal of product- and process-related impurities.
The reduction of the aggregate-, LCD and LC content is efficient with this method.
However, a second, at best orthogonal chromatography step such as Hydrophobic
interaction chromatography (HIC) or Multimodal chromatography (MMC) would
be necessary for a more efficient removal of these impurities. Yield is average at
89%. The method effort is low due to the application of a flow-through mode
(FT mode). The theoretical properties for removing process-related impurities and
viruses are very promising. The removal of product- and process-related impurities
was verified in the small-scale model (see chapter 4.3.3.3 at page 121).
Cation exchange chromatography (CIEX):
In figure 4.1 can be seen that the application of a high pH (but lower than the IEP of
the monomer) is favorable. In that way, only the monomer and the aggregate bind
to the negatively charged resin, whereas all the other impurities flow through the
column. A pH-value of 7.30 and conductivity of 3.5mS/cm is therefore a suitable
application buffer for the removal of impurities.
Unfortunately, aggregation is induced by this method. This may be caused by a
fast conductivity shift from 3 to 15mS/cm (binding to elution), which might induce
aggregate formation. The method effort is very high due to the performance of a
bind-elute (BE) mode and due to the small bead size of 40 µm, which results in a
low flow rate.
Comparison of AIEX and CIEX for purification of NF-CUN297Q
The most significant disadvantage of CIEX compared to AIEX is the aggregate-
inducing property. A significant advantage of AIEX compared to CIEX is, that the
DBC10% of impurities towards the AIEX resin will not be reached in practice due
to their low concentration compared to the monomer. In contrast, the DBC10% of
the monomer on a CIEX resin can very easily be reached and must be evaluated.
Another advantage of AIEX is the applicability of a higher pH compared to CIEX
resulting in better impurity removal (see figure 4.1). AIEX ensures a faster process
step, because the FT mode is faster than the BE mode. Furthermore, a FT mode
requires less development effort, because no elution buffer must be developed. The
elution buffer of the BE mode has a higher conductivity than the FT-buffer and
therefore co-elutes more impurities than the FT-buffer.
One advantage of CIEX is the enrichment of the monomer, whereas AIEX dilutes
the monomer.
In conclusion, AIEX exhibits more advantages than CIEX for purification of NF-
CUN297Q and should be applied. In addition, CIEX is not suitable, especially
because of the aggregate-enriching properties.
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Monomer
LCD/LC
HCP
HCDNA
Viruses
Endotoxins
pH 1 2 3 4 5 6 7 8 9
M1M2
Figure 4.1: Isoelectric points/areas (IEP) of process- and product-related impurities
Marker M1: pH-conditions for Anion exchange chromatography
Marker M1: pH-conditions for Cation exchange chromatography
LCD = Light chain dimer; LC = Light chain; HCP = Host cell proteins; HCDNA = Host cell
DNA
Hydrophobic interaction chromatography (HIC):
Due to the fact that the performance of a protein on a HIC chromatography medium
is difficult to predict, seven different media were evaluated for their suitablity to
separate the monomer from LCD/LC with the same buffer conditions. Because
of the relatively low aggregate content, this KSBP could not be evaluated in the
purification chromatograms. LCD/LC on the other hand, represent almost 50% of
KSBP and can therefore be used as “reporter impurities”. The resin with the best
peak separation was chosen for further investigation; Phenyl HP. LCD and LC elute
at a lower conductivity than the monomer and are therefore more hydrophobic than
the monomer. This was an expected behavior, because in mAbs, heavy and light
chain heterodimerize not only via disulfide bonds, but also through hydrophobic
interaction in the molecule parts directed to the complementary chain. If one of
these chains is not paired, it exposes a huge hydrophobic flank resulting in increased
hydrophobicity compared to a mAb-monomer. The aggregate is also more hydro-
phobic than the monomer; when the monomer is exposed to stressful conditions
such as low pH, the tertiary structure partially unfolds and exposes hydrophobic
flanks resulting in aggregation. Some of these flanks are still exposed on the surface
of the aggregate and result in higher hydrophobicity compared to the monomer.
In conclusion, the method is suitable for the removal of aggregates and LCD/LC.
Yield is average at 90%. An advantage of this HIC-process is the possibility to
perform the process in FT mode (see AIEX). The conductivity, which is required for
separation is not very high (18mS/cm) and did not show any influence on biological
activity.
In contrast to that, it is not possible to predict the properties of process-related
impurities on HIC. Those properties were verified in the small-scale model (see
chapter 4.3.3.3 at page 121).
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Multimodal chromatography (MMC):
The properties of KSBP and process-related impurities on a MMC chromatography
medium are almost impossible to predict. Because of the HIC-properties of MMC
chromatography media, processes are much more salt tolerant than classical CIEX
applications. Required load and elution conductivities are usually much higher and
were determined with 20 and 63mS/cm respectively. The high load conductivity
resulted in reduced binding capacity for the monomer. The even higher elution
conductivity might have an influence on biological activity of the monomer and
might lead to co-elution of previously bound impurities. The application of a BE
mode is a disadvantage in later production process.
Removal of aggregates and LCD/LC is very efficient with this MMC method. Un-
fortunately, the yield is too low with only 75%. This might be the consequence of
the high binding conductivity as already assumed earlier (see above). The MMC
process would be suitable for further optimization. However, the process was not
developed further because the results of AIEX and HIC were more promising and
were verified with a small-scale model.
Summary and conclusion:
Biological activity does not decrease after application of the polishing methods; no
difference in binding properties and T-cell proliferation induced by the API was
observed.
In conclusion, a very reasonable arrangement for polishing is the use of AIEX and
HIC. The methods utilize different chemical properties of the API and the impurities
and therefore ensure high purity. Despite the fact that no theoretical predictions
about removal properties for process-related impurities are feasible for HIC, those
predictions are very promising for AIEX and were verified with a small-scale model.
The intended application of AIEX would therefore be the removal of LCD/LC, some
aggregates, process-related impurities and viruses, whereas HIC removes LCD/LC
and especially aggregates.
When a polishing process is performed with the AIEX method first and then the
HIC method, no buffer exchange would be required. Subsequently after performance
of AIEX in FT mode, (NH4)2SO4 is added to increase conductivity and a second
FT-mode is performed with HIC. Thus, because of two FT modes, the process can
be performed very fast and no elution buffers must be developed.
4.3.3.3 Process verification
Process verification refers to the small-scale model AH1 (see results part 3.3.3 at
page 92 ff. and appendix chapter 5.3 at page 139).
Process AH1 combines the initial purification using KappaSelect and the polishing
applications anion exchange and hydrophobic interaction chromatography. The
process exhibits very effective removal properties for aggregates and LCD/LC. This
correlates to previous results (see above).
Monomer yield decreases with increasing load of KSBP onto the process columns.
Process AH1.2 with 131% KSBP load exhibits a higher concentration than process
AH1.3 with 90% KSBP load. This might result in more unintended retention of
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the monomer to the AIEX or HIC resins. Thus, 100% load, which equals 130mg
KSBP for the small-scale model should be pursued.
For all three produced batches, SDS-PAGE, SEC (Superdex), CIEX / UHPLC were
nearly identical. CIEX / UHPLC shows three acidic variants, two basic variants and
one main peak of the API in all three batches with similar peak areas. Thus, this
pattern indicates a stable, robust and reproducible process. Usually, glycosylation
is responsible for this phenomenon. NF-CUN297Q is not N-glycosylated. The acidic
variants may be the result of posttranslational modifications such as asparagine
deamidation. Basic variants may be the result of pyroglutamate formation from
N-terminal glutamine (Brorson and Jia, 2014; Rehder et al., 2006).
HCP and HCDNA are efficiently removed especially during AIEX purification and
meet their specifications. This correlates to earlier predictions (see above). The
removal of leached KappaSelect (LKS) could not be verified because of an influence
of LCD/LC on the ELISA readout. LCD and especially LC did not completely
denature at 95 °C for 15min. and seemed to bind to KappaSelect ligand with their
binding sites resulting in a false-low signal. The theoretical properties of AIEX for
removal of LKS-Ligand are very promising due to its low IEP of 5.
Determination of endotoxin-level has no informative value, since the research-
equipment might be contaminated. The endotoxin concentration will be determined
when process AH1 is performed in process scale under GMP-conditions. The risk
of contamination will be very low, because no gram-negative bacteria such as Es-
cherichia coli will be used for production. However, removal properties of AIEX for
endotoxins are very promising because of the low IEP of Lipopolysaccharides.
All titration curves of flow cytometric analysis of IPCs are comparable, no loss of
affinity is observed during purification. All titration curves of the T-cell proliferation
assay of the IPCs are comparable, no loss in proliferation-inducing properties during
purification can be observed. Potency assay (Promega) is a very sensitive assay. A
minor reduction of potency compared to the reference can be observed in all three
batches. Perhaps the polishing resins alter the secondary and / or tertiary structure
of the monomer to a small extent, which cannot be observed in flow cytometric
analysis or T-cell proliferation assays. This loss of potency is not critical as long as
it is reproducible. All three batches show almost the same extent of potency loss
and the EC50=3.0 ng/mL still indicates a high potency. Thus, this phenomenon
can be considered as not critical.
In conclusion, the developed small-scale model AH1 is suitable for up-scaling to a
production process. The API produced with a process based on small-scale model
AH1 is suitable for application in a clinical phase I/IIa trial. A summary of the
achievement of quality objectives can be found in table 5.5 at page 151.
4.3.4 Viral and TSE safety
The three orthogonal virus reduction steps pH-inactivation, anion exchange chroma-
tography and nanofiltration combined with the profound testing of the parental cell
line and production under GMP-conditions reduce the risk of viral contamination of
the final product tremendously. The effects of the virus reduction steps can only be
discussed theoretically because the required viral clearance study was not performed
so far.
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pH-inactivation is a commonly applied method to reduce viral load and usually ex-
hibits a logarithmic10 reduction value (LRV) of 4 for viruses. The isoelectric points
of viruses are mostly acidic (see figure 4.1) and therefore they bind to the positively
charged anion exchange resin at pH 8.00. In the applied flow-through mode, the
viral load gets reduced as previously discussed for product- und process-related im-
purities. This methods usually exhibits a LRV of 5 for viruses.
Nanofiltration can be performed in less than 1.5 h with all three selected filters
Planova™ 15N, 20N and BioEx. Thus, all filters would be suitable for nanofiltration
in the production process. Nanofiltration usually exhibits LRVs of 4 to 6 for viruses.
Nevertheless, product recovery is an issue for Planova™ BioEx with only 88%. This
may be due to the fact that the filtration fibers consist of hydrophilic modified
polyvinylidene fluoride instead of cuprammonium regenerated cellulose in Planova™
15N and 20N. This might lead to enhanced adsorption of the API. Monomer re-
covery is slightly better in Planova™ 20N and filtration time is much shorter than
in Planova™ 15N. The suffix 15N does not mean that the actual pore diameter of
the filter is smaller and therefore holds back more viruses. Process development
scientists of “Asahi Kasei” asserted that a statement about the comparability of
virus removal between 15N and 20N can only be made after removal validation
of spiked viruses from the API (viral clearance study). These results and the fact
that Synimmune GmbH has the most experience with Planova™ 20N resulted in the
decision to apply this filter.
The confirmation of the viral safety assurance level of 10´6 can only be obtained in
viral clearance studies with a small-scale model of the process. This study is not
part of this thesis. However, the theoretical LRVs for viruses are very promising for
this process.
TSE safety is achieved by completely avoiding the use of animal-derived raw mate-
rial.
4.3.5 Preliminary formulation development
The development of the antibody formulation is regarded as preliminary. The tested
buffers were suggestions by Warne et al. for antibody formulations for a clinical
phase I trial (Warne, 2011). Despite a lack of fit for some mathematical models,
the results of the formulation development were evaluated. However, formulation
buffer development for a clinical phase III trial should include evaluation of more
potential buffer components.
The suitability of a test formulation was assessed in thermodynamic and kinetic
stability studies of the bispecific antibody in the respective buffer.
In the formulation screening experiment, three factors (parameters) which might
influence each other were altered simultaneously. The three factors were pH-value,
concentration of Trehalose and concentration of Tween® 20 or 80. The responses
were the melting temperature Tm1, the aggregate- and the monomer content after
1 week at 40 °C of thermal stress. Evaluation and illustration of the connection of
factors and responses was performed with an DoE approach.
For formulation screening of Tween® 20-buffers, the responses have their optimum
in different parts of the evaluated buffer composition area (design region). However,
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a high Trehalose concentration and a certain amount of Tween® 20 is necessary for
optimal thermodynamic and kinetic stability of the protein. The effects of these
two responses are pH-dependent.
The relevance of the responses for evaluation can be balanced with the sweet-spot
analysis tool. Cutoff for Tm1 was set not as strict as for responses aggregate and
monomer content after 1 week at 40 °C. The reason for this is that the latter re-
sponses represent kinetic stability, which correlates more to the shelf-life of a protein.
In addition, Tm1 is already very high even in unfavorable buffers compared to other
proteins (Menzen and Friess, 2013). The sweet-spot area was further investigated
in the formulation optimization experiment.
In the formulation screening experiment of Tween® 80-buffers, only response “Ag-
gregate content [%] at 40 °C after 1 week” was evaluated. A direct correlation
of Tween® 80-concentration and aggregation can be seen. This observation was
completely surprising; Tween® 80 is a common surfactant to prevent protein aggre-
gation, not to induce it. All subsequent experiments with Tween® 80-buffers were
omitted.
For formulation optimization, the sweet spot area of the Tween® 20-buffers from
the formulation screening experiment was further investigated.
Trehalose concentration was kept constant at 100 g/L and therefore only two
factors were altered during the experimental setting; pH-value and Tween® 20-
concentration. A standard optimization design includes so-called star-points. The
central composite design face centered (CFF)-design was chosen. The assessment
of aggregate and monomer content was performed after 4 weeks instead of 1 week
because no difference in SEC-profiles was detectable after 1 week. This indicates
a high kinetic stability of the protein. Due to the fact that more experiments
were performed in the design region, the optimization design resulted in a better
mathematical model fitting than for the screening experiments. All non-significant
connections between factors and responses were omitted from the model fitting, this
is an accepted convention.
For evaluation of the formulation optimization experiments, Tm1 was rated more
important. The sweet spot analysis results in a relatively large area of suitable
buffer compositions. The following buffer was chosen as preliminary formulation
buffer:
• 20mM Histidine pH 6.4
• 100 g/L Trehalose
• 0.05% Tween® 20
ICH-Guideline Q5C states that the determination of the expiration date should be
based on real-time/real-temperature studies (ICH-Q5C, 1995). Nevertheless, the
use of accelerated stability studies for determination of thermodynamic and kinetic
stability of a protein in certain formulation buffers is common (Weiss et al., 2009).
However, it has been shown that promising results in accelerated stability studies
do not always correlate to a longer shelf-life (Wang et al., 2007). Thus, these results
must be verified with real-time/real-temperature studies.
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In conclusion, API formulated in the developed preliminary formulation buffer
should be suitable for application in a clinical phase I/IIa trial. A summary of the
achievement of quality objectives can be found in table 5.5 at page 151.
4.4 Review of the development process
The special aspect of this thesis was the realization of good manufacturing practice
(GMP)-compliant late-stage development of a protein-based pharmaceutical drug
at an university-related setting. This section evaluates the technical feasibility to
achieve previously defined quality and quantity objectives at a small spin-off com-
pany operating at an university campus.
The profound characterization of biological activity of product-related impurities
was performed with standard equipment of the Department of Immunology. Process
development is possible with qualified personal and minimal resources. However,
the development process requires a profound overview over various technical and
legal requirements. Nevertheless, a viral clearance study must be entrusted to a
specialized company. In addition, the success of the preliminary formulation devel-
opment can only be assessed in real time/real temperature experiments. However,
the formulation development approach performed in this thesis should be applicable
for a wide range of antibody therapeutics.
The development process was performed in a period of 1.5 years. The investment
costs were about 150,000e and include a UHPLC, an A¨KTA-FPLC, a Q-PCR-
device, an orbital shaker and a 10L wave reactor. These expenses do not include
standard university equipment such as scales, centrifuges and gel chambers. Person-
nel costs were 55,000e and the expenses for chemicals, reagents, chromatography
columns, cell culture media, kits and plastic supply were about 24,000e. This cal-
culation of costs does not include expenses for the transfection plasmid, the cell line
or the viral clearance study. Those development expenses are very low compared to
the development costs at a contract manufacturing organization.
In conclusion, a small spin-off company operating at an university campus is capable
of developing a production process and formulation buffer for a biopharmaceutical
drug for application in a clinical phase I/IIa trial. This fundamental work lowers
the expenses for GMP-development and -production at a contract manufacturing
organization. The consecutive process development for a clinical phase III trial
should be performed by a pharmaceutical company with development experience.
4.5 Outlook
The next step towards a clinical phase I/IIa trial is to up-scale process AH1 and to
perform a verification run under GMP-conditions. The process data should be uti-
lized to verify the up-scaling and to verify or adapt specifications for critical quality
attributes (CQAs). The department of quality control must develop an ELISA for
leached KappaSelect and validate all required assays. The formulated API can be
used for safety studies (ICH-Guidelines S1-S11). The master and working cell banks
must be developed and characterized.
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Subsequently, a viral clearance study can be performed. The virus removal of the fol-
lowing process steps should be validated: viral inactivation via pH, AIEX-polishing
and nanofiltration. In addition, a validation of the final sterile filter and of the
filling of drug product is requested. After validating the safety assays of the quality
control department, the production and quality parts of an investigator medicinal
product dossier (IMPD) can be written. The IMPD is a direct prerequisite for a
clinical trial.
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5.1 List of abbreviations
°C Degree Celsius
AC Affinity chromatography
ACF Animal component-free
ADC antibody-drug conjugate
ADCC Antibody-dependent cellular cytotoxicity
AIEX Anion exchange chromatography
AH1 Polishing process combination AIEX, HIC number 1
ALL Acute lymphoid leukemia
AML Acute myeloid leukemia
API Active pharmaceutical ingredient
Appl. Application
AU Absorption units
BE mode Bind-elute mode
CCF central composite design face-centered
CDC Complement dependent cytolysis
CDR Complementary determining region
CHO Chinese hamster ovary
CIEX Cation exchange chromatography
CD Cluster of differentiation
Conc. Concentration
Cond. Conductivity
CQA Critical quality attribute
Cs Caesium
CV Column volume
Da Dalton
DBC10% Dynamic binding capacity at 10% flow through
DNA Deoxyribonucleic acid
DPBS Dulbecco’s Phosphate buffered saline
DSF Differential scanning fluorimetry
EC50 Effective concentration for 50%
ELISA Enzyme-linked immunosorbent Assay
E:T Effector : target ratio
FACS Fluorescence-activated cell sorting
FCS Fetal calf serum
FDA Food and drug administration
FF Fast flow
FFF Field flow fractionation
FPLC Fast protein liquid chromatography
FT mode Flow-through mode
g Gram
GMP Good manufacturing practice
Gy Gray
h Hour
HCDNA Host cell deoxyribonucleic acid
HCP Host cell protein
HIC Hydrophobic interaction chromatography
HP High performance
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ICH International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use
IEP Isoelectric point
IEX Ion exchange chromatography
IMDM Iscove’s modified Dulbecco’s medium
IMPD Investigator medicinal product dossier
IPC In process control
IU International units
KS KappaSelect
KSBP KappaSelect binding protein = Aggregates, Monomer, LCD and LC of
NF-CUN297Q
L Litre
LC Light chain
LCD Light chain dimer
LKS Leached KappaSelect
LPS Lipopolysaccharides
LRV Logarithmic10 reduction value
m Meter
M Molar
mAb monoclonal antibody
MEM-NEAA Minimum essential Medium - Non-essential Amino Acid Solution
MCB/WCB Master cell bank / Working cell bank
MDS Myelodysplastic syndrome
MFI Mean fluorescence intensity
min. Minute
MMC Multimodal chromatograpy
Mon Monomer
MRD Minimal residual disease
MW molecular weight
NFAT Nuclear factor of activated T-cells
OD280 Optical density at λ = 280 nm
Osm Osmol
Pa Pascal
PBMC Peripheral blood mononuclear cell
pH pondus Hydrogenii
Ph.Eur. Pharmacopoeia europea = european pharmacopoeia
PHA Phythemaglutinine
pKa Negative log of acid dissociation constant
PLS Partial least squares
ppm Parts per million
PSB Primary seed bank
QPCR Quantitative polymerase chain reaction
R&D Research and development
Ref Reference
RLU Relative luminescence units
RPMI Roswell Park Memorial Institute medium
RSD Residual standard deviation
S Siemens
scFv Single chain Fragment variable (antibody fragment)
SDS-PAGE Sodiumdodecylsulfate - Polyacrylamide gel electrophoresis
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SEC Size exclusion chromatography
TFF Tangential flow filtration
TMP Trans membrane pressure
TSE Transmissible spongiform encephalopathy
(U)HPLC (Ultra) high performance liquid chromatography
V Volume
5.2 Amino acid sequence of NF-CUN297Q
Heavy chain:
QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGE
IDPSDSYKDYNQKFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITT
TPFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMISRT
PEVTCVVVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKQLPSPIEKTISKAKGQPSGDIQMTQSPSSLS
ASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGG
GSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGK
GLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAV
YYCARSGYYGDSDWYFDVWGQGTLVTVSS
Light chain:
DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQ
SISGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSNTWPYTFGGGTKLEI
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
NRGEC
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5.3 Small-scale model
5.3.1 Purification
Table 5.2: Small-scale model - Process Parameters for AH1.1-3; IPC = In process control
AH1.1 AH1.2 AH1.3
KappaSelect V = 10mL; h = 20 cm; v = 400 cm/h
Application Name Supernatant Spin150128-A Spin150512-E
Volume Supernatant [mL] 1064 1060 790
Amount KSBP [mg] 143 (110%) 178 (135%) 119 (90%)
Wash with PBS until OD280 ă 20mAU ă 20mAU ă 20mAU
Elution Frac from to 100mAU to 100mAU
Volume Elution [mL] 12.8 13.9 12.3
pH 2.86 2.86 2.78
Preparation for AIEX (Capto Q)
Add. 150mM Tris pH 9.60 [mL] 5.40 5.45 5.45
pH 7.994 7.999 7.997
Cond. [mS/cm] 4.65 5.02 4.32
Add. water [mL] 10.5 14 9
Cond. [mS/cm] 2.98 3.02 3.01
Volume (sum) [mL] 28.7 33.35 26.75
ùñIPC-1
AIEX (Capto Q): V = 9.4mL; h = 20 cm; v = 150 cm/h
Application Volume [mL] 26 30 21,7
Amount Monomer [mg] 71.70 85.85 50.71
Elution Frac from to 50mAU to 100mAU
Volume Elution [mL] 33.5 37.6 28.8
ùñIPC-2
Preparation for HIC (Phenyl HP)
Add. 1M (NH4)2SO4 [mL] 2.8 3.4 2.2
Cond. [mS/cm] 18,6 18.5 18.75
Conc. [mg/mL] 2.05 2 1.72
HIC (Phenyl HP) V = 9.4mL; h = 20 cm; v = 120 cm/h
Application Volume [mL] 31.6 37 27
Amount Monomer [mg] 60.39 66.96 43.15
Elution Frac from to 50mAU to 100mAU
Elution volume 37 42 32
ùñIPC-3
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Figure 5.1: Small-scale model for production process - Process AH1.1
Column dimensions: 2 x Hiscreen™ (V = 9.4mL; h = 20 cm) for each purification step
Amount KSBP: 142.5mg (110%)
A: KappaSelect; v = 400 cm/h; BE mode DPBS and 0.1M Glycine pH 2.5
B: AIEX; Capto Q; v = 150 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 3mS/cm
C: HIC; Phenyl HP; v = 120 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 18.5mS/cm
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Figure 5.2: Small-scale model for production process - Process AH1.2
Column dimensions: 2 x Hiscreen™ (V = 9.4mL; h = 20 cm) for each purification step
Amount KSBP: 178mg (135%)
A: KappaSelect; v = 400 cm/h; BE mode DPBS and 0.1M Glycine pH 2.5
B: AIEX; Capto Q; v = 150 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 3mS/cm
C: HIC; Phenyl HP; v = 120 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 18.5mS/cm
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Figure 5.3: Small-scale model for production process - Process AH1.3
Column dimensions: 2 x Hiscreen™ (V = 9.4mL; h = 20 cm) for each purification step
Amount KSBP: 119mg (90%)
A: KappaSelect; v = 400 cm/h; BE mode DPBS and 0.1M Glycine pH 2.5
B: AIEX; Capto Q; v = 150 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 3mS/cm
C: HIC; Phenyl HP; v = 120 cm/h; FT mode 50mM Tris pH 8.00 / Cond. 18.5mS/cm
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5.3.2 Analysis
5.3.2.1 Compendium of Analysis
Table 5.3: Small-scale model - Compendium - Results for IPC
Concentration was determined via OD280-measurement; Aggregate-, monomer- and LCD/LC-
content was determined via SEC Superdex; HCP-content was determined via ELISA; HCDNA-
content was determined via QPCR; Note: results for SDS-PAGE, Flow cytometric analysis, T-cell
proliferation assay and potency assay (Promega) are not included in this compendium; IPC = In
process control; KSBP = KappaSelect binding protein; HCP = Host cell proteins; HCDNA = Host
cell DNA, QPCR = Quantitative PCR; LCD = Light chain dimer; LC = Light chain
AH1.1 AH1.2 AH1.3
IPC-1 conc. [mg/mL] 4.97 5.34 4.44
Amount KSBP [mg] 142.64 178 119
Aggregates [%] 6.88 5.84 7.2
Monomer [%] 55.49 53.59 52.63
LCD/LC [%] 37.63 40.56 39.58
Amount Monomer [mg] 79.15 95.39 62.51
HCP [ppm] 5584 4591 7569
HCDNA [ppm] 629 497 884
IPC-2 conc. [mg/mL] 2.1 2.2 1.87
Amount KSBP [mg] 70.35 82.72 53.86
Aggregates [%] 3.61 5.56 3.96
Monomer [%] 93.22 90.48 92.91
LCD/LC [%] 2.63 3.29 2.51
Amount Monomer [mg] 65.58 74.85 50.04
HCP [ppm] 46.0 52.8 57.2
HCDNA [ppm] ă 1.5 ă 1.5 ă 1.5
IPC-3 conc. [mg/mL] 1.59 1.45 1.29
Amount KSBP [mg] 58.83 60.9 41.28
Aggregates [%] 0.28 0.32 0.33
Monomer [%] 97.69 97.15 96.88
LCD/LC [%] 1.47 1.87 2.05
Amount Monomer [mg] 57.47 59.16 39.99
HCP [ppm] 20.6 20.0 21.8
HCDNA [ppm] ă 1.5 ă 1.5 ă 1.5
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5.3.2.2 SEC analysis via Superdex™ 200 Increase 10/300 GL
IPC-3
IPC-1
IPC-2
Mon
LCD LC
Mon
Mon
Figure 5.4: Small-scale model - SEC (Superdex) - Process AH1.1
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of In-process controls (IPC1-3); Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
LCD LC
Mon
Mon
Mon
IPC-3
IPC-1
IPC-2
Figure 5.5: Small-scale model - SEC (Superdex) - Process AH1.2
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of In-process controls (IPC1-3); Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
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Figure 5.6: Small-scale model - SEC (Superdex) - Process AH1.3
UHPLC BioRS 3000
Column: Superdex™ 200 Increase 10/300 GL
Analysis of In-process controls (IPC1-3); Mon = Monomer, LCD = Light chain dimer, LC = Light
chain
Table 5.4: Small-scale model - SEC (Superdex)
Peak detection and quantification via software “Chromeleon 7.2”; Analysis of In-process controls
(IPC1-3) of process AH1
Aggregate [%] Monomer [%] LCD [%] LC [%]
IPC-1 6.9 55.5 22.1 15.6
AH1.1 IPC-2 3.6 93.2 1.1 1.6
IPC-3 0.3 97.7 0.4 1.1
IPC-1 5.8 53.6 22.4 18.2
AH1.2 IPC-2 5.5 90.5 1.5 1.8
IPC-3 0.3 97.2 0.9 0.9
IPC-1 7.2 52.6 22.2 17.4
AH1.3 IPC-2 4.0 92.9 1.1 1.4
IPC-3 0.3 96.9 0.9 1.2
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5.3.2.3 SDS-PAGE
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Figure 5.7: Small-scale model - SDS-PAGE
IPC-1-3 for verification batches AH1.1 to AH1.3; A = unreduced condition; B = reduced condition;
marker: “PageRuler™ Prestained Protein Ladder”
5.3.2.4 CIEX / UHPLC
AH1.1 IPC-3
AH1.3 IPC-3
AH1.2 IPC-3
Figure 5.8: Small-scale model - CIEX / UHPLC
UHPLC BioRS 3000
Column: MAbPac™ SCX-10 RS, 5 µm BioLC™ 2.1x50mm
Analysis of In-process control 3 (IPC-3) of process AH1
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5.3.2.5 Flow cytometric analysis
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Figure 5.9: Small-scale model - Flow cytometric analysis - NALM-16 cells
Titration of monomer-normalized IPC-1 (‚), IPC-2 () and IPC-3 () of process AH1 on NALM-16
cells; Isotype = NP-C16N297Q (SP2/0) 50 µg/mL; Reference (˝) = NF-CUN297Q (SP2/0); Detec-
tion: GaH-Fc-PE
148 CHAPTER 5. APPENDIX
AH1.1
0
10
20
30
40
50
100 101 102 103 104 105
conc. ng/mL
M
F
I 
(m
e
d
ia
n
)
AH1.2
0
10
20
30
40
50
100 101 102 103 104 105
conc. ng/mL
M
F
I 
(m
e
d
ia
n
)
Controls
FA
C
S-
bu
ffe
r
Is
ot
yp
e
0
10
20
30
40
50
M
F
I 
(m
e
d
ia
n
)
AH1.3
0
10
20
30
40
50
100 101 102 103 104 105
conc. ng/mL
M
F
I 
(m
e
d
ia
n
)
Controls
FA
C
S-
bu
ffe
r
Is
ot
yp
e
0
10
20
30
40
50
M
F
I 
(m
e
d
ia
n
)
Controls
FA
C
S-
bu
ffe
r
Is
ot
yp
e
0
10
20
30
40
50
M
F
I 
(m
e
d
ia
n
)
Figure 5.10: Small-scale model - Flow cytometric analysis - Jurkat cells
Titration of monomer-normalized IPC-1 (‚), IPC-2 () and IPC-3 () of process AH1 on Ju-
rkat cells; Isotype = NP-C16N297Q (SP2/0) 50 µg/mL; Reference (˝) = NF-CUN297Q (SP2/0);
Detection: GaH-Fc-PE
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5.3.2.6 T-Cell proliferation assay
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Figure 5.11: Small-scale model - T-cell proliferation assay
Titration of monomer-normalized IPC-1 (‚), IPC-2 () and IPC-3 () of process AH1; Refer-
ence (˝) = NF-CUN297Q (SP2/0); E:T = 1:1; N = NALM-16; P = PBMC; PHA = 10 µg/mL
phytohemagglutinin
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5.3.2.7 Potency assay (Promega)
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Figure 5.12: Small-scale model - Potency assay (Promega)
Titration of monomer-normalized IPC-3 of batches AH1.1 (), AH1.2 (İ) and AH1.3 (); Overall
EC50 of the three batches is 3.0 ˘ 0.2 ng/mL, which corresponds to 33.3% ˘ 0.8% relative potency
compared to reference.
Reference (✽) = NF-CUN297Q (SP2/0); RLU = relative luminescence units; E:T = 2:1; E = modif.
Jurkat; T = NALM-16
5.3.3 Specifications and Achievements for the Small-Scale
model
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Table 5.5: Definition and achievement of quality objectives - Specifications and results for critical quality attributes
CQA Specification Achievement
Identity
Distinctive Identification of Aggregates, Monomer, LCD and LC identified
Purity
Aggregates ă 1% (SEC Superdex) 0.3%
LCD ă 1% (SEC Superdex) 0.7%
LC ă 2% (SEC Superdex) 1.1%
HCP ă 100 ppm (ELISA) 20.8 ppm
HCDNA ă 10 ppm (QPCR) ă 1.5 ppm
LKS ă 10 ppm (ELISA) theoretical
Endotoxins 5 IU/h/kg (Ph.Eur. 7.0 part 2.6.14) theoretical
Viral safety Assurance level of 10´6 theoretical
TSE safety Absence of TSE proteins achieved
Biological activity
FACS comparable binding properties to cells presenting the antigens verified
of interest compared to an appropriate reference and
no loss of binding activity during purification
T-Cell comparable proliferation-inducing properties of T-cells compared verified
proliferation to an appropriate reference and no loss of activation
properties during purification
Potency Assay comparable activity of the purified API of three batches verified
(Promega)
Stability
Melting temperature Tm1 ą 72 °C (DSF) verified
40 °C 4 weeks ă 1% Aggregate (SEC Superdex) verified
ą 95% Monomer (SEC Superdex) verified
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5.4 Contributions
Figure 1.2 at page 6 Synimmune GmbH, Tu¨bingen
Figure 2.1 at page 32 Synimmune GmbH, Tu¨bingen
Figure 3.16 at page 71 GE Healthcare, Mu¨nchen
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